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CHAPTER! 
GENERAL INTRODUCTION 
1.1 Backgrouud and brief history of xenotransplantation 
Donor organ shortage can be seen as a consequence of the success of allotransplantation and 
is mainly a problem of the western countries. Due to the progress in transplantation medicine, 
more patients with end-stage organ failure can be treated. However, many patients will never 
receive an organ, since the waiting lists increase every year. According to the United Net\vork 
for Organ Sharing (UNOS) over 160,000 patients worldwide are registered as candidates for 
organ transplantation on a waiting list. In the USA more than 79,000 people are awaiting an 
organ transplant and approximately 16 will die each day without receiving one. 
Within the Eurotransplant area (Austria, Belgium, Germany, Luxembourg and The 
Netherlands) in 1999 3,075 patients received an unrelated cadaveric kidney transplant, 
whereas 12,393 patients remained on the waiting list. Alternatives for kidney patients are 
hemodialysis and living-(related) kidney donation. 708 patients received a heart transplant in 
1999, and 608 were still on the waiting list at the end of that year. An alternative for heart 
patients is the artificial heart, but the possibilities of this device are limited. In the same year, 
236 lung transplantations were performed and 345 people were waiting for a transplant, 
whereas 46 patients who needed a heart and lung transplant were waiting for these organs and 
28 were transplanted. Up to 25% of patients on the waiting list are dying as no suitable organ 
is available in time (1). The shortage of human organs has increased interest in 
xenotransplantation as a possibility to solve this problem. 
The first reports of transplantation of animal tissue to humans occurred long before clinical 
allotransplantation had been established (2). In 1905 slices of rabbit kidney were used to treat 
renal failure (3). In 1923, a patient lived for 9 days with a grafted lamb kidney (4). Since the 
1960's pioneers in the field of xenotransplantation have performed clinical transplantations 
from primates-to-humans with different success. In table I a brief overview is given. In 1964, 
Reemtsma obtained great success in a series of kidney transplants from chimpanzees to 
humans with a graft survival of 9 months (5) and Starzl achieved graft survival of2 months in 
patients who received baboon kidneys (6). In 1984 Bailey performed an orthotopic 
transplantation of a baboon heart that functioned for 20 days in a neonate and in 1985 Bailey 
transplanted a baboon heart, which survived for I month (7). In 1992, a pig liver survived for 
3 hours in a human (8), and more recently 1996 a pig heart was transplanted into a human but 
this xenograft survived less than 24 hours (9). Most efforts in xenotransplantation failed 
because of rejection responses in the recipients (2). In xenotransplantation, i.e. the 
transplantation of cells, tissues or organs from one species to another different species, e.g. 
pig-to-human, the intensity of the xenograft rejection depends on the phylogenetical distance 
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between the donor and the recipient. Based on the different patterns of rejection, this 
distinction is called concordant and discordant (10). 
Table 1. Overview ofxenotransplantations from primate-to-human 
Donor Organ Surgeon Year Number Best result 
Chimpanzee Kidney Reemtsma 1964 12 9 months 
Liver Starzl 1964 3 14 days 
Heart Barnard 1977 1 4 days 
Baboon Kidney Hitchcock 1964 1 5 days 
Kidney Starzl 1964 6 2 months 
Heart Barnard 1977 I 4 days 
Heart Bailey 1985 1 1 month 
Liver Starzl 1991 2 2.5 months 
Pig Heart I Religa 1991 1 <24 hours 
Heart Baruah 1996 1 <24 hours 
1.2 Xenotransplantation: concordant I discordant 
Concordant xenografts are cells, tissues or organs transplanted in phylogenetically closely 
related species, i.e. mouse-to-rat, hamster~to~rat, goat~to-sheep, monkey-to-baboon, 
nonhuman primate-to-human. These grafts reject more vigorously than allografts. The 
mechanism of rejection is thought to be mediated by a combination of humoral and cellular 
factors (11). Long~term. graft survival can not be guaranteed by conventional 
immunosuppressive therapy because of the potent induced antibody response in concordant 
xenotransplantation. However, with immunosuppressive therapy, the reported survival of 
concordant cardiac grafts in nonhuman primates exceeds 500 days (11;12). 
Discordant xenografts are cells, tissues or organs transplanted between phylogenetically 
widely distinctive species, i.e. guinea pig-to-rat, pig-to-monkey, pig-to-human. Discordant 
xenotransplant rejection is characterized by the occurrence of hyperacute rejection (liAR) 
(11;13-15). 
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1.3 Animals for organ donation 
Due to the shortage of allografts for transplantation of patients with end-stage organ failure 
and by lack of success in developing artificial organs, investigators have been looking for a 
suitable donor animal (16). The general idea was to generate donor animals transgenic for 
human complement regulatory proteins. The requirements for an appropriate donor animal 
are: (I) the size of the donor organs must be conform the size of human organs, (2) the 
animals must be bred easily, i.e. frequent litters with many descendants, and (3) virological 
abnormalities must be detectable. 
The monkey 
The monkey as a potential donor source would be an obvious choice because of the small 
distance to hwnans, phylogenetica11y seeD. Furthennore, the anatomy corresponds to the sizes 
of hwnan organs. However, the monkey has become a rare species and hard to breed (one 
descendant per year). Through this, the choice using the monkey as an animal source for 
organ donation, is an emotionally sensitive matter. Next to the ethical reasons, physiologic 
limitations of the transplant and the possibility of transferring infectious agents from the 
transplant into the host may also be important (17). Considering the mentioned arguments, the 
monkey was Dot chosen as animal source for organ donation. 
The pig 
The pig seems to be the second potential donor organ source, although it would be a 
discordant situation. Several years ago, researchers thought it would be difficult to assess how 
the public was going to react to the possibility of using pig organs for human transplantation 
in the future, although, we consume pigs at large scale. Furthermore, porcine heart valves 
have been used for years now for the replacement of diseased human heart valves. Moreover, 
pig organs correspond to the sizes of human organs, they breed easily and frequent, and have 
large litters. A possible risk for transmission of xenozoonoses, particularly pig endogenous 
retroviruses (poERY), should be born in mind. 
Due to physiological compatibilities as well as ethical and infectious considerations, pigs 
have now emerged as the most likely source of future xenografts (18;19). The introduction of 
pigs made transgenic for human complement regulatory proteins and new immunosuppressive 
regimens seem very promising for future clinical experiments. However, strategies to create 
transgenic donor animals have been tried in pigs with different success (18;20-23). Knockout 
techniques are not available in pigs yet, but are under development (23). Additional 
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clarification of infectious risks and patient strategies are remaining obstacles to application in 
the clinical arena (l8). 
1.4 Mouse and rat 
Preclinical pig studies, as described above, are useful, but expensive. Moreover, during 
creation of transgenic animals, also non-transgenic animals are bred due to the Mendelian 
inheritance of alleles. Although this occurs in smaller animals as well, it is less expensive and 
easier to perform studies in rodents. An advantage of generating transgenic mice and rats is 
that the gestation takes 21 days, which is faster as compared to pigs, i.e. 11 0-ll8 days (24). In 
addition, once the pigs have been born, they are too small for experimental usage. Thus, it 
takes six months before the transgenic pig can be used. Transgenic mice and rats can be used 
three months after conception. The most important motivation for using rodents in our 
experiments is that the mechanisms of rejection can be more accurately investigated. 
Presently, there are three single transgenic pig and mouse lines available, i.e. hCD55, hCD46 
and hCD59. In rats, the hCD55 line is available only. Double transgenic pigs (20;25) and 
mice (26;27) have been generated recently. Considering the arguments and since the efficacy 
of mUltiple human CRPs has never been studied properly in pigs, we have decided to study 
this in rodents. 
1.5 Allotransplantation 
Cardiac transplantation 
One of the historical landmarks in clinical transplantation has certainly been organ 
transplantation in general, and heart transplantation in particular. The world's first 
transplantation of a human heart was performed by Barnard in Cape Town, Africa, on 
December 3'd 1967, with 18 days survival. A second patient received a human heart on 
January 2nd 1968 and survived for several years (28). Graft survival after heart transplantation 
using immunosuppression was equivalent to that of cadaveric kidney transplantation. 
Presently, the patient one year survival rate after heart transplantation is approximately 80%. 
Over 90% of them achieve a sufficient heart function and more than 70% get back to normal 
social life (1). 
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1.6 Rejection phases in allo- and xenotransplantation 
Comparable to the immune response in infectious disease, rejection in organ transplantation is 
mediated by antibody formation, complement activation and cellular immunity, 
1.6.1 Allotransplantation 
Due to differences in surface-antigens between two human individuals in allotransplantation, 
a transplanted organ does provoke a rejection response. These surface-antigens are knmvn as 
'major histocompatibility complex' (MHC) antigens or human leucocyte antigen (HLA). 
MHC contains class I-antigens (A-, B- and C·antigens) and class II-antigens (DP-, DQ- and 
DR-antigens). These antigens playa pivotal role in the normal inllnlme response. :MHC class 
I-antigens regulate the CDS+-T-Iymphocytes (T,-and T,-cells). Class II-antigens control the 
CD4+-lymphocytes (Th- and T,-cells). These helper T-cells help immune responses or induce 
them. T h-cells can positively influence the maturation response of other T - and B·cells, and 
also regulate the cytotoxic and suppressive functions of T c- and Ts-cells. T h-cells can be 
divided into Thl - and Th2-cells. Thl-cells produce cytokines, like I1-2 and IFN-X, whereas Th2-
cells produce I1-2, I1-4, I1-5, 11-6 and 11-10. These cytokines positively and negatively 
influence the immune response. rhl-cells regulate cytotoxicity and local inflammation, i.e. 
fight against intracellular pathogens (viruses, bacteria, parasites). Th2-cells are effective in 
stimulating the proliferation and antibody production ofB-cells, and therefore protect humans 
against "free' appearing micro-organisms. This is the humoral or antibody mediated 
immunity, i.e. immunity based on antibodies produced by B-Iymphocytes present in the 
blood. 
In human organ transplantation a difference in MHC molecules exists between donor and 
recipient, leading to an immune response of the recipient. To reduce the risk of organ 
rejection, HLA-matching is performed prior to transplantation (29) (30). In spite of HLA-
matching in the allogeneic situation, rejection can still occur. 
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Hyperacute rejection occurs within minutes to hours after transplantation and is caused by 
pre-existing antibodies, which react with J\.1HC-antigens on the vascular endothelium. This 
leads to complement and endothelial cell activation, resulting in local coagulation. Organ 
dysfunction and graft loss are the main consequences. The introduction of serological 
crossmatches before transplantation has decreased the incidence of hyperacute rejection 
immensely, but it is not completely erased due to the presence of complement-dependent and 
-independent antibodies (29). 
Acute rejection can occur within days or weeks up to one year after transplantation. It is 
mediated by a cellular immune reaction and type N allergy reaction. Almost every transplant 
patient goes through one or more rejection periods. Due to improved management of 
immunosuppressive therapy the graft survival has drastically improved. 
Chronic rejection can occur after months to years after transplantation, leading to graft 
failure. The most important histological feature in a chronically rejected transplanted heart is 
intimal hyperplasia. The myocardium appears to be no primary target, however, small 
triangular-shaped fibrosis in the heart muscle are remainders of infarctions as result of vessel 
occlusions (31). 
1.6.2 Xenotransplantation 
Concordant rejection 
The concordant rejection process, which is the type of rejection between closely related 
species, is very similar to that in allograft rejection. To study this type of rejection, in which 
grafts are rejected after a few days, the hamster-to-rat model is often used (32). Just like in 
allotransplantation, a variety of immunosuppressive regimens, combining both anti-humoral 
and anti-T-cell immunosuppression, have successfully been used to extend graft survival (33-
35). The first cardiac xenotransplantation was performed in 1964 from a chimpanzee to a 68 
old man by Hardy at the University of Mississippi (36). One hour after transplantation the 
patient died because of an inadequate cardiac output due to the small size of the donor heart. 
In 1985 a baboon-to-human cardiac xenotransplantation in a neonate was perfonned (7;37-
39). The baboon heart survived for 20 days, graft failure was a result of a progressive humoral 
response, i.e. an antibody-mediated rejection (7). This suggests that the antibody response is 
stronger than in allografung and that conventional immunosuppression is not sufficient to 
suppress concordant rejection (33). 
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Discordant rejection 
The discordant rejection processes can be divided into several rejection phases. First, 
hyperacute rejection (BAR), second delayed xenograft rejection (DXR) or acute vascular 
rejection (A VR), and third cell-mediated rejection. These phases are not exactly separated, on 
the contrary they affect each other. 
Hyperacute rejection (HAR) 
HAR of discordant transplants has been shown to be due to complement activation, either via 
the alternative or classical, antibody-dependent, pathway, and to activation of coagulatory and 
inflammatory pathways, leading to rapid xenograft rejection. HAR of a vascularized graft can 
take place in as little as 10 minutes, or a few hours (40). The histopathology of BAR is 
characterized by edema, interstitial haemorrhage, platelet thrombi, intravascular thrombosis, 
ischemic necrosis and severe injury to endothelial cells, accompanied by destruction of the 
internal organ structures (17;19;40;41). This process resembles the reaction seen after ABO-
mismatched allograft transplantation (33). 
Depending on the species combination, HAR is either initiated by the rapid deposition of 
xenoreactive natural antibodies within the graft and the subsequent activation of the classical 
pathway of complement activation (e.g. pig-to-primate) (42;43), or is mediated by direct 
activation of host complement through the graft endothelium (e.g. guinea pig-to-rat 
combination) (44). In addition to the activation of complement, neutrophil adherence, and 
vasoconstriction all may contribute to the pathogenesis of HAR in various models of 
xenograft rejection (45-47). 
Xenoreactive natural antibodies (XNA) and Galal-3Gal antibodies 
XNA are present in the circulation of all immunocompetent individuals without a known 
history of sensitization (48;49) and are predominantly directed against only one antigen, a 
saccharide, Galal-3Gal (50;51). Non-primate manunals, including the pig, express Galal-
3Gal (52;53), but humans and most primates do not (54). Natural antibodies in a non-
sensitized recipient are primarily, if not solely, JgM. Next to JgM, there is evidence that JgG 
may have a role in BAR in recipients of discordant xenografts (40;55). Binding of the XNA 
results in initiation of the complement cascade, leading to the formation of the membrane 
attack complex (MAC), which causes lysis and opsomsation of cell membranes, and induction 
of the inflammatory response, resulting in graft destruction. 
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There are several hypotheses about the source of circulating XNA. They may be produced by 
a distinctive class of B-cells; the Bt-cells (56). Or they are produced as cross-reacting 
antibodies during infections with enviromnental pathogenic agents (33). 
The importance of Galal-3Gal as the primary barrier to xenotransplantation was 
demonstrated by experiments in which anti-Galal-3Gal antibodies were specifically depleted 
from baboons using irnmunoaffinity columns. Antibody binding to the transplanted organs 
was limited and HAR did not occur (57). One approach to overcome the antibody-antigen 
reaction is to develop lines of pigs with low levels of Galal-3Gal antigen expression. The 
most obvious approach to developing such lines of donors is to 'knock ouf the enzyme that 
synthesizes the critical sugar, al,3-galactosyl transferase. Unfortunately, since embryonic 
stem cells are not available for the pig, this enzyme carmot be mocked out in pigs as it has 
been in ntice (17;58-61). 
Complement 
In a discordant model a xenograft is rejected hyperacutely within ntinutes to hours due to 
binding of natural antibodies to the vascular endothelium of the xenograft, which causes 
activation of the complement cascade of the recipient. 
The complement system is continuously activated. However, the reason that our body is not 
destructed, is due to the presence of soluble and membrane-bound complement regulatory 
proteins (CRPs), which de-activate the cascade. If cells, tissues or organs of a different 
species are transplanted into the human body, complement factors in the serum of the 
recipient do not correspond with the CRPs on the endothelium of the donor xenograft. 
Therefore, the donor CRPs can not de-activate the complement activation, resulting in 
hyperacute rejection of the xenograft. To this end, genetic modification of donor animals has 
been performed by implanting human genes, encoding for human CRPs. 
Acute vascular rejection (AVR) or delayed xenograft rejection (DXR) 
In discordant xenotransplantation, the first obstacle to overcome is HAR, which is primarily 
mediated by binding of antibody and complement, resulting in activation of endothelial cells. 
HAR can be averted by removing of natural anti-aGal antibodies through extracorporeal 
irnmunoadsorption (EIA), depletion/inhibition or blocking of complement, and/or the use of 
donor animals transgenic for CRPs (11), leading to a prolongation of graft survival. But still 
xenografts are rejected by a process designated as the second immunologic barrier, i.e. acute 
vascular rejection (A VR) or delayed xenograft rejection (DXR), which does occur in the 
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absence of T cells. The beginning of A YR coincides with a rise in antibody synthesis, mainly 
IgG antibody (62;63). These induced antibodies initiate A VR by mechanisms that appear to 
be independent of complement, although complement fractions may playa role (11;47;64). 
Since this type of rejection occurs over 2-4 days post-transplant, it is often referred to as acute 
humoral xenograft rejection. 
A VR involves type II endothelial cell activation, including up-regulation of pro-inflammatory 
antigens, induction of leukocyte adhesion molecules (P-IE-selectin, ICAM-l, VCAM-l), 
cytokine production, leading to chemotaxis of leukocytes (65), intravascular thrombosis, and 
infiltration of host granulocytes, monocytes/macrophages and natural killer (NK) cells into 
the graft. VVhether monocytes/macrophages and NK cells have major functions in mediating 
A YR, or whether they migrate into the xenograft as a response to the presence of antibody, 
remains unclear. 
Activation of endothelial cells 
After discordant organ transplantation, binding of XNA to endothelial cells (EC) and 
activation of complement result in EC activation, leading to destruction of the xenograft. 
Traditional immunosuppressive regimens are ineffective to block EC activation, only extreme 
immunosuppression can lead to a prolongation of xenograft survival. 
Endothelial cells form a physical barrier, through which the blood and its elements can flow 
and across which gases and fluids can transverse, but they also promote an anticoagulant 
enviromnent (40). If activation of endothelial cells occurs, the vascular integrity is lost. In 
addition, a pro-coagulant environment is created, since activated endothelial cells synthesize 
tissue factor and lose thrombomodulin. Two types of EC activation are mown (66). Type I 
activation includes retraction of ECs from one another, exposing underlying structures, like 
collagen. Expression on EC of P-selectin and von Willebrand factor (vWF), and secretion of 
platelet activating factor (P AF) and other inflammatory mediators occur. Type II EC 
activation includes loss of anti-thrombotic defenses, heparan sulphate and thrombomodulin, 
leading to thrombosis. Upregulation of the transcription of many genes encoding for adhesion 
molecules and cytokines will occur (67), resulting in infiltration of the xenograft with 
monocytes/macrophages, NK cells, and polymorphonuclear neutrophils (PMN). 
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Cellular immunity 
The probably most difficult immunologic barrier to overcome is the cellular immune 
response, in which it is assumed that similar mechanisms as in allograft rejection are 
involved. 
Leukocytes 
When HAR of a xenograft has passed within a few hours after transplantation, 
polymorphonuclear neutrophils (PMN) appear to be present in the graft. PMN infiltrate the 
xenograft more rapidly than NK cells and T-cells, because they adhere to the early adhesion 
molecule P-selectin, which is upregulated instantly after EC activation (68). In contrast, NK 
cells use the late adhesion mode1cules ICAM-l, VCAM-l and possibly E-se1ectin for their 
adherence (69;70). 
Monocytes / macrophages 
Monocytes can be found in early xenograft rejection. They activate xenogeneic EC by direct 
cellular contact via membrane bound tumor necrosis factor (TNF). This contact leads to up-
regulation of E-selectin, Il-8, monocyte chemotactic protein-I, and plasminogen activator 
inhibitor type-I, resulting in intravascular coagulation. These cyto- and chemokines stimulate 
the monocytes in further transendothelial migration, promoting inflammation, thrombosis and 
organ infarction (41;71). 
B- and T-lymphocytes 
B-cells have been detected in rejected porcine xenografts, however, their presence remains 
unclear. Lysis of xenogeneic targets can be inhibited by anti-CD3 or anti-CDS antibody, and 
partially inhibited by anti-CD2. T -cell-independent B-cells may playa central role in late 
xenograft rejection, but this remains controversial (41). 
Natural killer cells (NK cells) 
In vitro studies suggested that xenogeneic target cells may be susceptible to NK cell-mediated 
lysis because their :MIle class I molecules are not recognized by specific inhibitory receptors 
(70). Ex vivo cardiac perfusion experiments suggest that the combination of NK cells and 
XNA may be a major cause of organ injury. However, no definitive proof currently exists that 
NK cells are obligatory for the progression of cell-mediated xenograft rejection in 
vascularized discordant xenografts (41 ;69;72). 
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1.7 The complement system 
1.7.1 Nomenclature of the complement system (30) 
The proteins of the classical pathway and the Membrane Attack Complex (MAC) include 
Clq, Clr, CIs, C4, C2, C3, C5, C6, C7, C8, C9. Most of these proteins are zymogenes, i.e. 
pro-enzymes, which must be split before activation. Proteins of the alternative pathway are 
called factors: Factor B, Ba, Bb, D, H, I and P. When a complement component is activated, 
this is noted with a *. 
Complement receptors can be named 
1. after their ligand (e.g. C3a-receptor) 
2. with the help of the 'Cluster of Differentiation' (CD-) system 
3. according to a numerical system for receptors of the most important fragments of C3, 
complement receptor type I up to 4 (CRI - CR4) 
The descriptions for complement receptors are used concurrently, e.g. receptor for C3b = 
C3b-receptor = CD35 = CRI. 
CRI (= CD35) is a receptor for C3b and iC3b. It is an opsonin-receptor on neutrophils, 
monocytes and macrophages, which mediate endocytosis or phagocytosis. It is a co-factor in 
splicing C3b to iC3b (Factor H is more important), and it is a co-factor in splicing iC3b to 
C3c and C3dg (CRI is the only co-factor, which protects host cells against complement 
attack). On erythrocytes or platelets (dependent on the species) CRI can mediate the pick-up 
of opsonised immune complexes or bacteria and transport these to cells of the fixated 
mononuclear phagocyte-system. On B-Iymphocytes CRI in combination with CR2 can act as 
a receptor, which brings about lymphocyte-activation. 
The CR2 (= CD21)-receptor is primarily restricted to mature B-cells and follicular dendritic 
cells, and is involved in the activation ofB-cells (73). It is also the Epstein-Barr-virusreceptor 
(74). 
CR3 (= CDllb) is probably the major adhesion molecule on monocytes and neutrophils, and 
is involved in phagocytosis, adhesion of neutrophils and cytotoxicity of cells bearing 
activated complement components, like C3b. 
CR4 (= CDllc) is present on lymphocytes, neutrophils, monocytes and macrophages. It binds 
iC3b and functions in cell adhesion (75). 
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Complement proteins can be divided into superfamilies, which share structural and functional 
features, Complement control proteins, like factor H, a plasma-globulin, C4-binding protein 
(C4-bp), a heptamer plasma-protein, Decay Accelerating Factor (DAF, CD55), Membrane 
Co-factor Protein (MCP, CD46), Complement receptor type 1 (CRl, CD35) and type 2 (CR2, 
CD21), are regulators of complement activation, Factor H, C4-bp, DAF, MCP en CRI all 
inhibit formation of C3-convertase-enzymes by the classical and alternative pathways, 
respectively C4b2a* and C3bBb*, Some of these molecules have other, non-identical 
functions: inhibition of the binding of C2 to C4b, and Factor B to C3b; and Factor I acts as a 
co-factor, which is responsible for the catabolism of C3b and C4b, 
The complement system is part of the inborn immune system, which distinguishes self, i.e. 
host, from non-self (30;76), The essence of this distinction is the presence on host tissue of 
complement regulatory molecules and the absence of these molecules on non~self surfaces. 
These regulatory proteins protect the host against complement activation by avoiding the 
C3b-binding to the host cells. Non-self antigens, however, do not have these protective 
molecules, and therefore many C3b-moleeules will be attached to their surface, leading to 
elimination of the non-self antigens. 
The complement system contains many proteins, which mediate a cascade-reaction, at which 
each enzyme catalyses the next step, Activation of both the classical and alternative pathways 
takes place either on the membrane or in the fluid-phase. The most crucial component is C3, 
which connects the classical and alternative pathways. Activation of the cascade can proceed 
via NO pathways: 
1. an antibody-dependent mechanism, composed by the acquired inunune system (the 
classical pathway), initiated by the binding of specific antibody of the IgM or IgG class to 
surface antigens 
2. a non-specific mechanism, initiated by bacteria, viruses or other 'strange' polysaccharides 
(LPS) and by some antibodies (IgA) (alternative pathway of the inborn immune system), 
in which complement deposition is localised on the surface of target cells 
An overview of the complement cascade is given in figure 1. 
21 
classical pathway alternative pathway 
Ag:Ab 'strange' polysaccharides 
L.~!1 .... ~~"" C!!-faJrH 
C2 •••• +. C3bB 
, " Il' ' .. +- factorD 
C4b2a C3bBb 
C3 -------+. C3h 
C5 • C5b 
• 
+C7j +C6 
CD59 '" + nC9 + C8 
•••••• 
C5b-9 (=MAC) 
Figure 1. Overview of the complement system. 
1.7.2 The classical pathway 
C3 
C5 
This route is mainly activated via the binding of antibodies to antigens, i.e. immune 
complexes. Cl is the fITSt enzyme complex, which is a pentamoleculair Ca2+-dependent 
complex consisting of one Clq-molecule, WO Clr- and tvvo CIs-molecules. When activated 
CIs splits C4, C4a (a small, mild anaphylatoxic fragment) and C4b* (a large, unstable 
fragment with an active bindingsite) appear. Membrane-bound C4b* is a bindingsite for 
zymogen C2, resulting in the formation of the classical C3-convertase. This bounded C2 is the 
substrate for Cls*, which splits off the C2b-fragment. The C2a-fragment stays behind and 
binds to C4b, forming C4b2a-complex, i.e. C3-convertase of the classical pathway. 
C3a and C3b are formed via splitting the C3·molecule with C3-convertase. C3a is an 
anaphylatoxin. C3b binds with nearby cell surface molecules, like proteins and sugars. Since 
C3-convertases are localised on non-self surfaces or on immune complexes, C3b-deposition is 
mainly restricted to these places. Bound C3b acts as a center for further complement 
activation via the amplification-loop of the alternative route (see below). 
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Regulation of the classical pathway 
In the fluid-phase efficient regulation of the activation of the classical pathway is regulated by 
two mechanisms. Firstly, a Cl-inhibitor binds and inactivates Clr* and CIs*. Secondly, 
blockade of the formation ofC4b2a*, the C3-convertase of the classical route, by Factor I and 
C4-binding protein (C4-bp). Formation ofC4b2a* is inefficient in the fluid-phase because of 
the presence of Factor I and C4-bp, which together break down C4b. Besides, C4-bp 
stimulates the dissociation ofC2a out ofC4b2a*. 
Activation of the classical pathway. localised at the membrane, is regulated by inhibition of 
complementbinding to host cell surfaces via Decay Accelerating Factor (DAF, CD55) and 
Membrane Cofactor Protein (MCP, CD46). 
Anaphylatoxins 
C3a, C4a and C5a are anaphylatoxins. They can be described as small complement fragments, 
which are produced during activation of the complement cascade, and act as mediators in 
inflammation (77). Anaphylatoxins function via two receptors, the C3a receptor (C3aR), 
which binds C4a as well, and the C5a receptor (C5aR). C3a and C4a induces smooth muscle 
contraction, increases vascular permeability and mediates the release of (1) histamine from 
mast cells, eosinophils, basophils and neutrophils, (b) thromboxane A from macrophages, and 
(c) lysosomal enzymes from neutrophils. C5a is chemotactic, spasmogenic, increases vascular 
permeability and mediates the release of pharmacologically active mediators from a number 
of cell types (78). 
1.7.3 The alternative pathway 
Normally there is continuous and spontaneous activation of the most crucial component of the 
cascade, complement factor C3, in the plasma (,tick-over'), resulting in depositions of small 
numbers of C3b-molecules on host- and non-self-surfaces. On host-surfaces complement 
regulating molecules mediate the degeneration of C3-deposition and inhibit further 
complement activation. Activation of the alternative pathway is initiated after 'tick-over'-
activation of C3, and C3b-molecules are deposited on non-self surfaces, which lack regulating 
molecules. The 'tick-over-activation' mediates a continuous production of small C3b*, which 
has an active binding site for Factor B, resulting in the C3bB-complex. This complex is split 
by Factor D, through which Factor Ba is released. The residual complex, C3bBb*, is the 
fluid-phase-C3-convertase of the alternative route. Most of the C3b*, produced by C3-
convertase, is hydrolysed and inactivated by water. However, if C3b* would come in contact 
with non-self surfaces, it will bind and initiate the amplification-loop of the alternative route 
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(see below). C3b* which will also bind to host surfaces. but due to the presence ofCRPs. the 
amplification-loop will not be initiated. 
Regulation of the alternative pathway 
Activation of the alternative route in the fluid-phase, when C3b is not membrane-bound, is 
regulated by proteins, which correspond with complement regulatory molecules, which inhibit 
the activation of the classical pathway. Factor H stimulates the dissociation ofBb of both C3i 
and C3b. It also acts as cofactor for Factor I during the catabolism of C3i and C3b. 
For the host it is important that the amplification-loop is regulated. This is mediated by a 
positive feedback-system. which continues until all C3-molecules have been split, unless it 
will be inhibited by Factor I. 
In the membrane-bound phase. DAF and CRI stimulate the dissociation of C3bBb and release 
C3b from the complex. Furthermore, CRI and MCP are co-factors for the splicing of C3b by 
Factor I (these reactions are analogue with the functions of DAF, MCP and CRI during the 
regulation of the activity of the classical-raute-enzyme C4b2a*, which is membrane-bound). 
Amplification-loop 
To stimulate the activated complement system, two amplification mechanisms are known: 
I. a 'triggered' enzym cascade. The trigger is the binding of small numbers of Clq-
molecules, and the activation of a series zymogenes (pro-enzymes), both resulting in 
splitting large numbers of C3-molecules 
2. a positive feedback-loop, the amplification-loop. The loop starts by splitting small 
numbers of C3-molecules up to C3b-molecu1es, resulting in the formation of C3-
convertase-enzym, which splits more C3 
Host cells possess regulating molecules, which inhibit the amplification-loop by degeneration 
of C3b up to inactive products. Non-self surfaces have an unregulated amplification, leading 
to further activation of the complement cascade and destruction of the non-self antigens. 
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The regulation of membrane-bound C3b is the critical step during the non-specific distinction 
between self and non-self by the complement system. There are two options for membrane-
bound C3b: 
1. amplification: C3b plus Factor B -7 convertase-enzyme -7 more deposition ofC3b on the 
same surface 
2. inhibition: C3b is degenerated by Factor I, using one of the three co-factors, either Factor 
H (plasma, fluid-phase) or CRI and MCP (membrane bound) 
The presence of molecules, like DAF, CRI and MCP effectively limit the formation of C3-
convertases on host cells. However, deposition of C3b on non-self surfaces, which do not 
have the regulating molecules, lead to formation of the alternative-route-C3-convertase and 
thus more C3b-deposition, 
In summary, activation of classical and alternative pathways leads to the formation of C3-
convertase, which splices C3 in C3a and C3b, C3-convertase of the classical route is the 
combination ofC4 with C2, resulting in C4b2a*. C3-convertase of the alternative route is the 
combination of C3 with Factor B, leading to C3bBb*, Both the C3-convertases can be 
converted in a C5-convertase by adding C3b, C5-convertase catalyses the first step of the 
cascade, leading to the production of the membrane attack complex (MAC), 
1.7,4 Membrane attack complex (MAC) 
The final part of the complement cascade contains several complement-molecules, which are 
circular incorporated into the surface of the target cells. 'When this circular complex, i.e. the 
Membrane Attack Complex (MAC), is completed, an irreparable gap appears in the cell 
membrane, Through this gap leakage of the cell contents take place, which is fatal for the celL 
MAC is formed by enzymatic splicing of C5, Before C5 can be spliced by C5-convertase, it 
has to be bound to C3b, The classical route-C5-convertase is a trimolecular complex 
C4b2a3b*, in which C3b is bound to C4b, Altemative-route-C5-convertase is a trimolecular 
complex C3bBb3b*, in which one C3b is bound to another C3b, When C5 is split, the small 
peptide fragment C5a is released, which is anaphylatoxic, 
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Finally, the MAC is formed via non-enzymatic assembly of C5b-C9: 
C5b + C6 ~ C5b6 hydrophilic complex 
C5b6 + C7 ~ C5b67 hydrofobic complex ~ inserts in lipid-bilayer 
C5b67 
C5b678 
C5b6789 
+C8 
+ 14C9 
~ C5b678 
~ C5b6789 adding of C9 in steps 
= C5b-9 = MAC, gap, hole, plug 
Although small lysis occurs after binding of C8 to C5b67, the polymerised C9 causes the 
main part of the lysis. Hydrofobic molecules, which polymerise to form gaps are involved in 
general mechanisms against cellular cytotoxicity. T -lymfocytes kill target cells by insertion of 
a plug, called perforine, into the membranes. Perforine has structural homology with C9. 
Similar molecules can be found in the granulae of eosinophils. Certain bacterial toxins, like 
streptolysine 0, are gap-forming molecules. 
Regulation of the formation of the MAC 
Formation of MAC is regulated to reduce reactive lysis, i.e. the hydrofobic C5b67-complex 
ones fonned, can insert itself into other cell membranes closely related to the primary surface 
on which the complement activation is concentrated. Unregulated reactive lysis leads to 
damage of host cells or tissues. C5b67 can be inactivated in the fluid-phase before it attaches 
to host membranes by certain proteins, like S-protein ("'Vitronectine), which is plentiful 
present in the plasma. It forms the SC5b67-complex, which is unable to insert into lipid-
bilayers. Even if C8 or low density lipoprotein (LDL) bind to the SC5b67-complex, no 
insertion takes place. 
Host cells carry membrane proteins, which protect against lysis by the MAC. Protectin 
(CD59), which is anchored to a glycophospholipidprotein, which is present on lots of cell 
membranes, and binds to C8 of the C5b-8-complexes. It inhibits the insertion and unfolding 
of C9 in cell membranes. Furthennore, homologous restriction factor (HRF), also anchored to 
a glycophospholipid membrane-bound protein, which acts in similar ways as CD59, but is a 
weaker inhibitor for the insertion of C9. 
N.B. Nuclear cells, like the cells of the immune system of the host, are more resistent to lysis 
by complement than erythrocytes, because they can actively erase the MAC by endocytosis 
and exocytosis of membrane fragments, which contain MAC. 
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Consequences of complement activation 
Since the complement cascade is the first defence mechanism of the immune system against 
non-self molecules, sequential activation of the complement system results in: 
1. phagocytosis, i.e. opsonisation of target cells, which deposit C3b on their cell membranes 
2. lysis, i.c. direct killing of target cells via the formation of the Membrane Attack Complex 
(MAC), resulting in membrane damage 
3. release of peptides active In inflammation, e.g. chemotaxis of leukocytes, basically 
polymorphonuclear cells (PMN) and macrophages 
4. formation of immune complexes 
5. induction of specific antibody-responses by enhancing of the localisation of antigens to B-
lymphocytes and antigen presenting cells 
The process of complement activation constantly takes place in the body and it would destruct 
all of our cells, Fortunately, a regulatory system is present, which prevents the MAC to be 
completed and thus averts lysis of cells. This regulatory system comprices the complement 
regulatory proteins (CRPs), which provide the complement molecules to form the MAC. In 
humans three inhibitory molecules of the complement cascade have been identified: Decay 
Accelerating Factor, Membrane Co-factor Protein, both inhibitors at the level of C3 and C5 
convertase, and Protectin, an inhibitor at the level of C9. These complement regulatory 
proteins (CRPs) are present on the endothelium of all organs and they mediate the de-
activation of the complement cascade. 
1.8 The complement regulatory proteins 
As described above, CD46 and CD55 inhibit at the beginning of the complement cascade, at 
the C3 / C5 convertase level, while CD59 inhibits at the end of the cascade, at the level of 
formation of the membrane attack complex (MAC). 
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Decay Accelerating Factor (DAF / CD55) 
CD55 is a 70 kDa membrane protein, which is anchored to the membrane by covalent linkage 
to glyco-phosphatidyl-inositol (GPI), GPI provides fast movement on the membrane layer, 
and CD55 has the ability to release from and reinsert itself in the membrane via its GPI 
anchor (67), CD55 is found on virtually every cell and tissue (except NK cells), 
predominantly on endothelial and epithelial surfaces and also in plasma, urine, tears, saliva, 
synovial and cerebrospinal fluid (79;80), The structure of the gene for CD55 is comparable to 
that of CD46. Moreover, DAF and MCP synergize the actions of each other in preventing 
C3b deposition on the cell surface (81;82). 
CD55 enhances the degradation of C3-convertase (= C4b2a) of the classical pathway by (1) 
inhibition of the binding ofC2 to C4b (CD55 ofCRl), and by (2) stimulating the dissociation 
ofC2a from C4b (CD55 ofCRl). In figure 2 a schematic diagram of the DAF molecule is 
given. 
Decay Accelerating Factor = DAF = CD55 
inhibits association stimnlates dissociation 
,..C2a .... 
DAF DAF 
Figure 2. Schematic diagram of CD55 and its function. 
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Membrane Co-factor Protein (MCP / CD46) 
CD46 appears to be in two broad fonns of 59-68 kDa and of 51-58 kDa, but there is inherited 
variability in the quantity of the two fonns due to two different alleles of the CD46 gene as is 
shown by restriction fragment length polymorphism (67;83;84). CD46 is very widely 
distributed on epithelial and endothelial cells, fibroblasts, platelets, lymphocytes, 
granulocytes, placental tissue and spenn, hemopoietic cells and peripheral blood cells (except 
erythrocytes) (84). CD46 is a transmembrane protein, which acts as a co-factor during (I) the 
cutting of C3b molecules, and (2) the stimulation of the catabolism of C4b by Factor I (MCP 
of CRI). In figure 3 the MCP molecule and its function is given. 
Membrane Cofactor Protein = MCP = CD46 
stimulates catabolism of C4b via Factor I 
~o o FactorI 
C4b MCP 
Figure 3. Schematic diagram of CD46 and its function. 
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Protectin (CD59) 
CD59 is a 20 kDa membrane-protein, which is, like CD55, GPI-linked, but shares no other 
similarity with CD55. The distribution of CD59 over the tissue is as broad as that of CD46 
and CD55, although absent from several cell types. It is present in endothelial and epithelial 
surfaces of most organs, on leukocytes, platelets and erythrocytes, on spermatozoa, placental 
tissue, thyroid cells, and astrocytes. Like CD55, it is found in urine, saliva, cerebrospinal 
fluid, breast milk and anmiotic fluid with all the GPI anchor intact, including the fatty acid 
component, and it is not clear whether this is due to the characteristics of the OPI anchor or 
whether the soluble forms are shed from the cells by some other means (85). Little or no 
expression is found on many B-cell lines, islets of Langerhans and acinar pancretic cells, on 
the proximal tubules of the kidney, hepatocytes, or Kupffer cells (67;86). 
CD59 binds to C8 of the C5b-8-complexes (=pre-MAC) and inhibits the insertion and 
unfolding of C9 in cell membranes (figure 4). CD59 blocks 'low' in the complement cascade. 
Protectine = CD59 
CD59 + C8 -. C9 can not bind -. no MAC 
0 .. /88 Id C9 
88 
Figure 4. Schematic diagram of CD59 and its fimction. 
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1.9 Complement and complement regulatory proteins in human diseases 
Complement is implicated in several diseases in humans, both of autoimmune nature and of 
enhanced vulnerability to systemic infections (67). The mentioned diseases are only examples 
of the wide spectrum of diseases, in which complement plays a central role. 
A clearly described autoimmune disease is Paroxysmal Nocturnal Hemoglobinurie (pNH). 
The importance of CRPs in the regulation of complement-activity is obvious in PNH, a 
somatic deficiency of the biosynthesis of glycosylphosphatidylinositol (GPI) anchors in 
hemopoietic cells. In PNH the synthesis of GPr anchors is blocked. One consequence of this 
deficiency is that hemopoietic cells show a significant reduction of CD59 and DAF levels on 
their surface, resulting in an increased sensitivity for complement and spontaneous lysis of 
erythrocytes. It is a condition characterized in various forms by the absence of CD59, HRF, 
and/or DAF on red blood cells (87-89). Another unique relation between human disease and 
complement is the identification of CD46IMCP as a receptor for the measles virus (90). To 
infect human cells, measles viruses use the complement regulatory protein CD46 as a cell 
surfuce receptor (91). 
Complement deficiencies are involved in rheumatologic disorders, such as lupus 
erythematosus (LE) or meningitis (92). An increase in initial and terminal components of the 
complement cascade results in systemic sclerosis (93). MAC lesions contribute to the 
development of atherosclerosis and Alzheimer's disease (94). HIV~l triggers the classical 
pathway activation in an antibody-independent manner and utilizes the defense mechanism of 
opsonisation through CRI and CR3 for enhanced spreading and infectivity (95). 
1.10 Modification ofthe xenogeneic immune response 
Vascular xenografts are usually rejected hyperacutely due to naturally occurring antibodies 
and complement. HAR can be prevented via manipulating either of these systems. 1. 
Reduction or depletion of anti-aGaI antibodies. 2. Inhibition or depletion of components of 
the complement system. 3. Genetic engineering of the donor animal. 
1. Reduction or depletion of anti-aGaI antibodies can be achieved by plasmapheresis and/or 
imrnunoadsorption. However, the continuous removal of the recipient's natural antibodies, is 
proving difficult, because eventually they return (48). 
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2a. Human soluble complement receptor I (sCRI) inhibits complement activation by 
acceleration of the splitting of C3/C5-convertases, and for that reason blocking the 
complement cascade. seRl can prolong xenograft survival in the guinea pig-to-rat model 
from minutes to 32 hours (96). 
2b. Depletion of one or more complement components is accomplished by administration of 
cobra venom factor (CVF), because CVF is an analogue of C3b and therefore activates the 
complement system continuously (97;98). Complement depletion by CVF can prolong 
discordant xenograft survival form minutes to days, but complement-independent 
mechanisms mediate that grafts are fmally rejected by A VR (11 ;99-1 02). 
3. Since continuous depletion of xenogeneic natural occurring antibodies (anti-aGal) is 
difficult, specific approaches to therapy, including the genetic engineering of source animals, 
have been developed. One approach is to create a donor animal, which does not have aGal, an 
aGal knockout. In ntice this has already been a success (103). However, it is not yet 
attainable to develop an aGal knockout pig, as pig embryonic stem cells are not accessible 
(23). Another reasonable approach is to generate donor animals transgenic for human 
complement regulatory proteins, since these proteins inhibit the complement activation. CRPs 
are mostly species-specific, i.e. CRPs expressed on mouse, rat, porcine tissues do not modify 
human complement and vice-versa (11). hDAF transgenic pigs have been generated and 
positive results have been reported. In 1998, the survival of hDAF transgenic pig hearts 
orthotopically transplanted into baboon recipients was between 18 hours to 9 days (104). 
However, immunosuppressive therapy was necessary to maintain the graft. Moreover, these 
hearts were not rejected hyperacutely, but signs of A VR could be detected. In 2000, progress 
has been made in the discordant pig-to-baboon xenotransplantation model by using a hDAF 
transgenic pig donor heart and a clinically accepted maintenance immunosuppressive 
regimen. This combination resulted in the longest survival of an orthotopically transplanted 
heart ever: 39 days (105). Again inhibition ofHAR and subsequent control of humoral and 
cellular rejection were seen. 
1.11 Multiple transgenes 
Next to the single transgenic pigs, double transgenic pigs have been bred. Pig hearts double 
transgenic for both CD59 and CD55 have been generated and transplanted into 
immunosuppressed baboons. These hearts functioned for 85-130 hours until they were 
rejected by A VR. Wild-type hearts survived only for 20-80 ntinutes (20). In Australia 
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researchers have tried to breed triple transgenic pigs (CD55/CD59/anti-uGal) and 
transplanted porcine kidneys to non-immunosuppressed baboons (22). Control kidneys 
rejected hyperacutely, within 1 hour, but triple transgenic kidneys maintained function for up 
to 5 days. The triple transgenic kidneys showed cellular infiltration and the recipients 
developed thrombocytopenia and abnormalities in coagulation within 2 days of 
transplantation. The findings will have to be studied in rodents, since the development is 
easier in smaller animals. One double transgenic mouse strain for CD59/CD55 has already 
been developed and the above results can be confmned (l06). However, it should be kept in 
mind that these studies have been perfonned with small numbers of animals. 
The aim in the modification of the immune response is to find out which molecules are 
necessary to avert rejection and maintain graft function. The <ideal' transgenic donor animal 
should express the relevant molecules on the vascular endothelium. Once this "ideal' animal 
has been generated, cloning would be the best option to maintain the transgene expression. 
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CHAPTER 2 
AIM OF THE THESIS 
1.1 General outline 
Heart transplantation is an accepted treatment for certain forms of heart failure. Due to 
refinement in immunosuppressive therapy, survival rates after heart transplantation are 
excellent. As a result of this success, morc patients are considered for heart transplantation. 
This development has led to an increased need for donor hearts, while the amount of organ 
donations remained stable. Up till now, all attempts to substantially increase the number of 
organs for transplantation purposes have failed. A possible solution for the donor shortage is 
the use of animal hearts, c.g. pig hearts. However, the rejection process, which occurs after 
transplantation over a species barrier, i.e. xenotransplantation, is intense and takes place 
within minutes to hours. Immunosuppressive treatment has hardly any effect, because the 
rejection process after xenotransplantation is fundamentally different as compared to 
allotransplantation. In xenotransplantation, hyperacute rejection is caused by (xenoreactive) 
natural antibodies, leading to activation of the complement system. The activated complement 
damages the vascular endothelial cells of the donor organ. N orrnally the complement 
activities on the endothelium are inhibited by complement regulatory proteins (CRPs). 
However, during xenotransplantation the regulation of these proteins cannot function 
properly, because the complement of the recipient is not recognised. Since it is possible to 
implant human CRPs onto porcine endothelium, the rejection process between pig and human 
may be less intense and more similar as in allotransplantation. 
Research in this field is ongoing. Pigs are bred using genetic manipulation, which carry one or 
more human CRPs and which may function as donor source for humans. It has not yet come 
to that, because the process of genetic manipulation is slow. Besides, it has not been 
demonstrated that the choice of genetic manipulation is the right method. To this end, 
transgenic mice could be used instead, since human CRPs can be implanted into mice as well. 
The procedure is less expensive and quicker, since the pregnancy period of mice is only three 
weeks. These mice are used to study whether the concept of CRP transgenesis is valid. 
Additionally, the mechanism of rejection can be investigated in rodents, whereas pigs are 
usually used in the preclinical setting. 
1.2 Aims of this thesis 
The role of human CRPs in the regulation of hyperacute rejection was studied using 
• single transgenic mouse lines. By means of genetic manipulation, mice transgenic for one 
human CRP, i.e. hDAF, hMCP, hCD59, were produced. Hearts from these mice were 
perfused with human serum in the Langendorff circuit in order to study whether these 
hearts were protected against HAR (Chapter 3). 
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• double transgenic mouse lines. Mouse hearts transgenic for wo hCRPs, i.e. 
hDAFxhCD59, hDAFxhMCP, hMCPxhCD59, were tested whether they would avert 
HAR to a larger extent than single transgenes by perfusion with human serum in the 
Langendorff device (Chapter 4). 
• a single transgenic rat line. Only one transgenic rat line, hDAF, was available. These rat 
hearts were analyzed in the Langendorff circuit, either by perfusion with human serum 
(are the hearts protected against HAR ?) or with human blood (are the hearts protected 
against cell-mediated rejection as well ?) (Chapter 6 and 7). 
Since these isolated heart perfusions were ex vivo perfusions, we investigated 
• whether hDAF transgenic mouse and rat hearts were also protected against HAR, in vivo. 
Therefore, we transplanted these hearts into primates using a new cannulation-technique 
(Chapter 5 and 6). 
If HAR, which is mediated by antibodies and complement, is averted in vivo, an influx of 
eells, mainly natural killer (NK) cells and macrophages, into the xenograft can occur, 
resulting in A YR. In Chapter 8, we used the guinea pig-to-rat heart transplantation model to 
investigate whether A VR could be prevented by specific and non-specific depletion of 
macrophages and NK cells. 
In addition, in xenotransplantation ischemia reperfusion injury may playa pivotal role in graft 
dysfunction and organ loss. Heme oxygenase-l (HO-l) is a molecule lmown to diminish 
ischemia reperfusion (IJR.) injury. Therefore, we investigated whether upregulation of HO-I 
would lead to improvement of the performance of mouse hearts perfused with human serum 
in the Langendorff circuit (Chapter 9). 
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CHAPTER 3 
RELATIVE ROLES OF HCD46 AND HCD55 IN THE 
REGULATION OF HYPERACUTE REJECTION 
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7 I I F.G. GROSVELD-, R.L. MARQUET , J.N.M. IJZERMANS 
lLABORATORY FORExpERlMENTAL SURGERY, ERASMUS UNIVERSITY ROTTERDAM 
'LABORATORY FOR CELL BIOLOGY & GENETICS, ERASMUS UNIVERSITY ROTTERDA.,\1 
adaptedfrom Transplantation Proceedings, 32, 903-904, 2000 
and 
European Surgical Research (ESSR), 32, Supplement 1, 2000 
Introduction 
It is now well established that hyperacute rejection (HAR) of discordant xenografts can be 
overcome by the use of donors that are transgenic for complement regulatory proteins 
(CRP's). We and others have demonstrated that particularly regulation at the level ofC31eads 
to the desired effect: mouse hearts transgenic for hCD46 (MCP) showed a marked increased 
survival time when perfused with human serum, whereas hCD59 transgenes did not (I). The 
present experiments were done to see whether expression of a second CRP (hCD55) would 
further improve survival. 
Materials & Methods 
Animals 
Mice 
Twelve-to-sixteen weeks old male and female heterozygous transgenic mice, weighing 
approximately 20 grams, were used. They were generated by microinjection of mouse ova 
with yeast artificial chromosome (YAC) constructs of the entire genomic DNA encoding for 
hCD46 or hCD55 at the Department of Cell Biology & Genetics of the Erasmus University 
(2). The hCD55-mouse strain contained 10 integrated copies in the genome. The hCD46 J-
mouse strain contained a single copy of hCD46, whereas the hCD46 II-mouse strain 
contained 10-12 copies of hCD46. These mice show regulation of mRNA and protein 
expression as is seen in humans. The expression of the relevant protein on spleen, kidney, 
heart, liver and lung was verified by anti-hCD55 and anti-hCD46. The background of the 
hCD55-mice was BJOCBA and for hCD46-mice the FVB strain, which were used as controls. 
BJOCBAxFVB mice were used as controls for hCD55xhCD46 mice. hCD55xhCD46 double 
transgenic mice were bred by crossing the single transgenic mouse strains. The heterozygous 
Fl offspring was used in this study. Through tailing, each mouse was checked for expression 
of the single and double transgenes. 
The animals were housed in a certified animal breeding facility under standard conditions and 
had free access to standard mouse chow (AM II, Hope Farms, Woerden, The Netherlands) 
and water acidified to pH 2.2 ad libitum. The experimental protocols adbered to the rules laid 
down in the Dutch Animal Experimentation Act (1977) and the published Guidelines on the 
Protection of Experimental Animals by the Council of the EC (1986). The Committee on 
Animal Research of Erasmus university Medical Centre, Rotterdam, The Netherlands, had 
given permission to perform the experimental protocols. 
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The Langendorff device 
To test the effects of complement regulatory proteins, it is necessary to perfuse transgenic 
mouse or rat hearts with human serum. In figure 1 a schematic overview of the Langendorff 
circuit is given. Oscar Langendorff deserves credit for first devising a method to permit 
investigation of the mechanical activity of the completely isolated mammalian heart in 1895 
(3). 
In our Langendorff system two bottles are present. The large bottle contains Krebs-Henseleit 
(KH) medium. KH is an artificial medium. If the KH medium is saturated with oxygen, hearts 
will beat for a long time. The smaller bottle contains the human serum solution, i.e. human 
serum diluted with KH. 
De Langendorff~ops[elling 
Figure 1. A schematic overview of the Langendorffcircuit. 
After removal of the heart from the laboratory animal, a cannula is inserted in the ascending 
aorta. By means of retrograde perfusion, i.e. perfusion against the Donnal physiological 
direction, the aortic valves closes (figure 2). Because of this, the medium is driven into the 
ostia coronaria. After passing through the coronary vascular system, the medium flows off 
into the coronary sinus, which drains on the right atrium. 
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Perfusiemedium 
Rechter coronair arterie ' ~. Linker coronalr arterie 
_.::.:..:.:....+_ Linker ventrikel 
Rechter ventrikel 
Figure 2. Retrograde perfusion ofa Langendorffheart. 
When the heart is cannulated, it is connected to the Langendorff system. First, the heart is 
perfused with KH (bottle 1) to acclimatize. Through the assembly of the medium, the heart 
regains its contractions again. After switching to human serum solution (bottle 2), the time is 
registered until complete cessation of heartbeats occurs. The contractility, coronary flow and 
heart frequency are investigated and restored on a computer. A small fishhook is attached to 
the apex of the heart, which is connected to a tension-meter. This meter transmits a signal to 
the computer. Pressure, temperature and humidity are being registered. Oxygen saturation is 
determined within one rrrinute by means of an auto-analyzer. 
Saturation, i.e. providing oxygen, of the medium is realised by means of an artificial lung 
(figure 3). The 'lung' is a cylinder with an outer chamber, in which oxygen is supplied and 
removed via two tubes, which are connected to the cylinder. On the inside of the cylinder, 
long semi~permeable tubing is twisted. Medium coming from the stock-bottle flows through 
this tubing. The oxygen exchange occurs according to the "tegenstroomprincipe", medium 
flows through the semi-permeable tubing from right to left; the oxygen in the outer chamber 
of the cylinder from left to right. The oxygen diffuses from the outer chamber into the 
medium. Finally, the medium returns to the stock-bottle, where it is heated up to 3TC (4). 
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Figure 3. Artificial lung of the Langendorffmodel. 
Surgical procedure 
Mice were anaesthetised with iso-flurane inhalation (phannachemie B.V. Haarlem, Holland) 
and the abdominal wall was opened. 0.6 mL Heparin (50 fU/mL) was injected into the 
abdominal inferior vena cava. Via two lateral incisions the thorax was opened and the heart 
was removed quickly. A 22-gauge indwelling cannula was inserted into the aorta and secured 
with a 4.0 ligature. The heart was directly perfused with oxygenated Krebs-Henseleit solution 
using a syringe and directly linked to the Langendorff device, as described by Verbakel et al. 
(5). Haemaccel was added to optimize the performance of the mouse hearts during perfusion. 
Before switching to human serum, acclimatisation of the hearts was accomplished by 
perfusion with Krebs-Henseleit-Haemaccel solution for 10 minutes. Hearts were monitored 
constantly for heart rate and flow using multichannel registration. Sunrival time was defined 
as the time between the start of serum perfusion and complete cessation of heartbeats. 
Human serum 
Frozen, pooled, human O-type plasma was obtained from the blood bank of the University 
Hospital Dijkzigt (Rotterdam, The Netherlands). Human serum was made out of human 
plasma by adding 0.5 mL Thrombin to 200 mL human plasma, inducing clotting. After 
removal of the clot, the serum was diluted with Krebs-Henseleit-Haemaccel solution to obtain 
the perfusion concentration of 15%. For each experiment fresh human serum was prepared. 
Immunohistochemistry 
After cessation of heartbeats each heart was cut in two. One sample was fixed in 3.6% 
formaldehyde solution. Following dehydration and paraffin embedding, 4 I'm-thick sections 
were cut and stained with Hematoxylin & Eosin (H&E). The other part of the sample was 
snap frozen and stored at -80°C until sectioned for immunohistochemistry. Frozen tissue 
sections (7 I'm-thick) were prepared in a Microm HM 560 cryostat and stained with rabbit 
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anti-human C3c Fluorescin-Iso-Thio-Cyanate (FITC). The anti-human C3c-staining was done 
as described in detail by Verbakcl et a1. (5). Dilution of the primary antibody was 1 :400. 
Stained sections were examined under a fluorescence microscope. The intensity of C3c-
expression on the heart tissues was scored blindly via semi-quantitative analysis: 0 :::: no 
staining, 0.5 = mild staining, 1 = dense staining. 
Experimental groups 
The following mouse lines were tested: 
Group n 
Group 1: controls hCD46 I 5 
Group 2: hCD46 I 6 
Group 3: controls hCD46 II 5 
Group 4: hCD46 II 6 
Group 5: controls hCD55 12 
Group 6: hCD55 11 
Group 7: controls hCD55xhCD46 5 
Group 8: hCD55xhCD46 i 7 
An hearts were first perfused wIth KIebs-Henselelt for 10 minutes, before switching to 15% 
human serum. 
Statistical analysis 
The non-parametric Mann-Whitney test was used to evaluate the differences (considered 
significant when P < .05) in mean survival time (MST) between groups. 
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Results 
Survival time 
In table 1 sunrival times and mean survival times (in minutes) of the experimental groups are 
given. Both mouse hearts transgcnic for hCD46 I (group 2) and hCD46 II-mousc hearts 
(group 4) survived significantly longer than thcir controls (group I and 3) (P < .05). 
Moreover. the hCD55-mouse hearts (group 6) beated significantly longer than controls (group 
5) as well (P < .05). The survival times ofhCD55xCD46-hearts (group 8) and hCD46 I-hearts 
(group 2) was similar. hCD55xhCD46-hcarts did not beat longer than hCD46 II- and hCD55-
hearts (group 4 and 6). but they beatcd three times longer than their controls (group 7). 
Table 1. Survival times and mean survival times (MST) of transgenic mouse hearts and their 
controls (in minutes) perfused with 15% human serum in the Langcndorff device 
Type Survival Times MST 
hCD46 I 9-10-10-11->45 >17* 
, Controls hCD46 I 2-5-5-6-7-7 5.3 
hCD46 II 15-22-30-45->50 >32* 
Controls hCD46 II 3-4-7-9-14-20 9.5 
hCD55 10-15-22-23-29-30-30-30-30-35-40-52 . 28.8* 
Controls hCD55 3-4-4-5-5-6-7-7-8-8-11 6.2 
hCD46 II x hCD55 15-16-17-17-20 17* 
. Controls hCD46 II x hCD55 4-4-5-5-7-7-8 5.7 
* P< .05 
Immunohistochemistry 
Immunohistochemical examination of the hCD46IIxhCD55-hearts revealed diffuse staining of 
C3c in contrast to hCD55- and hCD46-hearts. which showed patchy staining around the 
vessels, not involving the parenchymal structures (figure 5). 
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Figure 5. Anti-human C3c-staining of transgenic and non-transgenic mouse hearts perfused 
with human serum in the Langendorff system. C3c deposition is seen in BCBA controls, 
whereas hCD55 and hCD55xhCD46 hearts showed reduced C3c-Ievels. 
BCBA control heart hCD55 heart 
hCD55xhCD46 heart negative control heart 
Conclusions 
Transgenesis with one complement regulatory protein, i.e. hCD46, has been demonstrated to 
be effective to increase survival of xenogeneic organs, and thus that these hearts were 
protected against HAR provoked by ex vivo perfusion with human serum in the Langendorff 
device. The aim of the present study was to see whether the xenograft survival would 
improve. if a second CRP (hCD55) was added. 
Our results indicate that hCD46-hearts show a threefold increase in survival as compared to 
controls, irrespective of the degree of tissue expression (MYII»>MYI). Furthermore, that 
complement regulation at the level of C3 by hCD55 leads to similar prolongation as 
regulation by hCD46. The main conclusion of this experiment is that expression of both 
hCD46 and hCD55 does not further enhance survival time. It thus appears that, as far as 
protection against HAR is concerned, inhibition at the level of C3 by one CRP provides the 
maximal attainable effect. However, it should be kept in mind that in the current experiments 
heterozygous animals were used; it may be expected that, if we had used homozygous strains, 
further improvement of xenograft survival can be obtained. 
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Abstract 
Hyperacute rejection (BAR) of discordant transplants is caused by direct and indirect 
activation of complement (C). Decay Accelerating Factor (DAF/CD55), Membrane Co-factor 
Protein (MCP/CD46), both inhibitors at the level ofC3, and Protectin (CD59), an inhibitor at 
the level ofC9, are complement regulatory proteins present on the endothelium of all organs. 
They mediate the de-activation of the complement cascade. We demonstrated earlier that 
mouse hearts transgenic for human CD55 (hCD55) or human CD46 (hCD46) are protected 
against BAR, provoked by human serum. The aim of our study was to compare the survival 
of single and double transgenic mouse hearts in the Langendorff circuit by means of ex vivo 
heart perfusion with human serum. The survival of mouse hearts transgenic for hCD55 or 
hCD46 perfused with human serum was significantly longer than non-transgenic controls. On 
the contrary, hCD59 hearts survived as long as their controls. In the double transgenic groups, 
hCD59xhCD55 and hCD59xhCD46 hearts survived longer as compared to non-transgenic 
controls. But compared to single transgenes they did not perform better. Surprisingly, 
hCD55xhCD46 hearts beated shorter as compared to hCD55 or hCD46 single transgenic 
mice. In conclusion, (I) hCD46 or hCD55 mouse hearts are protected against BAR, whereas 
hCD59 hearts are not, (2) hCD59xhCD55 and hCD59xhCD46 double transgenic mouse hearts 
are better protected against HAR than their controls, but not better than single transgenic 
mouse hearts (hCD55 or hCD46), (3) the combination hCD55xhCD46 is even worse than 
hCD55 or hCD46 alone, (4) to prevent BAR it is enough to be transgenic for one complement 
regulatory protein, which inhibits at the level of C3. 
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Introduction 
In the western countries it is a well-known fact that the number of human donor organs is 
limited (1-3). Xenotransplantation. ie transplantation of cells. organs or tissues between 
phylogenetically different species, seems to be a reasonable solution. The success of 
xenotransplantation depends predominantly on how well the immune response can be 
controlled. The rejection response starts with hyperacute rejection (HAR), followed by acute 
vascular rejection (A VR). These rejection phases lead to organ dysfunction and graft loss. 
HAR of discordant transplants is caused by xenoreactive natural antibodies (XNA) binding to 
the xenograft, leading to activation of the complement (C) system, either via the alternative or 
the classical, antibody dependent, pathway (4). The complement system is activated 
continuously because of the constant 'physiological' invasion of viruses, bacteria, and other 
polysaccharides. Our own cells are protected against this complement-mediated attack by the 
presence of complement regulatory proteins on the vascular endothelium of all organs. In 
xenotransplantation, the general idea is to manipulate the donor animal in order to minimize 
the incompatibility between the complement regulatory proteins present on the donor 
endothelium and complement factors in the plasma of the recipient. Therefore, introduction of 
human Decay Accelerating Factor (DAF/CD55), Membrane Co-factor Protein (MCP/CD46), 
both inhibitors at the level of C3, and Protectin (CD59), an inhibitor at the level of C9, into 
the genome of the donor animal can be performed. We demonstrated earlier that mouse hearts 
transgenic for human CD55 (hCD55) or human CD46 (hCD46) were protected against BAR, 
whereas hCD59 hearts were not (5-8). The aim of the present study was to test the protective 
effect against HAR of double transgenic mouse hearts in the Langendorff circuit by means of 
ex vivo heart perfusion with human serum. By using the PI offspring of parental mice 
transgenic either for hCD55, hCD46 or hCD59, we were able to investigate which 
combination of complement regulatory proteins was the most optimal in protecting against 
HAR. 
Materials and Methods 
Animals 
Mice 
Production of single transgenic mice was accomplished by micro-injecting mouse ova with 
entire genomic DNA encoding for hCD55, hCD46 or hCD59 using yeast artificial 
chromosomes (Y AC), which has been described by Yannoutsos et a1. (9). The hCD55-mouse 
strain contained 10 integrated copies in the genome. For the hCD46- and hCD59-mouse 
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strains this was 10-12 and 3 integrated copies, respectively. These mice show regulation of 
mRNA and protein expression as is seen in humans. The expression of the relevant protein on 
spleen, kidney, heart, liver and lung was verified by anti-hCD55, anti-hCD46 and anti-
hCD59. Via blot analysis the expression of the transgenes was evaluated as described by 
Yannoutsos et a1. (10). The Southern blot technique showed that the YAC DNA of the 
transgenes was incorporated into the mouse genome. The background of hCD55 and hCD59 
mice was BlOCBA, and used as control. For hCD46 mice this was the FVB strain. By crossing 
the single transgenic mouse strains, either transgenic for hCD55, hCD46 or hCD59, male and 
female heterozygous double transgenic mice were bred. These heterozygous FI offspring was 
used in this study. Through tailing, each mouse was checked for expression of the double 
transgenes. Splenocytes of mice transgenic for hCD55xhCD46, hCD59xhCD55 and 
hCD59xhCD46 were analyzed by F ACS-analysis, and mouse hearts were tested for 
expression of the transgene(s) by innnunohistochemistry. 
The animals weighed approximately 20 grams and were tvvelve-to-sixteen weeks old. The 
animals were housed in a certified animal breeding facility under standard conditions and had 
free access to standard mouse chow (AM II, Hope Farms, Woerden, The Netherlands) and 
water acidified to pH 2.2 ad libitmn. The experimental protocols adhered to the rules laid 
down in the Dutch Animal Experimentation Act (1977) and the published Guidelines on the 
Protection of Experimental Animals by the Council of the EC (1986). The Committee on 
Animal Research of Erasmus university Medical Centre, Rotterdam, The Netherlands, had 
given permission to perform the experimental protocols. 
FACS-analysis of splenocytes 
Expression of human complement regulatory proteins on 25000 mouse splenocytes of single 
CD55, single CD46, single CD59 or double CD55/CD46, CD59/CD55, CD59/CD46 
transgenic mice was assessed using a F ACS scan flow cytometer, as described earlier (11). 
Mouse monoclonal antihuman-CD55-, -CD46-, and CD59-FITC-antibodies were used. 
Verification of the transgene expression 
The expression of human complement regulatory proteins was verified by 
immunohistochemical staining of the double transgenic heart tissues with primary anti-
human-CD55-, -CD46- or -CD59-antibodies, which were biotinylated. Avidin-Texas Red 
conjugate was used as secondary antibody. Hearts were sliced in sections of 7 ~m with a 
cryostat and stored at -20°C. Later these tissue sections were air-dried for 30 minutes, after 
which they were fixed in acetone for I minute at 4'C. After air-drying for 10 minutes, the 
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seetions were ineubated with the primary antibody (either biotinylated CD55, CD46 or CD59 
antibody; dilution I; I 0) for I hour, After washing with Phosphate Buffered Saline / Bovine 
Serum Albumine (PBSIBSA) (3x10 minutes), the seetions were ineubated with Avidin-Texas 
Red eonjugate (1;500) for 30 minutes, Seetions were washed with PBSIBSA (3x2 minutes) 
again. Finally, the seetions we dehydrated using a series of 70%, 90% and 100% ethanol, 
washed in Xylol, and eovered with Entallan. 
The Langendorff circnit 
Prior to the surgical procedure, mice were anaesthetised with iso-flurane inhalation. The 
abdominal wall was opened and 0.6 mL Heparin (50 IU/mL) was injeeted into the abdominal 
inferior vena cava. Via two lateral incisions the thorax was opened and the heart was removed 
quickly. A 22-gauge indwelling cannula was inserted into the aorta and secured with a 4.0 
ligature. The heart was contiguously perfused with oxygenated Krebs-Henseleit solution 
using a syringe and directly linked to the Langendorff device, as described by Verbakel et al. 
(8). Haemaeeel was added to optimize the performanee of the mouse hearts during perfusion. 
Before switching to human serum, acclimatisation of the hearts was accomplished by 
perfusion with Krebs-Henseleit-Haemaccel solution for 10 minutes. Hearts were monitored 
constantly for heart rate and flow using multichannel registration. Survival time was defined 
as the time between the start of serum perfusion and complete cessation of heartbeats. 
Human sernm 
Frozen, pooled, human O-type plasma was obtained from the blood bank of the University 
Hospital Dijkzigt (Rotterdam, The Netherlands). Human serum was made out of human 
plasma by adding 0.5 mL Thrombin to 200 mL human plasma, inducing clotting. After 
removal of the clot, the serum was diluted with Krebs-Henseleit-Haemaccel solution to obtain 
the perfusion concentration of 15%. For each experiment fresh human serum was prepared. 
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Experimental groups 
Group Krebs-Henseleit Human serum n 
Group 1: BIOCBA control hearts Yes yes 15 
Group 2: FVB control hearts Yes yes 13 
Group 3: hCD55 hearts Yes yes 15 
Group 4: hCD46 hearts Yes yes 16 
Group 5: hCD59 hearts Yes yes 21 
Group 6: hCD59xhCD55 hearts Yes yes 14 
Group 7: hCD55xhCD46 hearts Yes yes 18 
Group 8: hCD59xhCD46 hearts Yes yes 5 
All hearts were perfused for 10 mmutes WIth Krebs-Henselelt to acclunalIze, before switching 
to 15% human serum. 
Immunohistochemistry of 'rejected' hearts 
After cessation of heartbeats each heart was cut in two. One sample was fixed in 3.6% 
formaldehyde solution. Following dehydration and paraffin embedding, 4 fim-thick sections 
were cut and stained with Hematoxylin & Eosin (H&E). The other part of the sample was 
snap frozen and stored at -80°C until sectioned for immunohistochemistry. Frozen tissue 
sections (7 fim-thick) were prepared in a Microm HM 560 cryostat and stained with rabbit 
anti-human C3c complement Fluorescin-Iso-Thio-Cyanate (FITC), rabbit anti-human 19A, 
IgG and IgM, and rabbit anti-human C9. The anti-human C3c-staining was done as described 
in detail by Verbakel et aJ. (8). Anti-human -IgA-, -IgG-, -IgM-staining was done in the same 
way as antihuman C9 staining as described earlier (8); dilution of all primary antibodies was 
1:400. 
Anti-human C3c~stained sections were examined under a fluorescence microscope. Anti-
human C9-, 19A-, IgG-, IgM-stained sections were scored under a light microscope. The 
intensiry of C3c- and C9-expression on the heart tissues was scored blindly via semi-
quantitative analysis: 0 ~ no staining, 0.5 ~ mild staining, I ~ dense staining. IgA-, IgG-, 
IgM-intensities were also analyzed semi-quantitatively: 0 ~ no staining, 0.5 ~ mild staining, 1 
= moderate staining, 2 = dense staining. 
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Statistical analysis 
The non-parametric Kruskall-Wallis test was used to cheek which test had to be done. To 
analyse the differences in survival time and C9-depositions between the experimental groups, 
the non-parametric Mann-Whitney test was used. The Student's t-tcst was performed on the 
results obtained from the anti-human C3c-, 19A-, IgG- and IgM-staining. The level of 
significance being P < .05. 
Results 
Expression of transgenes 
Splenocytes of double transgenic mice showed a strong expression of the transgene by FACS 
analysis. This is illustrated in the second and third row in figure 1. Verification of the 
expression of the single transgenic mouse splenocytes also showed a strong expression (the 
first upper three pictures in fIgure 1; sec legend p. 62). 
Immunohistochemical staining 
Mouse hearts double transgenic for hCD55xhCD46, hCD59xhCD55 and hCD59xhCD46 
exhibited the complement regulatory proteins on both the endothelium and along the 
cardiomyocytes. In figure 3 the results of these stainings are shown. 
Figure 1. FACS-analysis of 25,000 splenocytes of single and double transgenic mice. 
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Legend figure 1. 
hCD59 (red) hCD55 (green) hCD46 (red) 
control (black) control (black) control (black) 
hCD59xhCD55 hCDS9xhCDS5 hCD59xhCD46 
(hCD59: red) (hCD55: green) (hCD46: red) 
control (black) control (black) control (black) 
hCDS9xhCD46 hCD55xhCD46 hCD55xhCD46 
(hCDS9: green) (hCDSS: green) (hCD46: red) 
control (black) control (black) control (black) 
Survival time 
In table 1 and figure 2 mean survival times (in minutes) of the experimental groups are 
shown. Mouse hearts transgenic for hCD55 (group 3) or hCD46 (group 4) perfused with 15% 
human serum beated significantly longer than their non-transgenic controls (group 1 and 2. 
respectively). On the contrary. hCD59 hearts (group 5) survived as long as their controls 
(group 1). In the double transgenic groups. hCD59xhCD55 (group 6) and hCD59xhCD46 
(group 8) hearts beated longer as compared to non-transgenic controls (group 1 and 2). But in 
contrast to single transgenes (group 3.4 and 5) they did not beat longer. hCD55xhCD46 
(group 7) hearts beated as long as their controls. and shorter as compared to hCD55 or hCD46 
single transgenic mice. 
Table 1. Survival times and mean survival times (MST) ± SD of mouse hearts perfused with 
15% human serum in the Langendorff device (in minutes) 
Group Survival times MST±SD 
I. BCBA controls 3-4-4-4-4-5-5-5-5-5-6-6-8-8-8 1 5.3±1.6 
2. FVB controls 2-3-3-3-4-4-4-4-4-5-5-5-6 4.0 ± l.l 
3. hCDS5 I 5-5-5-5-5-6-7-10-10-11-15-15-30-30-30 12.6 ± 9.6* 
4. hCD46 3-3-4-6-6-6-10-10-11-13-15-15-15-15-30-30 13.7 ± 8.3* 
'5. hCD59 2-2-2-3-4-4-4-5-6-8-8-11-14-16-18-30-30-30-30-30-30 13.7 ± II.S 
I 
6. hCDS9xhCD55 4-S-S-10-13-15-1S-20-20-30-30-30-30-30 18.2 ± 10.3* 
7. hCDS5xhCD46 2-2-2-2-2-2-3-3-3-3-4-4-5-6-7-12-15-30 5.9 ± 7.0 
8. hCD59xhCD46 i 2-9-13-30-30 16.8 ± 12.7* 
* P< .05 
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Figure 2. Mean beating times in minutes per group. Group 1: B10CBA controls. group 2: FVB 
controls, group 3: hCD55, group 4: hCD46, group 5: hCD59. group 6: hCD59xhCD55, group 
7: hCD55xhCD46, group S: hCD59xhCD46. (1 vs3 P = .004, 2vs4 P = .001, lvs6 P = .001. 
lvsS P = .046, 2vsS P = .045, 3vs7 P = .002, 4vs7 P = .003, 6vs7 P = .0001). 
C3c. e9. JgA. JgG. JgM depositions 
H&E-stained sections of transgenic and non-transgenic hearts both exhibited edema, but these 
findings were more prominent in the non-transgenic hearts. In table 2 mean scores ofC3c, C9, 
IgA, IgG, IgM depositions are given. No significant differences were found in depostions of 
C3c, C9, 19A, IgG and IgM between non-transgenic and transgenic mouse hearts. Deposition 
of C3c and C9 was mainly localised diffuse along the cardiomyocytes, and sometimes at the 
vascular endothelium. IgA, IgG and IgM depositions were localised at both the endothelium 
oflarge and small blood vessels and diffuse along the cardiomyocytes as well. 
Table 2. Mean semiquantitative scores ± SD ofC3c, C9, IgA, IgG, IgM depositions. 
Group C3c C9 IgA IgG IgM 
1. BCBA controls 0.3 ± 0.3 0.6 ±0.2 O.S ± 0.4 0.9 ±0.5 0.7 ± 0.3 
I 
I 2. FVB controls 0.2 ± 0.3 0.5 ± 0.4 0.7 ± 0.4 1.0 ± 0.5 1.0 ± 0.6 
3. hDAF i 0.4 ± 0.4 0.5 ± 0.3 1.0 ± 0.7 1.0 ± 0.5 0.7 ± 0.3 
4.hMCP 0.5 ± 0.5 0.6 ± 0.4 0.9 ± 0.4 O.S ± 0.4 i O.S ± 0.4 
5. hCD59 0.3 ± 0.4 0.5 ± 0.3 O.S ± 0.5 O.S ± 0.4 O.S ± 0.4 
6. hCD59xhDAF 0.4 ± 0.3 0.5 ± 0.4 0.6 ± 0.3 1.0 ± 0.6 0.7± 0.3 
7. hDAFxhMCP 0.3 ± 0.4 0.5 ± 0.3 O.S ± 0.5 O.S ± 0.4 0.7 ± 0.4 
I 
S. hCD59xhMCP 0.5 ± 0.6 0.5 ± 0.3 0.6 ± 0.5 i 0.6 ± 0.5 0.6 ± 0.5 
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Figure 3. Immunohistochemical staining of single and double transgenic mouse hearts. A. 
hCD55 mouse heart stained with anti-hCD55, B. negative control, C. hCD59xhCD46 stained 
for hCD59, D. hCD59xhCD46 heart stained for hCD46. hCD46 and hCD59 single transgenic 
hearts looked the same as hCD55 (A). This also holds for the other double transgenic hearts. 
A B 
c D 
Discussion 
The aim of our study was to compare the survival of single and double transgenic mouse 
hearts in the Langendorff circuit by means of ex vivo heart perfusion with human serum. 
Although it is important to find out which protein, or combination of proteins can be used to 
prevent HAR, there are remarkably few functional comparisons of complement regulatory 
proteins in the literature (12). Our transgenic mouse lines were analyzed by Southern blot 
analysis of genomic tail DNA (10;11), but also by immunohistochemistry and F ACS analysis 
of splenocytes. We found that the entire genomic DNA encoding for human complement 
regulatory protein was successfully integrated into the mouse genome and that the proteins 
were expressed on the vascular endothelium. Mouse hearts transgenic for hCD55 or hCD46 
perfused with human serum survived significantly longer than their non-transgenic controls, 
which confirms earlier results found by us and others (5;7;9). However, hCD59 hearts 
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survived as long as their controls. Others have found (13-18) that hCD55, hCD46 and hCD59 
all give protection against HAR. The controversy about CD59 could firstly be explained by 
the fact that our hCD59 mice had 3 integrated copies of the entire DNA encoding for hCD59 
and may therefore have a lower expression of the protein, resulting in a worse protection 
against HAR. Additionally, hCD55 and hCD46 had 10 and 10-12 integrated copies, 
respectively, and their expression may be higher, leading to a better protection against HAR. 
In addition, it is proven that CRPs are not that species-specific, but the amount of expression 
of the CRPs is important (19). Secondly, because of the wide range in beating times, our 
hCD59 mouse hearts just did not survive significantly longer than their controls, but a trend is 
present. 
About the double transgenes we have found that hCD59xhCD55 and hCD59xhCD46 hearts 
beated longer as compared to non-transgenic controls, but not compared to single transgenes. 
Studies with hCD59xhCD55 transgenic mice (20) and pigs (21) support our results. To our 
knowledge, the hCD59xhCD46 combination has not been tested before. 
hCD55xhCD46 hearts survived as long as their controls, and significantly shorter as 
compared to hCD55 or hCD46 single transgenic mice. In the literature one in vitro study 
could be found which reports that CD55 and CD46 synergize in preventing C3b deposition on 
the cell surface, and that the activities of CD55 and CD46, when present together~ are greater 
than the sum of the two proteins individually (22). This finding is in contrast to our findings. 
Our result suggests that CD55 and CD46 have a negative effect on each other. We may 
hypothesize that, since there is no difference in expression level between the CD55 and CD46 
proteins, the discrepancy between the single (hCD55, hCD46) and double (hCD55xhCD46) 
transgenic mice can be due to the fact that there is a functional hindrance between hCD55 and 
hCD46. 
The immunohistochemical staining with antihuman C3, C9, IgA, IgG and IgM antibodies of 
all hearts did not give extra information. No difference in C3 and C9 was found probably due 
to the fact that staining was performed after cessation ofheartbeats~ i.e. rejection of the hearts, 
at the end of the perfusion period. This also holds for 19A, IgG and IgM depositions. 19A 
deposition can be found when the alternative pathway of the complementcascade is activated. 
IgM and IgG are present if the classical pathway is activated. In our model 19A, IgG and IgM 
antibodies reached similar levels. We might conclude that the classical and the alternative 
pathways both contribute to the activation of the complement system, leading to endothelial 
cell damage, represented by cessation of heartbeats. 
We conclude that mouse hearts transgenic for hCD46 or hCD55 are protected against HAR, 
whereas hCD59 hearts are not. Furthermore, that hCD59xhCD55 and hCD59xhCD46 double 
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transgenic mouse hearts are better protected against HAR than their controls, but they are not 
better protected as compared to single transgenic mouse hearts (hCD55 or hCD46), However, 
the combination hCD55xhCD46 is even worse than hCD55 or hCD46 alone, In both single 
and double transgenic, and non-transgenic mouse hearts equal levels of antihuman C3c, C9, 
IgA, IgG, and IgM depositions have been found. The most important conclusion of our study 
is that it is enough to be transgenic for one complement regulatory protein, which inhibits at 
the level of C3, to prevent HAR, 
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Abstract 
In recent experiments, in which we compared hDAF transgenic rat hearts perfused with 15% 
human serum in the Langendorff device and hDAF rat hearts transplanted into cynomolgns 
monkeys, we demonstrated that in the ex vivo heart perfusion model both homozygous and 
heterozygous hDAF hearts survived longer as non-transgenic controls. Surprisingly, we found 
that only homozygous hDAF hearts were protected against hyperacute rejection in vivo. The 
first aim of this study was to detennine whether perfusion of mouse hearts with higher human 
serum concentrations or human blood might explain some of the differences found in survival 
time of the recently performed experiments with rat heart xenografts. Secondly, we 
investigated whether the observed differences in survival times of rat xenografts between in 
vivo and ex vivo transplantation would also hold for mouse hearts transgenic for hDAF. An 
ex vivo model was used to perfuse hDAF mouse hearts and controls with human serum or 
blood, and hDAF transgenic hearts and controls were transplanted into cynomolgns monkeys. 
hDAF transgenic mouse hearts survived significantly longer than their controls when perfused 
with 15% human serum, but no difference was found when 30% human serum was used, or 
when these hearts were transplanted into cynomolgus monkeys. However, in both in vivo and 
ex vivo model the amount of PMNs adhering to the vascular endothelium was significantly 
lower in hDAF transgenes as compared to their controls. In conclusion, in the ex vivo 
situation, the efficacy of hD AF transgenesis in preventing HAR is limited by serum 
complement concentration. 
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Introduction 
As complement plays a dominant role in the process of hyperacute rejection (BAR) of 
xenografts, regulation of complement activation is required to overcome HAR. This can be 
accomplished by over-expression in the donor of, preferably, recipient-type complement 
regulatory proteins (CRPs), such as Decay Accelerating Factor (DAF, CD55), Membrane 
Cofactor Protein (MCP, CD46) or Protectin (CD59). Inbibition of HAR has been achieved 
using this transgenic approach with varying success, depending on the experimental model (1-
9). The Langendorff perfusion system has been employed by us to evaluate the relative 
importance of human CRPs on the perfonnance of mouse hearts perfused with human serum. 
In this ex vivo model ofxenotransplantation, we showed that over-expression of human MCP 
(hCD46) or human DAF (hCD55), but not hCD59, protected hearts against hyperacute 
rejection (10-13). 
Recently, we perfused hDAF transgenic rat hearts with human serum in the Langendorff 
device and the results were compared with the survival data of hDAF rat hearts transplanted 
into cynomolgus monkeys. Surprisingly, we found that both homozygous and heterozygous 
hDAF-hearts, when perfused with human serum in the ex vivo perfusion system, showed 
prolonged survival in contrast to control hearts, whereas in vivo only homozygous hearts were 
protected against HAR (14). This finding might be explained by the assumption that HAR of 
a xenograft is determined by the balance between protection at the site of the graft (i.e. the 
level of expression ofhDAF) and the magnitude of the immunological complement-mediated 
assault provided by the recipient (i.e. complement levels). It may be speculated that a 
combination of various transgenic CRPs is more effective in protecting the xenogeneic graft. 
With the availability of multiple transgenic mice strains, we wanted to test and examine the 
predictive value of the ex vivo heart perfusion system for in vivo xenotransplantation fIrst, 
before we studied the relevance of multiple transgenics in modifIcation of xenogeneic 
rejection. Our main goal was to investigate whether serum concentration in relation to a 
certain level of hDAF expression in mouse hearts influences HAR and activation of 
endothelial cells leading to adherence of PMN s. And furthermore, to determine whether 
perfusion of mouse hearts with higher human serum dosages (tipping of the balance) or 
human blood (presence of cells) might explain some of the differences found in survival times 
of the recently performed experiments with rat heart xenografts. 
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Materials and Methods 
Animals 
Mice 
Heterozygous and homozygous BIOCBA-mice transgenic for hDAF and their non-transgenic 
counterparts were used. The animals weighed approximately 20 grams and were twelve40-
sixteen weeks old. Production of these transgenic mice was accomplished by injecting mouse 
ova with the entire genomic DNA encoding for hDAF using yeast artificial chromosomes 
(YAC), which has been described by Yannoutsos et al. (13). The hDAF-mouse strain used, 
contained 10 integrated copies in the genome and the expression of the relevant protein on 
spleen, kidney, heart, liver and lung was verified by anti-hDAF (4). Splenocytes of mice 
traosgenic for hDAF showed a strong expression of the traosgene by FACS analysis. The 
animals were housed in a certified animal breeding facility under standard conditions and had 
free access to standard mouse chow (AM II, Hope Farms, Woerden, The Netherlands) and 
water acidified to pH 2.2 ad libitum. The experimental protocols adhered to the rules laid 
down in the Dutch Animal Experimentation Act (1977) and the published Guidelines on the 
Protection of Experimental Animals by the Council of the EC (1986). The Committee on 
Animal Research of Erasmus university Medical Centre, Rotterdam, The Netherlands, and 
that of the Biomedical Primate Research Centre (monkey experiments), Rijswijk, The 
Netherlands had given pennission to perform the experimental protocols. 
Cynomolgus monkeys 
Two cynomolgus monkeys (macaca fascicularis) of the Biomedical Primate Research Centre 
(BPRC), Rijswijk, The Netherlands, were used as recipients. The first monkey was a five year 
old male with blood type AB, weighing 8100 grams and the second a six year old female with 
blood type A, weighing 4900 grams. The animals had been used for allogeneic skin 
transplantation experiments more than six months before the present study. Their 
hematological and immunological status was normal. The animals were housed in a certified 
animal facility at the BPRC (Rijswijk, The Netherlands) under standard conditions. 
The Langendorff circuit 
All mice were sedated with Diazepam (5 mg! kg Lm.) to reduce the escape risk. Prior to the 
surgical procedure, they were anaesthetised with iso-flurane inhalation (pharmachemie B.V. 
Haarlem, Holland). The abdominal wall was opened and 0.6 mL Heparin (50 TIJ/mL) was 
injected into the abdominal inferior vena cava. Via two lateral incisions the thorax was 
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opened and the heart was removed quickly. A 22~gauge indwelling cannula was inserted into 
the aorta and secured with a 4.0 ligature. The heart was contiguously perfused with 
oxygenated Krebs-Henseleit solution (NaCI: 1I8.0mM, KCI: 4.70mM, CaC!,: 2.52mM. 
MgSO,: 1.66Jlli'V!, NaHC03: 24.88mM, KH,PO,: 1.18mM, glucose: 5.55mM, 
Natriumpyruvate: 2.0mM (Merck, Darmstadt, Germany)) using a syringe and directly linked 
to the Langendorff device. The Langendorff circuit consisted of a roller pump, two double-
layered glass reservoirs of 500 rnL and 150 rnL connected with the heart via a three-way cock, 
and a water column providing a perfusion pressure of 70 crnH20. Oxygenation was obtained 
by continuous gassing with a mixture of 95% 02 and 5% CO2 (carbogen) through 10 meters 
of silastic tubing, which was inserted into the tubing of the perfusion circuit, providing a P02 
of 300 to 600 mmHg. A temperature of 37 °c of the perfusate solution was maintained by 
heated water running between the double~layered glass of the reservoirs and along the final 
part of the perfusion system. The largest reservoir was filled with a solution containing 30% 
Haemaccel and 70% Krebs-Henseleit buffer. Haemaccel was added to optimize the 
perfonnance of the mouse hearts during perfusion. The smaIl reservoir was filled with human 
serum or human blood diluted with the solution from the large reservoir. Before switching to 
human serum or blood, acclimatisation of the hearts was accomplished by perfusion with 
Krebs-Henseleit-Haemaccel solution for 10 minutes. Hearts were monitored constantly for 
heart rate and flow using multichannel registration. Survival time was defmed as the time 
between the start ofserumlblood perfusion and complete cessation of heartbeats. 
Heart transplantation 
The surgical procedure of removal of the heart was the same as described above, except that 
the mice were anaesthetised with ether. 
The monkeys were pre-medicated with Ketamin (100 mg) and Atropin (0.4 mg), and 
intubated after administration of Xylocain spray. Iso-flurane inhalation was nsed as 
anaesthetic. During the operation infusion with NaCI + glucose 2.5% was given. The 
inguineal area of the monkey was opened and the left femoral artery was dissected. An 
arterial line (polyethylene tubing, diameter 1.4 =) was inserted and fIXed with a 4.0 ligature, 
at the end of this arterial line a three-way cock was attached. After flushing the line, 
heterotopic heart xenotransplantation was perfonned by connecting the 22~gauge cannula 
attached to the murine aorta (as described above) with the arterial line from the monkey. Only 
survival time was measured, which was defmed as the time between the start of blood 
perfusion and complete cessation of heartbeats. Venous blood pumped from the mouse heart 
(about 3 rnL per minute) was not recirculated into the monkey, but was coliected in a jar. In 
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each monkey six transplantations were performed: three transgenic hearts and three controls, 
which sequentially were connected to the same cannula. After the procedure, the monkeys 
were euthanised. 
Human serum and blood 
Frozen, pooled, human O-type was obtained from the blood bank of the University Hospital 
Dijkzigt (Rotterdam, The Netherlands), Human serum was made out of human plasma by 
adding 0,5 mL Thrombin to 200 mL human plasma, inducing clotting, After removal of the 
clot, the serum was diluted with Krebs-Henseleit-Haemaccel solution to obtain perfusion 
concentrations of 15% and 30%. For each experiment fresh human serum was prepared. 
O-type EDTA blood was collected in 9 mL test tubes containing EDTA at the blood bank and 
immediately processed as follows, After centrifugation (10 minutes, 2000 rpm), the plasma 
was removed and replaced by a similar volume of serum, which was prepared as described 
above, To obtain the 15% solution for perfusion, the blood was diluted with Krebs-Henseleit-
Haemaccel stock solution. Finally, 0.1 mL heparin (50 mlmL) was added to this diluted 
solution to achieve anticoagulation. 
Experimental groups 
The experimental groups consisted ofhDAF transgenic hearts and their controls perfused with 
either 15% and 30% human serum, or 15% human blood. In addition, in two groups hDAF 
transgenic and control hearts were transplanted into cynomolgus monkeys. 
Immunohistochemistry 
After cessation of heartbeats each heart was cut in two. One sample was fIXed in 3.6% 
formaldehyde solution. Following dehydration and paraffin embedding, 4 11m-thick sections 
were cut and stained with Hematoxylin & Eosin (H&E). The other part of the sample was 
snap frozen and stored at -80 'C until sectioned for inununohistochemistry (C3c and C9). 
Frozen tissue sections (7 11m-thick) were prepared in a Microm HM 560 cryostat and stained 
with rabbit anti-human C3c complement Fluorescin-Iso-Thio-Cyanate (PITC) and rabbit anti-
human C9. 
C3c staining: the frozen sections were thawed at room temperature for I hour, fIXed with 
acetone for 10 minutes and air dried for 15 minutes. With a Peroxidase-Anti-
Peroxidase(P AP)-pen circles were drawn around the tissue sections and washed with PBS 
0.1% BSA three times. Diluted (1:160) anti-human C3c FITC-antibody was added to the 
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sections and incubated for 60 minutes in wet surroundings. The abundant antibody was 
washed away with water and the sections were put in Mayer's hematoxylin for 40 seconds 
and secondly in an ammonia-solution. After dehydration, the sections were put in Xylene. The 
slides were covered with Entalan. 
C9 staining: the frozen sections were thawed at room temperature for 1 hour, fixed with 
acetone for 10 minutes and air dried for 15 minutes. With a PAP-pen circles were drawn 
around the tissue sections and washed with PBS 0.1 % BSA three times. Sections were 
incubated for 5 minutes with peroxidase block (Envision kit) in wet surroundings and cleanse 
three times with PBS. Diluted (l :400) anti-human C9-antibody was added and the sections 
were incubated for 30-60 minutes in wet surroundings. Again sections were washed three 
times with PBS. Sections were incubated with 'labelled polymer-HRP' (Envision kit) for 30 
minutes and washed three times with PBS. Diaminobenzidine (DAB) (Envision) was added 
and sections were incubated for 5-15 minutes. The DAB-reaction was stopped by flushing 
with water for 5 minutes. Sections were put in Mayer's haematoxylin for 40 seconds, washed, 
and were then put in an ammonia-solution. Dehydration was followed by a Xylene step. The 
slides were covered with Entalan. 
Anti-human C3c-stained sections and anti-human C9-stained sections were examined under a 
fluorescence microscope and a light microscope, respectively. The intensity of C3c- and C9-
expression on the heart tissues was scored blindly via semi-quantitative analysis: 0 ::::: no 
staining, 0.5 = mild staining, 1 = dense staining. 
All transgenic and non-transgenic mouse hearts of both the monkey and Langendorff model 
were stained for H&E, C3c and C9. Using H&E stained sections, the transplanted transgenic 
and non-transgenic hearts were examined for edema, hemorrhage, microthrombosis and 
polymorphonuclear (PMN) cell adhesion. In twenty vessels the amount of PMN-cells 
adhering to the vessel wall and the amount of cells lying intraluminally was counted. The 
percentage of cells adhering to the vessel wall was calculated. This was also done for the 
transgenic and non-transgenic hearts perfused with human blood in the Langendorff device. 
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Statistical analysis 
The non-parametric Mann-'Whitney test was used to analyse the differences in survival times 
between the experimental groups. The difference between the experimental groups in 
percentage PMN-adhesion and C3c-deposition was done by using the Student's t-test. The 
level of significance being P < .05. 
Results 
Langendorff perfusions 
Survival times 
When heat-inactivated human serum is used for perfusion, the hearts kept on beating until 45-
60 minutes (data not shown). The results obtained in the experimenral groups are sunnnarised 
in table 1. Control hearts perfused with 15% human serum had a mean survival time (MST) of 
4.4 minutes, whereas transgenes showed a MST of 24 minutes (P = .006). The survival times 
following perfusion with 30% human serum were shorter than after perfusion with 15% 
serum for both the controls and the transgenic hearts (MSTs of 1.0 and 1.5 minutes with P-
values of .003 and .005, respectively). Perfusion of control hearts with 15% human blood led 
to a better performance than perfusion of control hearts with serum, leading to a MST of 17 
minutes (group I versus group 5, P = .065). Transgenes perfused with blood performed 
similarly as blood-perfused controls: MST of 12 minutes (P = .223). 
The mean heart rate for both hDAF transgenes and controls measured by multichannel 
registration was 100 beats I min. After switching to human serum or blood, it remained the 
same for hDAF transgenes and decreased slightly in the control group to 90 beats / min. 
During the 10 minutes perfusion with Krebs-Henseleit the flow trhough transgenic and non-
transgenic hearts remained constant at a mean level of 7 mL I min. After switching to human 
serum the flow lingered. However, when switched to human blood, the flow decreased to a 
mean level of 3 mL / min. The flow became 0 mL / min when the hearts stopped beating. 
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Figure 1. A medium sized vessel of a non~transgenic heart with "hairy" endothelium (H&E, 
400x). HAR is caused by xenogeneic natural antibody and complement depositions, resulting 
in activation of endothelial cells. The major features of HAR in vivo are platelet aggregation 
and adhesion, fibrin deposition, interstitial edema. hemorrhage, PMN adhesion, 
vasoconstriction and "hairy' endothelium. In the Langendorff ex vivo perfusion system these 
features are not prominent. 
Figure 3. A medium sized vessel of a non~transgenic heart which was transplanted into a 
primate (H&E, 400x). Myocardial edema, hemorrage and micro-thrombosis, characterised by 
fibrin deposition and deposition of erythrocytes and platelets can be seen. Furthermore, PMN 
infiltration and adhesion was observed. 
77 
Table 1. Survival times and mean survival times (MST) of hDAF transgenic mouse hearts 
and their controls perfused with 15% and 30% human serum (HS), and 15% human blood 
(HB) in the Langendorff system. Three hDAF transgenic mouse hearts and three controls 
were transplanted into each monkey. 
Mouse hearts + 15% HS Survival time (minutes) MST (minutes) 
Group I: BIOCBA (n-5) 3-4-4-5-6 14.4 
Group 2: hDAF (n-8) 5-15-22-29-30-30-30-30 24 
Mouse hearts + 30% HS 
Group 3: BlOCBA (n-6) 1-1-1-1-1-1 . 1.0 
Group 4: hDAF (n=4) 1-1-2-2 1.5 
Mouse hearts + 15% HB 
, Group 5: BIOCBA (n-13) 1-3-4-5-7-10-17-28-30-30-30-30-30 17 
Group 6: hDAF (n-8) 1-2-2-3-5-24-30-30 . 12 
:Mouse hearts to monkeys Survival times (minutes) MST (minutes) 
Group 7: BIOCBA (n-6) 14-6-8-9-9-13 8.2 
i Group 8: hDAF (n-6) 5-6-9-11-12-13 9.3 
P-values oflable I: 
group 1 versus group 2 (P=.006), group I versus group 3 (P=.003), group 3 versus group 5 
(P=.001), group 2 versus group 4 (P=.005), group I versus group 7 (P=.033), group 2 versus 
group 8 (P=.016), group 3 versus group 7 (P=.002), group 4 versus group 8 (P=.OI). 
Histology 
Microscopic examination ofH&E stained sections of the transgenic and non-transgenic hearts 
perfused with human serum showed normal cell architecture of the cardiomyocytes; ""hairy" 
endothelium was only seen in rejected non-transgenic hearts (figure 1). The major features of 
HAR in vivo are platelet aggregation and adhesion, vasoconstriction, fibrin deposition, 
interstitial edema, hemorrhage, PIYrN adhesion and "hairy' endothelium. In the Langendorff 
ex vivo perfusion system these features are not prominent. H&E sections of both non-
transgenic and transgenic hearts perfused with human blood showed edema, hemorrage and 
presence of PIYrNs. A difference in percentage PIYrN-adhesion to the vascular endothelium 
was found: transgenic hearts (46 ± 12%) showed a significantly lower amount of PMN-
adherence than non-transgenic hearts (73 ± 9%) (P = .0001). 
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Complement deposition 
C3c-levels of groups 1 and 2 in relation to survival time showed that in both groups rejection 
is not necessarily related to C3c deposition. In the controls 2 out of 4 rejected hearts showed 
no C3c deposition, whereas 2 showed a marked deposition. In the transgenic hearts 2 out of 6 
were negative and 4 showed moderate to strong C3c deposition. In figure 2 C3c-levcls are 
given as observed in hearts perfused with 15% human blood. Here, controls showed 
significantly more deposition of C3c than transgenic hearts (mean scores of 0.65 and 0.25, 
respectively; P < .05). Light microscopical examination of tissues stained for anti-human C9 
antibodies, which were perfused with human serum and blood, exhibited no difference in 
amount of deposition of C9. In both non-transgenic and transgenic hearts C3c and C9 
depositions were mainly localised at the vascular endothelium and diffuse along the 
cardiomyocytes. 
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Figure 2. C3c-Ievels in hDAF transgenic mouse hearts and controls perfused with 15% 
human blood. C3c was mainly localised at the vascular endothelium and diffuse along the 
cardiomyocytes. On the x-axis the experimental groups are given. The y-axis depicts the 
semi-quantitative C3c-levels with 0 = no, 0.5 = mild and 1 = dense staining. 
Mouse-to-monkey heart transplantation 
Survival times 
The data from the two monkeys were pooled. Each monkey received control and hDAF 
hearts. The survival times obtained in groups 7 and 8 are given in table 1. There was no 
significant difference in survival times (P ~ .517); controls had a MST of 8.2 minutes; 
transgenic hearts had a MST of9.3 minutes. 
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Histology 
Both transgenic and non-transgenic hearts exhibited myocardial edema. In controls hemorrage 
and micro-thrombosis, characterised by fibrin depostion and deposition of erythrocytes and 
platelets, was seen (figure 3). Furthennorc, PMN infiltration and adhesion was observed. 
Rejected transgenic hearts showed less hemorrhage, less micro~thrombosis, and the amount of 
PMNs adhering to the vessel wall was significantly lower than in controls: 59 ± 11% in 
controls versus 32 ± 6% in hDAF trans genies (P = .000). Both transgenic and non-transgenic 
mouse hearts showed a similar diffuse deposition of C3c and C9 on the vascular endothelium 
and cardiomyocytes. 
Discussion 
HAR is the major cause of organ failure in discordant xenogeneic transplantation models, and 
is caused by activation of the complement, binding ofxenoreactive natural antibodies (XNA) 
to the donor endothelium and by blood cell-endothelial cell interactions. Complement is 
nonnally controlled by regulatory factors. Manipulation at the level of complement is a 
manner to prevent HAR. To this end, DAF-, MCP- and CD59-transgenic donor animals 
(mouse/rat/pig) have been generated and tested in ex vivo and in vivo models. In our study, 
one of our aims was to detennine whether the intensity of endothelial cell activation leads to 
activation of PMNs and clotting, and if, at a certain hDAF expression, the process was serum 
dosage dependent. We found that hDAF mouse hearts were markedly protected from HAR 
when perfused with 15% human serum, whereas such protection was not observed when these 
hearts were transplanted in cynomolgus monkeys. However, in the latter model we did 
observe other relevant differences between transgenic and non-transgenic hearts. Transgenic 
hearts showed less hemorrage and thrombosis and fewer PMNs adhering to the vascular 
endothelium as compared to non-transgenic controls. Apparently. this protection was not 
sufficient to produce prolonged survival in a non-immunosuppressed monkey. In contrast, we 
have earlier found differences in survival times between hDAF transgenic rat hearts and their 
controls transplanted into non-immunosuppressed monkeys (14), and in only one study, in 
which two hDAFlhCD59 transgenic porcine cardiac xenografts and their controls were 
transplanted into non-immunosuppressed baboons, controls rejected in 60-90 minutes and 
transgenic xenografts survived for 6 and 69 hours (15). In our primate model, we did not 
observe a difference in xenograft survival. This might be due to the amount of complement 
present in the blood and the number of CRPs present on transgenic vascular endothelium. 
80 
The next objective of our study was to see whether the differences between ex-vivo and in 
vivo might disappear when the in-vivo situation was mimicked. This was done 1) by 
increasing the human serum concentration from 15% to 30% and 2) by perfusion with human 
blood. And indeed, the protective effect ofhDAF seemed to vanish. The mean survival times 
of both transgenic and non-transgenic mouse hearts perfused with 30% human serum were 
not significantly different. These results indicate that the efficacy of transgenesis is related in 
a dose-dependent manner with the human serum concentration. Consequently, a relative 
excess of complement abolishes the protective effect of CRPs. This dysbalance between 
complement effectors and inhibitors leads to an overwhelming complement-mediated attack 
with rapid endothelium destruction. resulting in a short graft survival time. bDAF did not 
protect against HAR when hearts were perfused with 15% human blood, despite of a low 
serum concentration. In our model, it was observed that bDAF had a significant inhibitory 
effcct on the adhesion of leukocytes to the vascular endothelium and deposition of C3c. This 
may be explained by the following theory: once the complement cascade is activated, the 
anaphylatoxins C3a and CSa, are released, resulting in chemotaxis of leukocytes to 
inflammatory sites, where they produce cytokines and mediate the inflammatory response. Of 
the vatious membrane-associated complement inhibitors, DAF, MCP and CRI may be the 
most useful because they prevent generation of the anaphylatoxins C3a and C5a, as well as 
the membrane attack complex (16;17). Furthermore, a lower amount of adhering leukocytes 
in transgenic mouse hearts was found, because the C3-pathway of the complement cascade is 
blocked by hDAF, which leads to lower levels of C3a and CSa, and consequently to less 
chemotaxis and leukocyte adherencc. In the literature this theory is supported by other 
research groups: expression of DAF should decrease the production of CSa and may reduce 
the degree of neutrophil infiltration into the organs (IS); CDSS (DAF) reduces the generation 
ofC3a, CSa, iC3b, and CSb-7, all of which have deleterious effects on graft survival (17), and 
activation of complement on endothelial surfaces promotes neutrophil adhesion (18;19). 
In sununary, in our model, ex-vivo human serum perfused mouse hearts expressing bDAF 
were protected against HAR, whereas in vivo hDAF mouse hearts were not. Differences in 
graft survival were only found, when perfusion with a low serum concentration was 
employed. Using a higher serum concentration or blood, no differences in survival times were 
found, but differences in edema, hemorrage, complement depositions and PMN adherence did 
occur. The Langendorff perfusion model allows evaluation of CRPs, but only in the early 
stages of complement-mediated injury, including the adherence ofPMNs. 
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Abstract 
Background. Production of transgenic pigs for multiple transgenes is part of a potential 
strategy to prevent immunological events involved in xenograft rejection. Use of a genetically 
engineerable rodent as a donor in primates could allow testing in vivo of the effects of 
different transgenes on controlling xenograft rejection. As a first step in the development of a 
donor containing multiple transgenes, transgenic rats for human decay accelerating factor 
(DAF) were used as heart donors to test their resistance against complement (C)-mediated 
rejection by non-human primates. 
Materials and Methods. Transgenic rats were generated by using a construct containing the 
human DAF cDNA under the transcriptional control of the endothelial cell (EC)-specific 
human ICAM-2 promoter. DAF expression was evaluated by immunohistology and by FACS 
analysis of purified ECs. Resistance of transgenic hearts against C-mediated damage was 
evaluated by ex vivo perfusion with human serum and by transplantation into cynomolgus 
monkeys. 
Results. Immunohistological analysis of DAF expression in several organs from two 
transgenic lines showed uniform expression on the endothelium of all blood vessels. ECs 
purified from transgenic hearts showed 50% DAF expression compared to human ECs, and 
>70% reduction of C-dependent cell lysis compared to control rat ECs. Hemizygous 
transgenic hearts petfused with human serum showed normal function for >60 min vs. 11.2 ± 
1.7 min in controls. Hemi- or homozygous transgenic hearts transplanted into cynomolgus 
monkeys showed longer survival (15.2 ± 7 min and >4.5 hr, respectively) than controls (5.5 ± 
1.4 min). In contrast to hyperacutely rejected control hearts, rejected homozygous DAF hearts 
showed signs of acute vascular rejection (A VR) characterized by edema, hemorrhage, and an 
intense PMN infiltration. 
Conclusions. We demonstrate that endothelial-specific DAF expression increased heart 
transplant survival in a rat-to-primate model of xenotransplantation. This will aid in the 
analysis of A VR and of new genes that may inhibit this form of rejection, thus helping to 
define strategies for the production of transgenic pigs. 
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Introdnction 
The use of porcine organs for clinical transplantation is an approach in overcoming the 
shortage of human organs. The first obstacle to xenotransplantation is the recipient's innate 
immune response which results in xenograft hyperaeute rejeetion (HAR) (1). Rejection of 
transplants performed between discordant species, such as pig~to-primates, involves the 
binding of prefonned xenogeneie natural antibodies (XNA) directed against Galal-3GaI 
epitopes on the endothelial eell (EC) surface (2;3). Interaction between XNA and their targets 
promotes complement (C) activation, leading to graft endothelium injury and activation (4-7). 
Prevention of xenograft HAR has been successfully achieved by either inhibition of XNA 
binding through depletion of XNA or reduetion of Galal-3Gal expression on ECs (8;9), or 
blockade of complement activation (10). Transgenic pigs expressing human complement 
regulatory proteins (CRPs). including decay accelerating factor (DAF) and/or CD59, have 
been produced to avoid complement-mediated graft damage (11-13). Dramatic improvement 
of xenograft survival has been obtained using these transgenic transplants in the pig-to-
primate model of xenotransplantation (14-16). These studies demonstrated that human DAF 
and/or CD59 expression on graft ECs. in association with antibody depletion and/or 
immunosuppressive regimen, efficiently overcome HAR. However, optimal transgene 
expression levels as well as its optimal tissue distribution remained to be detennined. 
Since xenograft HAR can be circumvented by the use of transgenic animals for CRPs, 
humoral and eell-mediated processes involved in delayed xenograft rejeetion or A VR may be 
further controlled by the production of transgenic animals expressing other transgenes acting 
on these processes in addition to CRPs. To this end, prior to the generation of transgenic pigs, 
production of transgenic small laboratory animals is needed. These animals would not only 
serve as tools for analysis of DNA construction for transgenesis but more importantly would 
help us investigate in vivo the biological relevance of transgene expression on xenograft 
rejection. In addition, models bearing close resemblance to the pig-to-primate one may be 
particularly useful. In this regard, although transgenic mice have been used to define the 
expression of DNA construction (17;18) and their organs perfused ex vivo, their reduced size 
make it nearly impossible to graft their organs in primates. 
We previously established an in vivo experimental model for xenotransplantation using the rat 
as organ donor and an Old World primate (eynomolgus) as recipient. In this rat-to-primate 
combination, HAR occurred 5 min after vascular anastomosis, with features mimicking HAR 
(19) and EC injury (7) observed in the pig-lo-primate model. In addition. we demonstrated 
that, in vitro, human DAF and CD59 efficiently protect transfected xenogeneic rat ECs 
against cell lysis mediated by non-human primate sera (20). In the present study. we 
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investigated the ability of human DAF expressed by the endothelium to delay HAR by 
producing transgenic rats for the human DAF. Endothelium-specific transgene expression was 
analyzed by immunohistochemistry in tissue sections and quantitated in vitro by isolation of 
cardiac ECs followed by flow cytometry. Ex vivo perfusion of transgenic hearts with human 
serum demonstrated the ability of human DAF expression to prevent XNA and C-mediated 
organ damage. Correlation betvveen the DAP expression level on graft Ees and graft survival 
time was documented following cardiac heterotopic transplantation using hemizygous and 
homozygous transgenic rats as donors and unmodified cynomolgus as recipients. 
Histopathological features of acute vascular rejection (A VR) of DAF-expressing cardiac 
xenograft were characterized by polymorphonuclear leukocytes (PMN) infiltration, interstitial 
edema, and focal myocardium necrosis. 
Materials and Methods 
Generation of transgenic rats 
The plasmid expression vector phICAM2DAF (figure IA) contains a 1.9 kb EcoRI fragment 
of the human CD55 cDNA, 334 pb of the promoter region of the human intercellular adhesion 
molecule 2 (ICAM2) gene (nucleotides -292 to +44), a universal intron, and the SV40 polyA, 
as previously described (21). The 3.12 kb KpnI-SacI fragment was excised from 
phICAM2DAF and isolated by elektrophoresis through a 1 % agarose gel, electroeluted, 
purified through an Elutip column (Schleicher & Schull, Keene, NH), and diluted to a 
concentration of 2 nglmJ in 5 mM Tris-HCI and 0.1 mM EDTA, Ph 7.4. Fertilized rat eggs 
were recovered from superovulated Sprague Dawley (SD) females mated with SD males 
(Charles River, Saint-Aubin-Les-Elbeuf, France). DNA solution (2 nglfll) was microinjected 
into the male pronucleus and transferred into both oviducts of day 0 pseudopreguant SD 
females as previously described (22). 
Identification of the transgenic founder animals and their progeny was determined by 
polymerase chain reaction (PCR) analysis of genomic DNA obtained from tail biopsies 
digested with proteinase K in total volume of 450 fll for 16 hr at 56°C and then confirmed by 
Southern blots. PCR analysis was perforroed on 2 fll of the DNA solution diluted to 1/20 with 
oligonucleotides specific for human DAF (sense: 5'GAC GCT AGT AAT CAT GGG CD'; 
antisense: 5'TAG GAA AGG AAT CAC TCT CA3') for 30 cycles of amplification (94°C for 
30 sec; 50°C for 30 sec; 72eC for 30 sec). For Southern blot analysis, 10 flg of DNA was 
digested by BamHI, fractionated on 1 % agarose gel, and alkali blotted. Hybridization was 
carried out with a 32ap-dCTP-radiolabeled 3.12 kb KpnI-SacI fragment of the phICAM2DAF 
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construct uscd for microinjection as a probe (probe showed in figure lA). Determination of 
transgene copy number in genomic DNA from progeny and discrimination between 
hemizygous and homozygous rats was evaluated by probing a Southern blot of BamHI-
digested tail DNA and known quantities of the microinjected fragment diluted in genomic 
DNA, followed by PhosphorImager analysis (Molecular Dynamics, Sunnyvale, CAl. 
Endothelial cell (EC) isolation and culture 
ECs were isolated from heart and lung. Briefly, tissues collected on transgenic or 
nontransgenic animals were cut in small pieces and then incubated with 1.8 U/ml Dispase II 
(Boehringer Mannheim, Mannheim, Germany), 0.5 mglm! DNase I (Boehringer Mannheim) 
and 1% fetal calf serum (PCS) (Gibco BRL, Grand Island, NY) in Hank's buffered salt 
solution (HESS) (Gibco BRL) for 4 hr at 37'C. Biopsies were then incubated ovemight in 2 
fU/ml collagenase B (Boehringer Mannheim) at 4°C. Cell suspension was washed three times 
in HESS medium before being plated on gelatin-coated tissue culture dishes (Nunc, 
Napervile, IL). DAF-expressing porcine endothelial cells were isolated from transgenic pig 
aortas by collagenase digestion (1 VlmI; Boehringer Mannheim). Human umbilical vein 
endothelial cells (HUVEC) were prepared as previously described (23). Pnrity of EC 
preparations was checked by the uprake of Dil-Ac-LDL as previously described (20). 
Endothelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 
4.5 gIliter glucose (Gibco BRL) and supplemented with 20% serum [fetal calf serum (PCS) 
(Gibco BRL) and human serum for rat ECs and HVVECs, respectively], 5 fU/m! heparin, 200 
~glml Endothelial Cell Growth Supplement (Collaborative Biomedical Research, Becton 
Dickinson, San Jose, CAl, 2 mM glutamine, 100 U/m! penicillin, and 100 ~glml streptomycin 
(Gibco BRL). Cells were analyzed between passages I and 4. 
FACS analysis 
Endothelial cells (1-2 x 10' cells/sample) were suspended with trypsin-EDTA (Gibco BRL), 
washed twice with phosphate-buffered saline (PBS) containing 1% bovine serum albumin 
(BSA) and 0.01 % NaN" and then incubated on ice for 30 min with a saturating concentration 
of the relevant monoclonal antibody (MAb). This step was followed by three washes in cold 
1% BSAlO.l % NaN,IPBS. Staining with a FITC-labeled-F(ab')2 fragment of either goat anti-
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mouse, sheep anti-rabbit, or mouse anti-human immunoglobulin G (IgG) or IgM (Jackson 
Lab., West Grove, PAl was performed at 4'C for 30 min. Three washes in 1% BSAlO.l% 
NaN,lPBS were performed before fixing the cells in 1% paraformaldehyde in PBS. The 
following antibodies were used in this study: rabbit polyclonal serum anti-human von 
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Willebrand factor (vWf) (Dako, Trappes, France), anti-human DAF (lH4) MAb (CRTS, 
Nantes, France), and anti-rat ICAM-I MAb (SeiJ<agaku America, RockvilJe, MD). For 
analysis of human Ig binding on rat ECs, cells were incubated with purified human anti-
Galal-3Gal antibodies (10 ~g1ml, 100 ~V2 x 10' cells) for 30 min at 4'C, washed, and then 
incubated with specific FIFC-Iabeled goat F(ab')2 anti-human IgM (Fc~) or IgG (FcX) 
(Jackson Laboratories) antibodies. 
Analysis of complement activation was investigated following incubation of rat Ees with 
human serum (dilution 1:10) in DMEM medium for 30 min at 37'C. Immunostaining was 
performed using FITC-IabeJed anti-human factor B, C3, C4 MAb (Atlantic Antibodies, 
Stillwater, MN) and an anti-human C5b-9 polyclonal serum as first antibodies revealed using 
FITC-Iabeled goat anti-rabbit IgG or IgM (Jackson Lab). Fluorescence was measured on 
10,000 cells per sample using a F ACScalibur (Becton Dickinson). Data are depicted in 
histograms plotting mean fluorescence intensity (MFI) on a log scale (x-axis) versus cell 
number (y-axis). 
Complement-dependent cytotoxicity assay 
Cells were labeled with 51Cr (50 ~Ci/I x 10' cells) for I hr at 37'C. Protection of DAF-
expressing cells was assessed by incubating slCr-labeled rat Ees (2 x 104 cells) with 
cynomolgus primate serum (as a source of xenogeneic antibodies and complement) (100 j..ll, 
dilution 1:4 to 1:16) for 4 hr at 37'C. Chromium release was measured in supernatants, and 
the percentage of cell lysis was calculated by the following formula: (experimental epm - cpm 
medium only)/(IOO% lysis cpm - cpm medium only). All experiments were done in triplicate, 
and the results are expressed as the mean of the percentage of specific lysis ± SD values. 
Immunohistochemistry 
Tissues for immunohistology were included in OCT compound (Miles Laboratories, Elkhardt, 
IN) snap-frozen in precooled isopentane, and stored at _70°C until use. Human placenta and 
tissues from nontransgenic rats were included in every experiment as positive and negative 
controls, respectively. Frozen 5-).Ufl tissue sections were acetone fixed, hydrated with PBS, 
incubated with hydrogen peroxide at 0.15% in methanol for 20 min, blocked with rat serum at 
10% in PBS/J % BSA, and incubated at room temperature for 60 min with MAb at I 0 ~g/m1. 
Tissue sections were then incubated with biotin-conjugated horse anti-mouse IgG absorbed 
with rat serum proteins (Vector, Burlingame, CAl followed by horseradish peroxidase 
streptavidin (Vector) and developed with very intense purple (VIP kit, Vector). Slides were 
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then counter stained with hematoxilin and mounted with glycerol. The following antibodies 
were used in this study: anti-rabbit vWf, anti-human DAF (1H4), and purified human anti-
Galal-3Gal antibody. Negative controls were performed using an isotype-matched irrelevant 
MAb (3GS). Semi-quantitative analysis of DAF expression on endothelium was obtained by 
visual evaluation of the intensity of specific staining, which was ranked from 0 to 4 (0, no 
staining; 1, low intensity; 2, medium intensity; 3, high intensity; 4, very high intensity). 
Cardiac xenografts were analyzed for complement and xenogeneic antibody binding by 
immunofluorescence. Cynomolgus Ig binding was revealed through FITC-Iabeled goat 
F(ab')2 anti-human IgM (Fcll) or IgG (FcX) (Jackson Laboratories) antibodies. 
Ex vivo perfusion of transgenic hearts with human serum 
Rats were anesthetized with ether and the hearts were removed rapidly. A 22-gauge in-
dwelling cannula was introduced into the aorta and secured with a ligature. Using a syringe, 
the hearts were perfused immediatly with oxygenated perfusate and subsequently connected 
to Langendorff circuit. The circuit was oxygenated by continuous gassing with a mixture of 
95% 0, to 5% CO,. The perfusate was kept at 3rC by continuous heated water. The largest 
reservoir was filled with a solution containing 30% Haemaccel (Behring, Marburg, Germany) 
in Krebs-Henseleit buffer (in mM: NaCl 11S.0, KC14.7, CaCl, 2.52, MgSO. 1.66, NaHCO, 
24.SS, KH,PO. !.lS, glucose 5.55, sodium pyruvate 2.0). The small reservoir was filled with 
15% human serum (a pool of 20 human O-type plasma) diluted with the solution from the 
large reservoir. Before serum perfusion, hearts were allowed to stabilize by perfusing them 
with the Krebs-Henseleit-Haemaccel solution for 10 min. The hearts were monitored 
continuously for heart rate, apex amplitude, and flow by means of multichannel registration. 
Duration of heart function was defined as the time between the start of serum perfusion and 
complete cessation of heartbeats. Decomplementation was performed by heating of the serum 
for 1 hr at 56°C. Hemizygous rats (n = 5) from the transgenic line 52.2 were tested and 
compared to wild-type (WT) rats (n = 5). 
Cardiac xenografts transplanted into primates 
Transgenic and WT Sprague Dawley rats of 300-400 g body weight were used as donors and 
cynomolgus monkeys of 6-9 kg body weight were used as recipients. Heterotopic heart 
xenotransplantation was perfonned as previously described (19). To compare graft survival of 
hemizygous and homozygous transgenic hearts, one of each organ was concomitantly grafted 
onto the same recipient in each femoral vessel. Xenograft survival was determined by visual 
examination and palpation of the xenogeneic heart beating. Histological analysis of rejected 
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xenografts was performed on paraffin-embedded sections (5-~) stained with hematoxilin-
eosin. 
Statistical analysis 
All data (mean ± SD) were analyzed using the Student's t-test, with P < .05 being the level of 
significance. 
Results 
Production of human DAF transgenic rats and transgene integration analysis 
A total of 754 eggs was microinjected and subsequently reimplanted into 37 pseudopregnant 
foster mothers, 27 of whom gave birth to 145 rats. Transgene integration was first detected by 
PCR in six founder animals and then confinned by Southern blot performed on genomic 
DNA. Figure 1 shows the presence of human DAF sequence in a major restriction fragment of 
3.1 kb in these transgenic lines as determined by hybridizing Southern blots, using the 
ICAM2DAF cDNA construct as a probe. The hybridization pattern revealed that multiple 
copy numbers of transgenes, in a head-to-tail orientation, had been integrated in all of these 
animals within one integration site, with the exception of line 70.8. Evaluation was done by 
comparing the size and intensity of hybridized fragment with known amounts of the 
microinjected fragment. High copy numbers (10 to 100) were observed in transgenic rats 
58.3, 62.3 and 70.8. The transgene was transmitted to about 50% of the progeny for founders 
52.2, 52.4, 62.3 and 70.8 (37%, 37%, 50%, and 50%, respectively). In contrast, a low 
transmission rate of the transgene to the offspring was obtained with founders 54.9 (8%) and 
58.3 «3%), which suggests that the germ-line in these founders was mosaic for DAF 
integration. 
Tissue expression of human DAF in transgenic rats 
Expression of human DAF was investigated in several organs from transgenic rats, including 
heart, kidney, liver, and lung, and on lymphoid organs (thymus, spleen). Cryosections of 
tissues were analyzed by inununohistology with an anti-human DAF MAb and compared to 
tissues from nontransgenic control rats. Consistent levels of DAF were detectable in tissues 
on progeny from lines 52.2 and 62.3. A low level ofDAF was observed on line 52.4, while no 
expression was obtained for the lines 54.9, 58.3 and 70.8. For both transgenic lines (52.2 and 
62.3), ECs expressing the transgene were detected in all analyzed tissues, including heart, 
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kidney, lung, and liver. In these organs, DAF expression was restricted to both vascular (large 
and medium size vessels) and capillar endothelium as determined by comparison with the 
pattern of staining obtained with an antibody directed to vWf (data not sbown). All tissues 
analyzed from rat 52.2 showed higher expression of human DAF than those in corresponding 
organs from line 62.3. The nontransgenic (WT) control rats showed no staining of the tissues 
analyzed. Specific stainings for human DAF obtained in heart and kidney from an 
hemizygous transgenic rat (line 52.2) are presented in figure 2. Confmnation of endothelium-
specific DAF expression in transgenic hearts was achieved by comparison with the pattern of 
staining obtained with purified human antiGalal-3Gal (7). Relative levels ofDAF expression 
on cells from these tissues were compared and are summarized on figure 3. Expression was 
seen in a very small fraction of spleen cells in the white pulp. Similarly, a small fraction of 
medular thymic cells with dendritic prolongations showed expression of the transgene. High 
levels of expression were also detected in a fraction of granulocytes (7-10%) after indirect 
immunofluorescence labeling of leukocytes, red cells, and platelets followed by flow 
cytometry analysis (data not shown). 
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Figure 1. Analysis of transgene integration in transgenic rats. (A) Design of ICAM2DAF 
cDNA construct used for microinjection. (B) Southern blot from transgenic rats (DAF+1.). 
Genomic DNA (10 fLg) was digested by BamHI, separated through 1% agarose gel 
electrophoresis, and blotted. Known copy numbers of the microinjected fragment diluted into 
genomic DNA from a non-transgenic rat were used as controls. Blot was hybridized with a 
,':12p_dCTP labeled cDNA probe encoding the microinjected cDNA sequences (3.1 kb). 
BamHI releases a 3.1 kb fragment (arrow). 
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Figure 2. Expression of human DAF in transgenic rat tissues. Frozen sections (5 MID) from 
transgenic (hemizygous DAr!- rat from line 52.2) or wild type (WT) rat tissues were fixed in 
acetone for 10 min at room temperature, air-dried, and stained using an indirect 
irnmunoperoxydase technique. (A) Immunostaining of serial tissue sections from kidney or 
heart was performed with an anti-human DAF MAb as first antibody (magnification 200x). 
Negative controls were perfonned using an isotype-matched irrelevant MAb (data not 
shown). (B) Immunostaining of DAF+/· transgenic rat heart with human anti-GalC<I-3Gal 
antibodies or an antihuman DAF Mab as first antibody followed by staining with a 
peroxidase-labeled antihuman or anti-mouse Ig, respectively (magnification 400x). 
94 
myocardium ~:" vascular endothelium capillary endothclium 
0 
Heart 
:;=; 
, 3 
"~ 
4 
, 
5 
".,";':::::::i:E ... =tL~i::r~ 
hepatocyte:> 
Cllpillary endothelium 
F=::;-~~~---, 
rcspirutory epithelium 
o 1 Z 3 
Lung 
4 5 
.'''.Ii~ 
.""i.'., ,.d.lhdiom 1=" :;:;=;: •. ::;';:;t_.---, 
capillary endothelium~' _ ... ~ S.~ 
o Z 3 4 5 
Arbitrary units 
Figure 3. Semiquantitative analysiS of DAF endothelial expression in tissues from 
transgenic line 52.2. DAF expression in endothelial cells from different tissues was 
detennined by innnunochemistry on cryosections as described in Materials and Methods. 
Results are expressed according to the intensity of specific staining (0= no staining; I = low 
intensity; 2= medium; 3= high; 4=very high). 
Levels of human DAF expressed by ECs isolated from transgenic rats 
Endothelial cells from heart and lung were isolated from hemizygous (DAF+1-) and 
homozygous (DAF-1j rats derived from founder 52.2 and from a nontransgenic rat as control. 
Endothelial cell populations were over 95% pure as assessed through an anti-rat ICAM-I and 
anti-vWf antibodies. Cell surface expression of human DAF was investigated by flow 
cytometry following staining with an anti-DAF MAb. Figure 4 shows that the level of human 
DAF expressed on cardiac ECs from homozygous (DAF+I,) rat was about 50% the level of 
DAF on human ECs (HUVEC). As expected, DAF expression was higher in homozygous 
(DAF+I,) transgenic rats than in hemizygous (DAF-I,) rats. Similar results were obtained with 
ECs isolated from lung (data not shown). 
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Figure 4. F ACS analysis of human DAF expression by endothelial cells from hemizygous 
and homozygous transgenic rats. Endothelial cells were isolated from heart of wild type 
(WT) and transgenic rats, either hemizygous (DAF·!,) or homozygous (DAF+!'j. 
Immunostaining was performed using an antihuman DAF MAb to compare levels of DAF 
expression on endothelial cells. An anti-rat ICAM-I MAb and antihuman von Willebrand 
factor (vWf) antibody were used to assess the purity of endothelial cell preparations. 
Fluorescence was measured on 10,000 cells/sample using a F ACS-calibur. Data are depicted 
in histograms plotting mean fluorescence intensity (MFI) on a log scale (x-axis) versus cell 
number (y-axis). 
Protection of DAF-expressing rat ECs against primate antibodies and C· 
mediated eel/lysis 
The ability of human DAF to confer in vitro protection of rat ECs against primate xenogeneic 
(anti-rat) antibodies and complement-mediated cell lysis was investigated by incubating ECs 
isolated from transgenic rats with primate (cynomolgus) sera. Xenoreactivity of human serum 
for WT or transgenic rats EC was previously determined by flow cytometry analysis. 
Incubation of transgenic (hemizygous or homozygous) rat ECs with purified human anti-
Galal-3Gal antibodies showed binding of IgG and IgM XNA that was similar to that of ECs 
from WT nontransgenic rats (data not shown). Furthermore, ECs from either transgenic or 
control rats exhibited similar levels of Galal-3Gal expression as measured by the binding of 
96 
FITC-labe1ed Bandera simplicifolia lectin (data not shown). In vitro protection of DAF-
expressing rat Ees against antibodies and complement-mediated cell cytotoxicity was 
measured by incubating rat Ees with serial dilutions of primate (cynomolgus) serum. As 
shown in figure 5, primate serum induced a dose-dependent lysis of nontransgenic Bes for 
serum dilutions ranging between 6% and 25%. Compared to WT rat Ees, Ees isolated from 
transgenic rats were protected according to the level of human DAF expressed on the cell 
surface. \\!hen Ees were incubated in the presence of 25% serum, protection against cell lysis 
was 74 ± 6% (P < 0.05) and 43 ± 4% (P < 0.05) for homozygous and hemizygous, 
respectively, compared to WT rat ECs (9.6 ± 0.3%, 20.9 ± 0.1 %, and 36.8 ± 0.1% of cell lysis 
for homozygous, hemizygous, and WT, respectively). 
Flow cytometry analysis of complement activation on ECs, following incubation with human 
serum, confirmed the ability ofDAF expression to prevent C3 deposition on Ees since lower 
amounts of human C3 were detected on transgenic ECs than on WT ECs (figure 6). An 
overall reduction in C9 was also observed on rat ECs from homozygous transgenic rats 
whereas no effect ofDAF expression was observed for C4 and factor B deposition. 
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Figure 5. In vitro protection of ECs isolated from transgenic rats against primate 
xenogeneic antibodies and complement-mediated cell lysis. Cardiac endothelial cells from 
wild type (WT) and transgenic, either hemizygous (DAF+I.) or homozygous (DAF/"'), rats 
were labeled with Cr'l and incubated for 4 hr at 3TC with serial dilutions (from 25% to 
6.12%, 50 flllwell) of cynomolgus serum. Cell lysis was determined by measuring Cr51 
release in culture supernatant as described in Materials and Methods. All experiments were 
done in triplicate, and the results are expressed as the mean of percent specific lysis ± SD 
values. Results are representative of three independent experiments. 
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Figure 6. FACS analysis of in vitro human complement deposition on wild type versus 
transgenic rat ECs. Cardiac endothelia] cells were isolated from wild type (dotted line) and 
transgenic. either DAF-1. hemizygous (plain line) or DAF-1+ homozygous (bold line), rats. 
Immunostaining was performed on ECs incubated with human serum (dilution 1110) for 30 
min at 3TC. After incubation, ECs were washed and then incubated with either a FITC-
labeled antihuman C3, C4, or factor B MAb or with an antihuman C5b-9 polyclonal rabbit 
serum followed by a FITC-labeled anti-rabbit Ab. 
Ex vivo perfosion 
The functional ability of hearts from hemizygous DAF+1- rats to prevent complement 
activation was investigated by ex vivo organ perfusion with 15% human serum. Cardiac 
function, assessed by cardiac frequence, was monitored over a 60-min perfusion time (Figure 
7). Our data showed that for DAF-expressing transgenic rats (n = 5), heart rate was not 
affected by serum perfusion and remained stable throughout the experiment. Similarly, 
perfusion of WT rat hearts with heat-inactivated serum (n = 5) showed normal cardiac 
function (data not shown). In contrast, cardiac function failed rapidly after perfusion of WI 
98 
rat hearts with XNA and complement-containing hnman serum and stoped at 11.2 ± 1.7 min 
(n ~ 5). 
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Figure 7. Cardiac function of transgenic rat hearts during ex vivo perfusion with human 
serUID. Hearts frOID wild type (circles) (n ~ 5) or DAF'I. hemizygous transgenic (squares) (n 
= 5) rats were perfused with 15% human serum for 60 min using a Langendorff apparatus. 
Heart rate (y-axis) was monitored every min (x-axis) throughout the experiment. Every point 
of analysis corresponds to the mean value of five experiments and SD is shown for values 
taken every 5 min. 
Xenotransplantation of DAr transgenic rat hearts into primates 
Transplantation of transgenic hearts was performed on cynomolgus to assess whether the 
expression levels of human DAF on ECs were sufficient to prevent HAR. We previously 
demonstrated that in this discordant combination, cardiac xenografts were hyperacutely 
rejected in 5.5 ± 1.4 min following binding of primate XNA and activation of complement 
through the classical pathway (19). To overcome a potential variability in xenoreactivity of 
primate recipients, hemizygous and homozygous transgenic hearts were grafted in each 
femoral vessel from the same recipient. Survival times of transplanted transgenic hearts are 
reported in Table 1. These results show that levels ofDAF expression were correlated in vivo 
with the degree of protection against XNA and complement-mediated HAR. Nevertheless, 
protection for homozygous hearts compared to that for hemizygous hearts was higher than 
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expeeted from in vitro experiments (figures 5 and 6). Indeed, for hearts from hemizygous rats, 
rejeetion was delayed from 5 min to 15.5 min (n = 4) (P < 0.05 eompared to WT), whereas 
eardiae xenograft survival was up to >4.5 hr for homozygous rats (n = 2) (P < 0.05 eompared 
to WT or hemizygous transgenic hearts). Beeause the time ofrejeetion eould only be assessed 
on anesthetized primates, only a minimal estimation can be given here. 
Histology of DAF-1, rejected hearts, collected at the time of rejection, showed no significant 
evidence of edema or hemorrhage but showed microthrombosis, as previously described for 
nontransgenic rats (19). Nevertheless, differences were observed between tissue samples 
according to survival time. Indeed, a transplant which survived for 28 min, exhibited a 
significant PMN infiltration in the interstitium and binding to the endothelium of blood 
vessels compared to cardiac xenograft rejected at 11 min (figure 8). Biopsies from DAF 
homozygous heart transplants also showed an abundant leukocyte infiltration that was mostly 
composed of PMN, but also include a small fraction of monocytes. Vascular damage, focal 
necrotic lesions of myocardium, and interstitial hemorrhage were also observed. 
Immunohistochemical analysis revealed deposition along endothelial surfaces of recipient 
IgG, IgM, and complement components of the classical but not the alternative pathway (Table 
2). Less C3 and C9 fragment deposition was observed on transgenic tissues than on that of 
rejected organs from WT rats. 
Table 1. Survival time of heterotopic cardiac xenografts of transgenic rat hearts (hemizygous 
DAF+1- or homozygous DAF-1j transplanted into cynomolgus recipients. 
Wild type rat DW' DW+ 
Survival time 5.5 ± 1.4 min 15.2 ± 7.4 min* > 1.Shr**:l 
(10,11,12,28 min) >4.Shr**:l 
n-IO n-4 n-2 
Rat hearts were grafted on femoral vessels bIlaterally for hemIzygous and homozygous rats. 
Wild-type heart survival has been previously reported (19). 
:lAnalysis of the last time points for each graft showing beating hearts (next analysis at 24 hr 
showed rejection). 
*p < .05 for transplants from hemizygous DAF rats versus wild type rats. 
**P < .05 for transplants from homozygous DAF rats versus wild type rats or hemizygous 
DAF rats. 
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non-transgenic cardiac transplant rejected at 5 min 
DAF+1. cardiac transplant rejected at II min 
DAF+1'cardiac transplant rejected at 28 min 
DAF+1+ cardiac transplant rejected at > 1.5 hr 
Figure 8. Histological analysis of DAF-expressing cardiac xenografts. Hearts were 
collected at the following times of rejection: 5 min for wild type, II min and 28 min for 
DAF+1- transgenic rats, and after rejection for DAF+1+ transgenic rat. Tissue sections were 
counterstained with hematoxilin-eosin. (magnification 400x). 
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Table 2. Immunohistochemical analysis of cardiac xenografts for human Ig and complement 
deposition. 
Rats hDAF vWf bIgG hIgM C3 C4 C9 Fb 
Ungrafted wild type (n=3) 
-
++ 
- - - - - -
Wild type (n=3) - +++ ++ + ++ +/++ ++ 
-
, 
DAr" (n=3) +++ +++ ++ + + + -/+ -
DAF++ (n=2) ++++ +++ ++ + + + +/- -
.. Imm.1Ulostammg of xenograft cryosectlOns was performed as descnbed III Matenals and 
Methods. Results are expressed as a mean of experiments performed on two (DAF+1+ 
transgenics) or three (ungrafted, wild type, and DAF+1- transgenic) animals. (-: no staining, +: 
low intensity, ++: medium intensity, +++: high intensity, ++++: very high intensity). 
Discussion 
Genetically engineered animals offer a unique opportunity for using donor animal organs for 
clinical transplantation. Transgenic pigs, which express molecules that could control 
immunological events associated with xenograft rejection, could be the first suitable source of 
these transplants. Transgenic mice are useful models for the analysis of promoter tissue 
specificity and transgene expression levels (24;25). However, there are no mouse models 
available for the study of transplantation of vascularized organs into primates. Investigation of 
transgenic or knockout mouse models (although restricted to ex vivo perfusion experiments) 
can be informative for several aspects of trans gene function, but they do not allow analysis of 
the broad range of humoral and cellular interactions between graft and recipient that operate 
in vivo (25;26). Therefore, we have postulated that production of transgenic rats, which can 
be used for xenotransplantation into primates (19), could provide a useful in vivo model to 
test the benefits of genetic engineering interventions in xenotransplantation (22). The frrst 
step in validating this model was to demonstrate that endothelium-directed expression of 
human DAF in rat organs can delay xenograft HAR. 
Transgene distribution in transgenic organs is a major concern for xenotransplantation. For 
membrane-bound proteins such as CRPs, transgenes should be expressed at least on ECs (the 
first target of XNA binding and complement activation), since few other cell types in the rat 
(and also the pig) express the Galal-3Gal epitope (7). Our data show that endothelium-
restricted transgene expression can be obtained in transgenic rats by using part of the human 
ICAM-2 gene promoter, and that tissue distribution of transgene expression in transgenic rats 
is almost identical to transgene expression in lines of transgenic mice (18). 
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The ability of human DAF to overcome primate XNA and complement-mediated rat cell lysis 
was demonstrated in vitro on isolated transgenic rat Ees. The data generated from this study 
provided in vivo confinnation of our previous in vitro experiments performed on transfected 
rat ECs, which demonstrated the ability of human DAF and CDS9 to protect rat ECs from 
primate complement~mediated damage (20). Cardiac-derived Ees from rats homozygous for 
DAF expressed around SO% of the DAF levels observed in HUVECs. However, compared 
with other human cells, HUVECs express very high levels of DAF (3 x 10' molecules per cell 
compared with 8 x 104 molecules per cell for human leukocytes) (27;28). DAF levels on 
human Ees derived from organs have not yet been reported. 
Because Ees from transgenic rats homozygous for DAF were more resistant to primate 
serum-mediated damage than ECs from rats hemizygous for DAF. in vitro inhibition of 
complement-dependent EC lysis and complement fragment deposition was said to be 
correlated with DAF levels. In ex vivo perfusion experiments, hemizygous DAF hearts were 
very efficiently protected from complement-mediated damage from 15% human serum, but 
showed only limited survival in vivo. Although a statistically significant improvement of graft 
survival time for hemizygous rats was observed (5 min for WT rats versus 15 min for 
hemizygous DAF rats), this has little relevance in vivo. The difference in in vivo versus ex 
vivo survival time is probably due to higher XNA and complement concentrations in vivo and 
the contribution of recipient blood cells absent from the ex vivo experiments. In contrast, the 
prolongation of xenograft survival to a minimal period of several hours (> I.S hr to 4.5 hr) in 
homozygous DAF rats indicates that this level of transgene expression is sufficient to delay 
HAR in the absence ofXNA depletion or immunosuppression of the recipient. 
In some previous reports on the generation of transgenic animals for CRPs, levels of 
transgene expression have been quantified on ECs. Diamond et al. showed that expression of 
CDS9 on aortic ECs from transgenic pigs reached 20% of the levels of HUVEC, conferred 
50% protection against complement-mediated BC lysis in vitro, and compared with the 
controls, slightly prolonged xenograft survival (0.5 hr and I hr versus 2.2 hr and 3 hr, 
respectively) (29). Byrne et al. showed that aortic ECs expressed CD59 and DAF levels that 
were 67% and 4S% of HUVEC levels, respectively, and had a 3- to S-fold increased 
resistance against complement-mediated lysis in vitro (14). Xenografts were shown to have 
variable survival periods compared with controls (range 6 hr to S days versus O.S hr to I hr, 
respecfively), and survival could be prolonged by depletion by depletion of xenoreactive 
antibodies (16). Importantly, in these transplantation trials, recipients also received extensive 
immunosuppressive and anti-coagulant treatment (14;16;29). Taken together these studies 
suggest that although moderate levels of DAF transgene expression (20-40% of HUVEC 
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levels) are able to confer protection against HAR in conditions in which complement or 
antibodies are limited (in vitro or ex vivo perfusion), a minimal threshold of protection in vivo 
requires DAF levels that are at least close to 50% of HUVEC levels. In agreement with this 
hypothesis, Cozzi et al. reported that transgenic hearts, which expressed DAF at levels 
several-fold higher than HUVECs (13), showed effective protection during ex vivo perfusion 
with human blood, and xenograft survival was considerably prolonged (5.1 days versus 1.6 
days in controls) in the absence of any other treatment (15). However, these transgenic 
organs, even in immunosuppressed recipients, have been almost invariably rejected by A VR 
(30;31 ). 
Nontransgenic rat hearts transplanted into primates have been rejected with a histological 
pattern of HAR showing endothelial cell damage, platelet microthrombi, and little PMN 
vascular accumulation (19). In contrast, rat hearts transplanted into primates treated with 
cobra venom factor (19) or DAF transgenic hearts that have survived transplantation for at 
least 28 min have been rejected, with a histological pattern of A VR showing extensive 
thrombosis, leukocyte accumulation (mainly PMN) in the vessels and tissues, edema, and 
hemorrhage. Furthermore, increased levels ofDAF in transplanted organs (from homozygous 
and hemizygous DAF transgenic rats) result in longer periods of graft survival that correlate 
with progressive PMN infiltration, hemorrhage, and focal myocardial necrosis. Similarly, 
A VR is the most common result of xenotransplantation betvveen discordant species (guinea 
pig-to-rat or pig-to-primate) after XNA depletion, complement inactivation of recipients, or 
transplantation of CRP transgenic organs (4;10;12;14-16;32;33). Although A YR in these 
models share common pathological features (hemorrhage, edema, and presence of 
leukocytes), they also show differences in the type of infiltrating leukocytes. In transplant 
combinations involving rats as recipients, mononuclear cell infiltrates predominate (33;34), 
whereas combinations involving primates as recipients (especially when the primates do not 
receive immunosuppressive drugs) show leukocyte infiltrates with mononuclear cells and a 
high proportion ofPMN (4;15). 
Taken together, our results demonstrate that a moderate level of human DAF expression on 
rat endothelium prolongs xenograft survival beyond HAR and that the PMN infiltration, 
hemorrhage, and focal myocardial necrosis associated with A VR in pig-to-primate transplants 
are also present in rat-to-primate transplants. It is likely that higher levels of DAF expression 
are required to further improve xenograft survival, or that other factors in addition to 
complement (such as XNA binding to ECs and mechanisms such as coagulation and EC 
activation) must be controlled to prevent xenograft A YR. 
In conclusion, xenotransplantation of transgenic organs expressing CRPs, from either pig or 
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rat, prevents HAR but not the development of A VR, even when immunosuppressed primates 
are used as recipients (14-16;30;31). Therefore, there is an urgent need to express new 
transgenes to protect xenografts and decrease the side effects of immunosuppression. These 
transgenes should probably be aimed at decreasing Galal-3Gal expression or to inhibiting 
coagulation and tissue infiltration by leukocytes. The development of transgenic rats 
represents a more rapid alternative than the production of transgenic pigs for testing the 
usefulness of new strategies and allows an easier analysis of mechanism of action. In this 
regard, the backcross oftrangenic rats expressing DAF to prevent HAR, and the backcross of 
rats expressing F as ligand in the endothelium (35) that could inhibit PMN adherence to 
endothelium (36) may facilitate analysis of the role of early leukocyte infiltration in A YR. 
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Abstract 'Cellular immunity overrules the protective effect of hDAF as demonstrated in an ex 
vivo heart perfusion model' in Transplantation Proceedings 33(1-2): 781-782. 2001 
Abstract 
Background. In xenotransplantation the use of donors transgenic for recipient-type 
complement regulatory protein Decay Accelerating Factor (DAF/CD55) or Membrane Co-
factor Protein (MCP/CD46) protects grafts against hyperacute rejection (HAR), which is 
primary mediated by xenoreactive natural antibodies (XNA) and complement (C). In the 
Langendorff model we have previously demonstrated that rat hearts transgenic for human 
CD55 (hCD55), perfused with human serum were protected against HAR. However, in the ex 
vivo situation these hearts were found to be destroyed by a process- occurring after the period 
of HAR. We questioned whether transgenic hearts for hCD55 are also protected against 
adhesion and infiltration by cells implicated in the early phases of xenograft rejection. The 
aim of the present study was to analyse this process in the ex vivo heart perfusion model. 
Methods. hCD55 transgenic rat hearts and their controls were perfused with either heat-
inactivated or normal human blood solutions for 60 minutes. Although most of the hearts 
stopped beating within the 60 minutes perfusion period, the perfusion was not stopped to 
enable adhesion of cells during a fixed period identical for all groups. 
Results. Independent of the presence of C, H&E-stained tissues of hCD55 transgenic hearts 
revealed less adhering PMN-Ieukocytes to the endothelium as compared to controls (mean: 
31% versus 60%). Standard histology and immunohistochenristry showed that hCD55 
transgenic hearts exhibited less interstitial edema, hemorrhage, microthrombosis~ fibrin 
depositions and leukocyte infiltration as compared to controls. All hearts showed nrild to 
moderate levels of P-selectin and sinrilar levels of ICAM-I, C3c, C9, IgA, IgG and IgM 
depositions. 
Conclusions. hCD55 expressed on rat hearts not only inhibits complement activation, but also 
human leukocyte-adhesion and apparently functions as an anti-adhesion molecule. hCD55 is 
not only an efficient factor in protecting grafts against BAR, but protects the graft against 
adhesion ofleukocytes as well. 
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Introduction 
Hyperacute rejection (HAR) is the first immunologic barrier to overcome, before organs can 
be transplanted between discordant species (1-3). BAR is primary mediated by binding of 
xenoreactive natural antibodies to the vascular endothelium followed by complement 
activation, resulting in activation or damage of endothelial cells. The major features of HAR 
in vivo are platelet aggregation and adhesion, fibrin deposition, thrombosis, interstitial edema, 
hemorrhage and vasocontriction. HAR can be averted by blocking either xenoreactive natural 
antibodies or complement (4;5). The second immunologic barrier in the discordant situation is 
acute vascular rejection (A VR), which can occur without the presence of T cells. A VR 
involves type II endothelial cell activation, including up-regulation of proinflammatory 
molecules, infiltration of host monocytes and natural killer cells into the graft, and cytokine 
production, leading to chemotaxis of leukocytes (4). The third and probably most difficult 
immunologic barrier to overcome is the cellular immune response, in which similar 
mechanisms as in allograft rejection are involved. The use of donors transgenic for a certain 
recipient-type complement regulatory protein protects grafts against hyperacute rejection 
(BAR). We demonstrated earlier that rat hearts transgenic for human CD55 (hCD55), 
perfused with human serum, were protected against BAR (6). Although the hearts were not 
rejected by HAR, they were fmally rejected by a delayed form of BAR. Since CD55 prolongs 
the survival of hearts perfused with human serum by regulating the activation of endothelial 
cells, we wondered whether CD55 might have an extra effect, ie inhibiting the adhesion of 
cells to the vascular endothelium. Others have found that CD55 indeed can function as an 
anti-adhesion molecule (7). Therefore, the aim of our study was to analyze whether rat hearts 
transgenic for hCD55 are protected against cell-mediated inununity upon perfusion with 
human blood in the Langendorff device. The contribution of complement in the adhesion 
process was analyzed by using either normal or decomplemented (=heat-inactivated) blood. 
Materials and Methods 
Animals 
Rats 
Male and female heterozygous and homozygous hCD55 transgenic rats were bred by using a 
construct containing the hCD55 cDNA under the transcriptional control of the endothelial cell 
-specific human ICAM-2 promoter. hCD55 expression was evaluated by immunohistology, 
FACS analysis of purified endothelial cells, and Southern blot techniques as described by 
Charreau et a1. (6). Wistar rats were used as controls. When control hearts were perfused with 
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12% control blood solution, the mean beating time was 55 minutes, and if pure Krebs-
Henseleit solution was used, hearts kept on beating for 190 minutes, Based on the results in 
the controls, we performed a 60 minutes perfusion of all hearts in the experimental groups, 
The animals were housed in a certified animal breeding facility under standard conditions and 
had free access to standard rat chow and water acidified to pH 22 ad libitum, The 
experimental protocol was approved by the committee on Animal Research of the Erasmus 
University. 
Surgical procedure and ex vivo heart perfusion (Langendorf!) 
Prior to the surgical procedure, rats were anesthetized with isoflurane inhalation and LO mL 
Heparin (50 IU/mL) was injected intravenously, Via two lateral incisions the thorax was 
opened and the heart was removed, A l4-gauge in-dwelling cannula was inserted into the 
aorta and secured with a 4.0 ligature. The heart was contiguously perfused with oxygenated 
Krebs-Henseleit (KH) solution using a syringe and directly linked to the Langendorff circuit, 
as previously described by Verbakel et al, (8), All hearts were perfused with KH solution 
(pure KH solution, without Heamaccel) for 10 minutes and were then switched to perfusion 
for 60 minutes with 12% human blood or 12% heat-inactivated human blood, During this 60 
minutes perfusion, hearts were monitored constantly for apex frequency and flow using 
multichannel registratioIL Most of the hearts perfused with blood stopped beating within the 
60 minutes perfusion period, The perfusion was not stopped, to enable adhesion of cells 
during a fixed period identical for all groups, The time measured until they stopped beating 
was also noted. 
Perfusion solutions 
Frozen, pooled, human O-type plasma was obtained from the blood bank of the University 
Hospital Dijkzigt (Rotterdam, The Netherlands), For each experiment fresh human serum was 
prepared from thawed human plasma afrer the induction of clotting with Thrombin (0,5 mL 
Thrombin / 200mL human plasma). Heat-inactivation, ie complement inactivation, was 
realized by heating of the serum at 56° for 30 minutes, O-type blood was collected in 9-mL 
EDTA test tubes and immediately processed as follows, After centrifugation (2000 rpm, 10 
minutes), the plasma was removed and replaced by a similar volume of serum, To prepare the 
12% (heat-inactivated) solution for perfusion, the blood was diluted with KH stock solution, 
prepared as described earlier, In the blood solutions erythrocytes, platelets and white blood 
cells (WBC) were present, A sample of the 12% (heat-inactivated) human blood mixture was 
taken from each fresh prepared solution and the WBe count was performed in a blood cell 
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counter (Sysmex F300, Japan). The mean WEC concentration was 0.5 x 1Q91L. In all 
perfusion solutions we finally added 0.1-0.2 rnL heparin (50 IU/rnL) to prevent coagulation. 
Immunohistochemistry 
After 60 minutes perfusion each heart was cut in &0. One sample was fixed in 3.6% 
formaldehyde solution. Following dehydration and paraffin embedding, 4 }.tm-thick sections 
wcre cut and stained for Hematoxylin & Eosin (H&E). By means of standard histology, all 
hearts were analyzed for differences in amounts of leukocytes adhering to the endothelium. In 
these stained tissues twenty medium sized vessels were examined to evaluate the presence of 
leukocytes. In each vessel the amount of leukocytes adhering to the endothelium and the 
amount of leukocytes present in the lumen were counted. Finally, the percentage adherence 
was calculated. The other part of the sample was snap frozen and stored at -30 °C until 
sectioned for immunohistochemistry. Frozen tissue sections (6 }.tm-thick) were prepared in a 
Microm HM 560 cryostat and stained for rabbit antihuman C3c complement Fluorescin-Iso-
Thio-Cyanate (FITC), rabbit antihuman C9-antibodies, mouse antirat CD54 (=ICAM-l), 
rabbit antihuman CD62P (=P-sclectin), and rabbit antihuman IgA, IgG, IgM. To stain rat P-
selectin, rabbit antihuman CD62P was used, since this crossreacts with rat P-selectin. C3c and 
C9 staining was done as previously described by Verbakel (8). P-selectin, (1:200), IgA 
(1:400), IgG (1:400) and IgM (1:400) staining were performed in the same way as C9-
staining (12). ICAM-l stainings were perfonned in the following way: the frozen sections 
were thawed at room temperature for 1 hour, fixed with acetone for 10 minutes and air dried 
for 15 minutes. With a Peroxidase Anti Peroxidase(PAP)-pcn circles were drawn around the 
tissue sections and washed with PBS three times. Sections were incubated for 10 minutes with 
0.03-0.1% H,O, in humidified atmosphere and rinsed three times with PBS. After 
preincubation for 15 minutes with 0.1 % nonnal rabbit serum, diluted (1 :200) mouse antirat 
ICAM-l antibody was added and the sections were incubated for 60 minutes in humidified 
surroundings. Again sections were washed three times with PBS. Sections were incubated 
with secondary rabbit anti mouse antibody for 30 minutes and washed three times with PBS. 
Diaminobenzidine (DAB) was added and sections were incubated for 5-15 minutes. The 
DAB-reaction was stopped by flushing with water for 5 minutes. Sections were put in 
Mayer's haematoxylin for 40 seconds, washed, and were then put in an ammonia-solution. 
Dehydration was followed by a Xylene step. The slides were covered with a coverslip. 
Antihuman C3c-stained sections were examined under a fluorescence microscope, and 
antihuman C9-, P-selectin-, ICAl\II-I-, IgA-, IgG- and IgM-stained sections under the light 
microscope. The intensity of C3c- and C9-depositions, and P-selectin and ICAM-l-expression 
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on the heart tissues was scored blindly via semiquantitative analysis: 0 = no staining, 0.5 = 
mild staining, 1 = dense staining. IgA, IgG and IgM depositions were scored 
semi quantitatively as wen: 0= no staining, 0.5 = mild staining, 1 = moderate staining, 2 = 
dense. 
The experimental groups 
Group I: Control hearts perfused with 12% human blood (n=6) 
Group 2: hCD55 hearts perfused with 12% human blood (n=ll) 
Group 3: Control hearts perfused with 12% heat-inactivated human blood (n=8) 
Group 4: hCD55 hearts perfused with 12% heat-inactivated human blood (n=8) 
Statistical Analysis 
The non-parametric Kruskall-Wallis test was done to see what test had to be used. The non-
parametric Mann-Whitney test was performed on (!) the difference in cell adhesion in H&E 
stained tissues, and (2) P-selectin expression. The Student's t test was used to evaluate (1) 
xenograft survivaL (2) C3c deposition, (3) C9 deposition, (4) ICAM-I expression, (5) IgA. 
IgG and IgM depositions. All tests were considered significant when P < .05. 
Results 
Langendorf! perjilsions 
The mean beating times (MBTs ± SD) for all groups are shown in table 1. Control hearts 
perfused with human blood (group I) beated significantly shorter than group 2, i.c. hCD55 
hearts perfused with human blood (P = .008), and group 4, i.e. hCD55 perfused with heat-
inactivated (P = .045). Similar beating times were found in control hearts and hearts 
transgenic for hCD55 perfused with heat-inactivated human blood (group 3 and 4). 
Table 1. Mean beating times (MBTs) of hearts from hCD55 transgenic rats and controls 
perfused with either human blood (HB) or heat-inactivated human blood (HIHB) 
Group , MBT (min) ± SD 
1. controls + HB 19 ± 11 
2. hCD55+HB 43 ± 19 
13. controls + HIHB 34± 15 
4. hCD55 + HIHB 38 ± 19 
P< .05: Ivs2 
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Histology 
Standard histology showed interstitial edema, hemorrhage, fibrin depositions, microthrombi 
and cellular infiltration. The cellular infiltrates contained leukocytes, being predominantly 
polymorphonuclear cells (PMN) (figure I). 
A 
B 
Figure 1. Standard histology showed interstitial edema, hemorrhage. fibrin depositions and 
microthrombi. These features were more prominent in control hearts (A) than in hCD55 
transgenic hearts (B). Cellular infiltrates contained leukocytes, being predominantly 
polymorphonuclear cells (PMN). In controls (A) the percentage PMN adhesion is 
significantly higher than in hCD55 hearts (B). 
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Human leukocyte adhesion to endothelial cells 
The percentage leukocytes adhering to the vessel wall in rat hearts transgenic for hCD55 and 
control hearts, perfused with human blood are summarized in Table 2, In H&E-stained 
hCD55 hearts perfused with human blood only 34% adherence of leukocytes was found, 
whereas in control hearts perfused with human blood 66% of the leukocytes adhered (P ~ 
.003). H&E-stained hCD55 hearts perfused with heat-inactivated human blood (group 4) 
showed significantly fewer adhering leukocytes than control hearts perfused with heat-
inactivated human blood (group 3: P ~ .002). 
Table 2. Percentage ofleukocytes adhering to the vessel wall ± standard deviation (SD) in 
hCD55 transgenic rat hearts and controls perfused with 12% human blood (HB) or heat-
inactivated human blood (HIHB) in the Langendorff system. 
I Group i Percentage of adhering I 
Leukocytes (H&E) ± SD 
1. controls + HB 66± 14 
2.hCDS5 +HB 34± 12 
3. controls + HlHB 53 ± 14 
4. hCDS5 + HIHB 28±9 
P < .05: Ivs2,3vs4 
Adhesion molecule expression 
An overview of the mean adhesion molecule expression per experimental group (±SD) is 
given in Table 3. hCD55 transgenic hearts perfused with human blood (group 2) expressed no 
P-selectin on their vascular endothelium. This differed significantly from all the other groups 
(P < .003). Controls perfused with human blood (group 1), controls perfused with heat-
inactivated human blood (group 3), and hCD55 hearts perfused with heat-inactivated human 
blood (group 4) expressed similar levels of P-selectin. The ICAM-l expression was found to 
be similar in all experimental groups (data not shown). 
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Table 3. Mean score ± standard deviation (SD) of P·selectin. C3c, C9, 19A, IgG and IgM 
deposition in rat hearts perfused with human blood (HE) or heat-inactivated human blood 
(HIHB) 
Group P-selectin C3c C9 IgA IgG IgM 
1. controls + HB 1.2±1.0 0.8±0.4 0.5±0.4 1.5±0.7 0.7±0.3 1.5±O.7 
2. hCD55 +HB 0 0.3±O.5 0.2±0.3 0.7±0.4 0.8±O.4 0.8±O.5 
3. controls + HIHB 1.1±0.6 0.4±0.4 0.4±0.4 0.8±0.3 0.8±0.5 1.1±O.6 
4. hCD55 + HIHB 1.5±0.1 0.4,=0.4 0.4±0.4 0.9±0.5 0.9±0.2 1.0±0.7 
P < .05: P-selectm: 1 vs2, 2vs3, 2vs4 
Anti-human C3c and C9 depositions 
An overview of the means of antihuman C3c and C9 depositions per experimental group 
(±SD) are given in Table 3. C3c and C9 were mostly present diffuse along the 
cardiomyocytes and on some vessels. Both control groups expressed similar levels of C3c and 
C9 as compared to the hCD55 transgenes. A trend is seen in the pattern of C3c and C9 
depositions: control hearts perfused with human blood (group 1) expressed higher levels of 
C3c and C9 in contrast to the other experimental groups, although these differences were not 
significant. 
IgA, IgG, IgM depositions 
An overview of the means of antihuman IgA, IgG, IgM deposition per experimental group 
(±SD) are given in Table 3. Control and hCD55 transgenic hearts perfused with human blood 
exhibited 19A, IgG and IgM not only on the endothelium, but diffuse on the cardiomyocytes 
as well. In group 1, i.e. control hearts perfused with human blood, IgA and IgM reached high 
levels, whereas IgG did not, but these differences were not significant. In hCD55 transgenes 
perfused with human blood (group 2) all immunoglobulin levels were found to be similar. 
Control and hCD55 hearts perfused with heat-inactivated human blood (group 3 and 4) 
expressed the same levels of IgA, IgG and IgM. 
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Discussion 
In discordant xenotransplantation both natural antibodies and complement are crucial factors 
of inducing HAR. Since HAR has almost been solved by using donors transgenic for 
recipient-type complement regulatory proteins, it is the second immunologic barrier which 
has to be overcome: the acute vascular rejection (A VR) process. During A VR type II 
endothelial cell activation plays a central role via up-regulation of proinflammatory genes in 
endothelial cells and cytokine production (3;4;9-11). Thus promoting the adherence of 
leukocytes. 
The aim of our study was to analyse the intermediate phase between HAR and A VR in ex 
vivo perfused rat hearts, the so called delayed HAR phase. hCD55 transgenic rat hearts and 
controls were perfused vrith different blood solutions and adhering leukocytes were counted. 
If we consider the control group perfused wjth human blood, 66% leukocyte adherence was 
observed, which correlated with a moderate and mild expression ofP-selectin and IeAM-I, 
respectively. Antihuman C3c and C9 depositions were present on the vascular endothelium 
and along the cardiomyocytes. The most important finding of the present study was that 
hCD55 hearts perfused wjth human blood showed low levels of C3c and C9 depositions, a 
moderate expression of ICAM-I and no P-selectin, and fewer leukocytes adhering to the 
endothelial cells (34%) as compared to controls. The control group perfused wjth heat-
inactivated human blood, showed a similar leukocyte adhesion percentage as the hearts 
perfused with normal blood, indicating that not the absence of complement, but hCD55 is 
responsible for the inhibition of adherence. hCD55 hearts perfused with heat-inactivated 
blood, showed low levels of C3c and C9 depositions and, as expected, low numbers of 
adhering leukocytes (2S%). The adhering cells were predominantly polymorphonuclear cells 
(PMN). Adhesion of human PMN to porcine aortic endothelial cells and inhibition of 
adhesion by hCD55 has been demonstrated earlier (12). Our findings suggest that hearts 
expressing hCD55 might be protected against PMN~mediated rejection. Moreover, in 
previous experiments we found that rat hearts expressing hCD55 transplanted into primates 
showed a PMN-dominated infiltrate upon rejection (6). 
Our hypothesis was that when a delay in the activation of endothelium occurred, this would 
lead to a decline in the number of leukocyte-endothelium interactions and a low expression of 
P-selectin. This was only found to be true for the hCD55 hearts perfused wjth human blood 
(group 2). In the heart perfused wjth heat-inactivated human blood (group 3 and 4), we found 
significantly less leukocyte-endothelial cell interactions in the hCD55 transgenic hearts, but 
the level of P-selectin expression was as high as in controls. We may therefore tentatively 
conclude that hCD55 acts as an anti-adhesion molecule, independent of the presence of 
llS 
complement. The beneficial effect of a high expression of hCD55 in the donor is not only 
restricted to BAR, but also the ensuing process of A YR. 
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Abstract 
Hyperacute rejection (HAR) of a discordant xenograft can be avoided by complement 
manipulation, but delayed xenograft rejection (DXR) still leads to graft loss. It is generally 
assumed that macrophages and NK cells play key roles in DXR. In the present study the 
survival times and cellular infiltrate following guinea pig to rat heart transplantation was 
analyzed in the course ofDXR, following aspecific and specific manipulation of macro phages 
and NK cells. HAR was overcome by a single injection of cobra venom factor 1 day before 
heart transplantation. To aspecifically reduce the inflammatory response dominating DXR, 
dexamethasone (DEXA) was given. Treatment with DEXA markedly reduced infiltration by 
NK cells, macrophages, and granulocytes. It also led to prolonged graft survival times 
(median survival of 0.4 days, n ~ 10, P < 0.05). In the second series of experiments the 
specific roles of NK cells and macrophages in DXR were further assessed. Monoclonal 
antibody 3.2.3 was used to selectively deplete NK cells. Liposome-encapsulated 
dichloromehtylene-biphosphonate was given to achieve macrophage depletion. Neither of 
these specific treatments, alone or combined, led to prolonged graft surviva1. 
Immunohistology revealed that at day 2 after transplantation no NK cells or macrophages 
were present in grafts from the combined treatment group. Only a mild infiltration of 
granulocytes was observed. Collectively, these results strongly suggest that NK cells and 
macrophages are not likely to be pivotal cell types in DXR. 
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Introduction 
If a recipient of a discordant xenograft is treated appropriately to avoid hyperacute rejection 
(HAR), delayed xenograft rejection (DXR) occurs after a fcw days through as yet undefmed 
mechanisms. In the guinea pig (GP) to rat combination, administration of cobra venom factor 
(CVF) will overcome HAR of GP hearts, which then will survive for up to 3 days (1). DXR in 
this complement-depleted model is characterized by a prominent cellular infiltration and 
endothelial deposition of xenoreactive natural antibodies (2). It has been shown that DXR 
involves a T cell-independent infiltration of macrophages and NK cells, in association with a 
marked expression of proinflammatory cytokines (3), 
The aim of the present study was to investigate whether two different approaches to inhibit 
typical DXR-related infiltration, might prolong the survival of hearts in the GP to rat model. 
The aspecific approach consisted of treatment of recipients with dexamethasone (DEXA), a 
drug known for its capacity to inhibit inflammation in its broadest sense. In the more specific 
approach, NK cells and macrophages were selectively depleted by the following methods. 
Monoclonal antibody (mAb) 3.2.3 was used to deplete NK cells. This mAb recognizes a 
unique triggering structure present on fresh and Il-2-activated l\i"'K cells (4). Previous studies 
revealed that intraperitoneal treatment ofrats with mAb 3.2.3 for 3 days can completely and 
selectively eliminate NK activity in the spleen and peripheral blood for at least 10 days (5). 
To assess the role of macrophages, we eliminated macrophage function using liposome-
encapsulated dichloromethylene-biphosphonate (CI2MBP). On injection, these liposomes are 
rapidly phagocytosed by macrophages, leading to intracellular release of ChMBP which 
eventually kills the cell. Cl,MBP has been demonstrated to eliminate macrophages for about 7 
days after intravenous injection (6;7). 
Materials and Methods 
Animals 
Animals were obtained ftom Harlan-CPB (Austerlitz, The Netherlands). Male inbred Lewis 
rats were used as recipients and female Dunkin Hartley GPs as donors, GPs and rats weighed 
approximately 250 g when used. The experimental protocol was approved by the Committee 
on Animal Research of Erasmus University. 
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Heart transplantation 
GP hearts were transplanted heterotopically into rats according to the technique described by 
Ono and Lindsey (8). Graft function was assessed by daily palpation. End of graft survival 
was defmed as the day on which palpation indicated total loss of contractile activity, this was 
confirmed by inspection at laparotomy. 
Complement depletion 
To deplete recipients of complement CVF was used (Naja naja kaouthia). CVF purification 
was performed according to Beukelman et al. (9). A single dose of 0.1 mI CVF (with a 
complement-depleting activity of 30 000 U/mI) dissolved in 0.9 rnl PBS was administered 
i.v., I day prior to heart transplantation. 
Dexamethasone 
DEXA was reconstituted in PBS and injected Lm., daily in a dose of 0.5 mglkg, starting I day 
before transplantation. 
Graft infIltrating cells 
Immunohistological analysis of grafts undergoing DXR was performed at different intervals 
after transplantation, as described previously (10). Immunoperoxidase staining on frozen 
sections was done using the following monoclonal antibodies: 
ED-I, W3/25, OX8, 3.2.3 (courtesy of Dr. Eggermont DDHK, Rotterdam, The Netherlands) 
and HIS48 to demonstrate monocytes/macrophages, CD4+ T cells, CD8+ T cells, NK cells, 
and granulocytes, respectively. The amount of infiltrating cells was scored semiquantitatively 
(from- to + + + +). 
Depletion of NK cells 
Selective NK cell depletion was obtained by intraperitoneal administration of 0.1 mI purified 
mAb 3.2.3 (0.5 mg/ml) dissolved in 0.9 mI PBS on days -I, 0 and I. 
Depletion of Macrophages 
Liposome-encapsulated CI,MBP was used for selective depletion of macrophages. Liposomes 
were prepared as described previously (6). Rats received 0.5 rnl ClzMBP-liposomes 
suspension (5 mg ClzMBP/rnl) i.v. on days -4 and-\. 
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Study design 
Rats were divided into the following groups: group I (n ~ 19): no treatment, group 2 (n ~ 19): 
complement depletion by CYF, group 3 (n ~ 10): treatment with CYF and DEXA, group 4 (n 
~ 4): complement depletion by CYF and NK cell depletion by 3.23., group 5 (n ~ 5): 
complement depletion by CYF and macrophage depletion by liposomes, and group 6 (n ~ 9): 
treatments as in groups 4 and 5 combined. Analysis of infiltrating cells was done on day 2 
after transplantation on grafts from animals treated as in groups 2, 3 and 6, using 3 animals 
per group. Day 2 was chosen as the best representative for the presence ofDXR (see Table 1). 
Statistical analysis 
Student's t-test was used to evaluate the differences (considered significant when P < 0.05) 
betvveen group mean values. Survival times are given as median survival time (MdST) and 
range. 
Results 
Survival times 
The survival times obtained in groups 1-6 arc given in Table 1. Control GP grafts in group 1 
had a MdST of 16 min. (range 8-55 min.). Treatment with CYF resulted in a MdST of2 days 
(range 1-4 days). Addition of DEXA (group 3), not only led to a significantly prolonged 
MdST of 4 days (range 2-5 days) but also to an improved performance of the heart grafts. The 
hearts showed less edema and hemorrhage and kept on beating vigorously until 1 day before 
rejection. This compares favorably with hearts from group 2, which performed poorly from 
day 1 onwards, exhibiting extreme hemorrhagic edema. Depletion of NK cells (group 4) or 
macrophages (group 5) in recipients treated with CYF had no effect on graft survival time. 
The MdSTs were 2 days, similar to those following treatment with CYF alone. Also the 
combined treatment (group 6) did not lead to prolonged graft survival. 
Graft infiltrating cells 
The results are summarized in Table 2. In animals treated with CYF only, graft infiltrating 
cells mainly consisted of NK cells, macrophages, and granulocytes. Only a few T cells were 
demonstrable. Hearts from animals treated with CYF and DEXA contained no T-cells, NK 
cells, and macrophages and only a few granulocytes. Heart grafts from group 6, treated with 
3.2.3 and macrophage.depleting liposomes, showed a similar picture, no T cells. NK cells, or 
macrophages but only a mild infiltration of granulocytes. 
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Table 1. Graft survival times in the guinea pig-to-Lewis rat combination 
Group / treatment 'VIdST Range N 
1 none 16 minutes 8-55 19 
2CVF 2 days 1-4 19 
3 CVF and DEXA 4 days 2-5 10 
4 CVF and 3.2.3 2 days 2-3 4 
5 CVF and liposomes 2 days 2-3 5 
6 CVF and 3.2.3 plus liposomes 3 days 1-3 9 
Mdsr: medzan survIval tIme. CVF: cobra venom Jactor. DEXA: dexamethasone 0.5 
mg/kg/day. Group 2 vs group 3: P<O.05. Monoclonal antibody 3.2.3. to deplete NK cells: 0.1 
ml on days -I. 0 and 1. Liposome-encapaulated Cl2MBP to deplete macrophages: 0.5 ml on 
days -4 and -1. 
Table 2. Graft-infiltrating cells on day two following guinea pig-to-Lewis rat heart 
transplantation 
Group I treatment T l'IK 'VIo I Ma Gran 
2CVF 'if ++++ +++ +++ 
3 CVF and DEXA - - - 'if 
6 CVF and 3.2.3 plus liposomes - - - + 
Treatment: see Table 1. Infiltratmg cells: glven as mean scores. n-3 / group. T-cells: CD4+ 
and / or CDS+ cells. NK: 3.2.3. positive cells. Mo / Ma: ED-1 positive cells. Gran: HIS4S 
positive cells. 
Discussion 
It has been demonstrated repeatedly that when HAR of a discordant xenograft is blocked by 
preventing the activation of complement, grafts are still rejected after a few days (1 ;2; 11). The 
mechanism underlying this rejection process, called DXR, is still not clear. 
Immunohistological examination of grafts undergoing DXR has revealed that macrophages 
and NK cells are abundantly present, which suggests that these cells participate in the 
rejection process. Our present results confirm that grafts subjected to DXR are heavily 
infiltrated by maerophages and NK cells. From earlier studies we know that NK cells are 
already demonstrable from the day of transplantation onward, whereas macrophages start 
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infiltrating from day 1 (12). The assumption that the presence of macrophages and NK cells 
would imply their actual involvement in DXR sounds logical but is not supported by our 
current results. Firstly, when DEXA was given to CVF-treated recipients virtually no 
infiltrating cells could be demonstrated. Such grafts survived significantly longer than CVF-
treated controls, but still were rejected within an additional 2 days. The major gain of DEXA 
treatment was that the hearts performed much better because edematous enlargement of the 
grafts was postponed. It is known that DEXA is capable of inhibiting various aspects of the 
inflammatory response, including production of Il-6 and TNF a (13; 14). In earlier experiments 
we showed that DEXA had a profound inhibitory effect on the early TNFa response, which 
suggests that the early hemorrhagic deterioration of a graft during DXR may be mediated by 
this cytokine (11). The second line of evidence that macrophages and NK cells are innocent 
bystanders rather than the actual executors of DXR comes from our results obtained with NK 
cell and macrophage depletion. Neither the removal of NK cells nor the depletion of 
macrophages had any effect. Also, when both treatments were combined, no effect on 
survival was observed. In addition. immunohistochemical analysis of grafts from the latter 
group demonstrated the efficacy of the treatment, since no i\TJ< cells and macrophages were 
found to be present. Several other investigators have tried to define in vivo the effector cells 
in DXR. Fryer et al. (15) used similar macrophage-depleting liposomes, as we did in the 
present experiments, and also failed to improve discordant xenograft survival in two different 
GP to rat models. From our studies we conclude that DXR in the rather harsh GP to rat model 
is not likely to be mediated by macrophages and NK cells. 
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Abstract 
Heme oxygenase-l (HO-l) is a molecule known to diminish ischemiaircperfusion (I/R) 
injury. In xenotransplantation, ischemia rcperfusion injury may playa pivotal role in graft 
dysfunction and organ loss. The aim of the present study was to determine whether 
upregulation of HO-l would lead to improvement of the performance of mouse hearts 
perfused with human serum in the Langendorff circuit. Upregulation ofHO-l was realized by 
intraperitoneal administration of Cobalt Protoporfyrin IX (CoPP), and confinned by Northern 
blot analysis. Control animals were injected with NaCl. We first investigated the effect of 
HO-I upregulation alone on the perfonnance of non-transgenic mouse hearts. To evaluate the 
recovery of myocardial function, non-transgenic hearts, pretreated with either NaCl or CoPP, 
were perfused with Krebs-Henseleit (KH) solution for 10 minutes, after which 30 minutes of 
ischemia was given, followed by 45 minutes ofreperfusion with KH. Secondly, we analyzed 
the effect of HO-l upregulation on the perfonnance of hCD55 (hDAF) transgenic mouse 
hearts and their controls by perfusing with human serum. The infarct size was measured by 
staining of the hearts with tetrazoliurnchloride (TTC). A significant difference in the recovery 
of myocardial function was detected between control mice (group 1), in which 6 out of 13 
hearts were unable to regain contractions, and HO~ 1 induced mice (group 2), in which 3 out 
of 12 hearts were unable to regain contractions. The infarct size and the recovery of the flow 
were also significantly different, in advantage of the HO-l induced groups. Mouse hearts 
transgenic for hCD55 survived significantly longer than controls, in both CoPP and NaCl 
injected groups. In addition, a reduction of the infarct size was found in the HO-I induced 
transgenic group, as compared to their controls. Our findings indicate that upregulation of 
HO-l protects hearts from ischemic injury by reducing the infarct size. Furthennore, HO-l 
improves the perfonnance of the hearts, however, an additional effect of HO-l on the 
prolongation of xenograft survival could not be detected. 
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Introduction 
One approach to overcome the shortage of donor organs is the use of animals as a source of 
organs for transplantation, ie xenotransplantation. Xenotransplantation is defmed as the 
transplantation of cells, tissues or organs between different species. Progress has been made 
in clarifying some of the barriers to xenotransplantation and defining appropriate therapeutic 
interventions aimed at the removal of xenogeneic natural antibodies and at the limitation of 
complement activation, both responsible for hyperacute rejection (HAR) (I). Apart from the 
immunological mechanisms, lIR injwy may playa role in 'xenotransplantation, leading to 
early graft dysfunction. The exact mechanism remains unclear, but data suggest that oxidative 
stress and inflammatory responses playa major role. Reperfusion in itself is believed to bring 
about cellular injury. Oxygen free radicals and other toxic metabolites are fonned when 
oxygen and energy supply balances are restored during reperfilsion. One of the physiological 
protection mechanisms against the production of oxygen free radicals is upregulation of heme 
oxygenase. In vivo, heme oxygenase activity is upregulated by various stimuli, ie hypoxia, 
oxydized haemoglobin, oxygen free radicals, heavy metals, hydrogen peroxidase or 
metalloporphyrins, and it is considered one of the most sensitive indicators of cellular stress 
(2;3). There are three isoforms of heme oxygenase (HO). HO-I, also known as heat shock 
protein 32 (HSP32), is the rate-limiting stress enzyme, which catalyses the degradation of 
heme into equimolar amounts of biliverdin, carbon monoxide (CO) and free iron. HO-2 
catalyzes the same reaction as HO-I, but it differs in many respects and is regulated under 
separate mechanisms (4;5). HO-3 which is expressed constitutively, has very low activity and 
its function probably involves heme binding (6). In analogy with heat shock regulation, 
upregulation of HO-I may be an adaptive mechanism protecting cells from stress, in 
particular ischemia. The upregulation of HO-I has been shown to be cytoprotective and also 
reduces immune responses, i.e. decrease of IFNy and Il-2 production (2;7-9). Several 
mechanisms have been postulated for the cytoprotective actions of HO-I. The elimination of 
pro-oxidant free heme could decrease the formation of hydroxyl radicals. HO-I mediates the 
production of free radical scavengers with antioxidant properties. Carbon monoxide (CO) 
would act as vasodilator and inhibits platelet aggregation. ''"Free'' iron increases oxidative 
stress and upregulates the cytoprotective gene. ferritin (9-12). 
In our experiments, upregulation of HO-I activity was accomplished by administration of 
Cobalt Protoponyrin IX (CoPP). This metalloporphyrin is believed to have the capacity to 
produce an oxidant stress by generating or increasing the intracellular content of active 
oxygen species. thereby stimulating the expression of HO-l (2;7;13). The aim of the study 
was first to examine whether CoPP in our mouse model was able to bring about an 
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upregulation of HO-l. Secondly, we examined the effect of HO-I upregulation on the 
performance of mouse hearts perfused in the Langendorff device. Subsequently, the effect of 
HO-l upregulation was examined in hCD55 transgenic mouse hearts perfused with human 
serum. 
Materials and Methods 
Animals 
Male and female heterozygous and homozygous BlOCBA-mice transgenic for heD55 (hDAF) 
and their non-transgenic counterparts were used. The animals weighed approximately 20 
grams and were about sixteen weeks old. Production of the transgenic mice was accomplished 
by injecting mouse ova with the entire genomic DNA encoding for hCD55 using yeast 
artificial chromosomes (YAC), as described by Yannoutsos et a1.(14). The hCD55-mouse 
strain used, contained 10 integrated copies in the genome and the expression of the relevant 
protein on spleen, kidney, heart, liver and lung was verified by anti-hCD55(15). Splenocytes 
of mice transgenic for hDAF showed a strong expression of the transgene by F ACS analysis. 
The animals were housed in a certified animal breeding facility under standard conditions and 
had free access to standard mouse chow (AM II, Hope Farms, Woerden, The Netherlands) 
and water acidified to pH 2.2 ad libitum. The experimental protocols adhered to the rules laid 
down in the Dutch Animal Experimentation Act (1977) and the published Guidelines on the 
Protection of Experimental Animals by the Council of the EC (1986). The Committee on 
Animal Research of the Erasmus university Medical Centte Rotterdam, The Netherlands had 
given pennission to perfonn the experimental protocols. 
Experimental groups 
Group NaCl or I KH I Ischemia KH HS N 
CoPP , perfusion reperfusion perfusion 
1. controls NaCl Yes Yes Yes No 13 
2. controls CoPP Yes Yes Yes No 12 
3. controls NaCl Yes No No Yes 6 
4. hCD55 NaCl Yes No No Yes 4 
5. controls CoPP Yes No No Yes 6 
6. hCD55 CoPP Yes i No No Yes I 5 
KH - Krebs-Hensele!t perfuslOn, HS - human serum perfuslOn. 
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Mice were prereated with NaCI (no upregulation ofHO-I) or CoPP (upregulation ofHO-l). 
Groups 1 and 2: 10 minutes perfusion with KH, 30 minutes ischemia and 45 minutes 
reperfusion with KH. Groups 3,4,5 and 6: 10 minutes perfusion with KH, no ischemia. 
perfusion with human serum untill cessation of heart beats occurred. 
The Langendorff circuit 
16 hours before the experiments, mice wore injected with 0.6 mL of a single dose of either 
Cobalt protoporfYrin (CoPP) (3 mgikg) or NaCI (0.9%) intraperitoneally. All mice were were 
anaesthetised with isoflurane inhalation prior to the surgical procedure. The abdominal wall 
was opened and 0.6 rnL Heparin (50 IU/rnL) was injected into the abdominal inferior vena 
cava. Via two lateral incisions the thorax was opened and the heart was removed quickly. A 
22-gauge indwelling cannula was inserted into the ascending aorta and secured with a 4.0 
ligature. The heart was directly perfused with oxygenated Krebs-Henseleit-Haemaccel 
solution using a syringe and linked to the Langendorff device, as described previously (16). 
Acclimatisation of in all groups was accomplished by perfusion with Krebs-Henseleit-
Haemaccel solution for 10 minutes. In the first two experimental groups, 30 minutes of warm 
ischemia was given by interruption of KH perfusion. Thereafter, 45 minutes of reperfusion 
was given (17). Failure of the heart was manifest when the heart was unable to regain its 
contractions during reperfusion. Irrespective of heart perfonnance, the experiment was not 
ended until 45 minutes of reperfusion. After the initiate 10 minutes of perfusion with KH in 
groups 3,4,5 and 6, no ischemic period was included, but we directly switched to 15% human 
serum perfusion. Survival time was defined as the time between the start of serum perfusion 
and complete cessation of heartbeats. This was monitored by using multichannel registration. 
Heart rate and flow were registered as well. 
Human serum 
Frozen, pooled, human O-type plasma was obtained from the blood bank of the University 
Hospital Dijkzigt (Rotterdam, The Netherlands). Human serum was made out of human 
plasma by adding 0.5 mL Thrombin to 200 mL human plasma, inducing clotting. After 
removal of the clot, the serum was diluted with Krebs-Henseleit-Haemaccel solution to obtain 
the 15% perfusion concentration. For each experiment fresh human serum was prepared. 
Intraperitoneal Cobalt protoporfyrin IX (CoPP) and NaCI injection 
CoPP was dissolved in 0.2 M NaOH and adjusted to pH 7.4. The final volume was made up 
with 0.9% NaCl. Before each experiment fresh CoPP and NaCI solutions were prepared. 
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Sixteen hours before each experiment, control mice received 0.6 mL of 0.9% NaCI, and 
experimental mice were injected with 0.6 mL CoPP (3 mglkg), intraperitoneaIly. CoPP at this 
dose has been shown to upregulate HO-I in vivo during 24 hours (7;12). 
Determination of Heme Oxygenase-l (HO-l) expression 
Immunohistochemistry 
HO-l expression was evaluated by immunohistochemical staining of the heart tissues with 
polyclonal goat anti-HO-I antibody. Hearts were sliced in sections of 7 ~m with a cryostat 
and stored at -20'C. Later these tissue sections were air-dried for 30 minutes, after which they 
were fixed in acetone for 10 minutes at 4°C. After air-drying for 10 minutes, the endogenous 
peroxidase activity was blocked with 0.05% H20 2 in PBS solution for 15 minutes. The 
sections were incubated with a I: I 0 dilution of the primary antibody (goat-anti-HO-I) for I 
hOUT. Control sections were incubated with PBS. After washing with Phosphate Buffered 
Saline I Bovine Serum Albumine (PBSIBSA) (3x2 minutes), the sections were incubated with 
a 1 :200 dilution of the secondary antibody (rabbit anti-goat immunoglobulins) for 30 minutes. 
Sections were washed with PBSIBSA (3x2 minutes), and incubated with a 1:100 dilution of 
the tertiary antibody (PAP (goat» for 30 minutes. The sections were washed with PBSIBSA 
(3x2 minutes), after which peroxidase activity was visualized with di-amino-benzidin (DAB) 
Substrate-Chromogen solution. The tissue sections were rinsed of with water, fixed in 
formaldehyde and counterstained with Mayer's Hematoxylin, and again rinsed of with water. 
Finally, the sections we dehydrated using a series of70%, 90% and 100% ethanol, washed in 
Xylol, and covered with a coverslip. 
Northern blot analysis 
Total Rl~A was isolated from hearts of mice, either injected with NaCI (no upregulation of 
HO-I) or CoPP (upregulation of HO-I) using the RNAsol method. Total RNA was isolated 
from hearts ofntice, either injected with NaCI or CoPP. Heart tissue was freshly collected in a 
polypropylene tube, 2 mL R,'lAsol B Homogenate (lmL I 10 mg heart tissue) was added, 
whereafter the heart tissue was crushed with a sonificator. To collect RNA, 1 ml homogenate 
was mixed with 100 p.l chloroform, and centrifuged at 12000*g for 15 minutes at 4°C. The 
supernatant was discanded, 500 fll phenol was added, and centrifuged. The supernatant was 
removed, 500 p.l chloroform was added and again it was centrifuged, after which the 
supernatant was removed. To precipitate the R,'lA 500 fll isopropanol was added and this 
mixture was stored at _20°C for 30 minutes, after which centrifuged at 12000*g for 30 
minutes at 4°C. The supernatant was thrown away and a pellet has appeared, which contains 
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RNA. 1 ml 75% ethanol was added to the pellet and centrifuged at 7500*g for 8 minutes at 
4°C. The supernatant was thrown away and the pellet was air-dried for 10-15 minutes. To 
dissolve the RNA, 50).l1 sterile water was added to the pellet and incubated in a water bath 
(60°C) for 15 minutes. Aftct this period, the sample was put on ice again. To measure the 
amount of RNA in a photospectrometer (E260, E280, E320), 4 ).ll of the sample was mixed 
with 996 ).ll sterile water. When enough RNA was isolated, 20 ).l1 sample buffer (SB) was 
added and incubated in a 65°C water bath for 10-15 minutes. Finally, 1 ).ll ethidium bromide 
was added. Now the RNA sample was ready for electrophoresis. RNA was fractionated on a 
fonnaldehyde/1.0-1.5% agarose gel ovemoght at 25 V, and transferred to hybridization nylon 
transfer membrane. After washing the membrane with 2xSSC it was baked at 80°C for 2 
hours, prchybridized for 6-12 hours at 42°C with 10 ml of hybridization solution (containing 
9% dextran sulphate, 1M NaCl, lOx Denhardfs, 100 ).lg/ml denatured fragmented salmon 
sperm DNA, 50% formamide, 50mM TRIS pH 7.5. 0.5% SDS). and hybridized for 12-16 
hours at 42°C in 5 ml of the above hybridization solution. 
A HO-l probe of 600 base pairs (bp), representing nucleotides +628 to + 1132. and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe were labeled with [a32PjdATP 
(18-20). The membrane was washed with 2xSSC, air-dried, and exposed to x-ray film 
(Kodak) with intensifying screen at -80°C. Northern blots were quantified densitometrically 
by use of a Storm Phosphor Imager. Relative mRNA levels were calculated after correcting 
for RNA loading by normalizing the hybridization signal intensity with the GAPDH signal. 
After signal quantization, the membrane was kept for later rehybridizations (21). 
Infarct size measurement by 2,3,S-triphenyltetrazolium chloride (TTC) 
staining 
In preparation of the 2,3,5-triphenyltetrazolium chloride solution, the following protocol was 
used. Stock A: 2.04255 g KH,P04 was dissolved in 150 mL sterile water. Stock B: 8.019 g 
Na,HP04.2H,O was dissolved in 450 mL sterile water. 100 mM phosphate buffer was made 
by adding 400 mL of stock B to 100 mL of stock A. The buffer was ready to use when pH 
was between 7.0 and 7.4. To prepare a 2% TTC-solution, 2 g of TTC was added in 100 mL 
phosphatebuffer. TTC staining was performed on all hearts. After 45 minutes of reperfusion 
with KH or after switching to perfusion with human serum, the heart was detached from the 
Langendorff. A syringe containing 2 ml of TTC solution was attached to the cannula, and the 
heart was slowly flushed. Each heart was sectioned transversely into four parts. Areas that 
appeared pale white after TTC staining were ischemic, whereas viable myocardium appears 
red (22;23). Computer analysis (Research Assistant) was performed on the two middle 
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transverse sections of these four parts. The infarct size was measured as a percentage of the 
complete section. A mean percentage of the infarct size was calculated. 
Statistical analysis 
Data from individual experiments are reported as means ± standard deviation (SD). The non-
parametric Mann-Whitney and Chi-Square test, and Independent Student t test were used to 
analyse the data. Differences were considered significant when P < .05. 
Results 
Induction of Heme oxygenase by CoPP 
Immunohistochemical staining of the hearts with anti-HO-I antibody showed HO-l 
deposition on the vascular endothelium and along the cardiomyocytes, in both CoPP 
pretreated animals and controls (figure 1). In hCD55 transgenic and non-transgenic mice, 
pretreated with CoPP, Northern blot analysis showed that HO-I mRNA was significantly 
increased as compared to transgenic and non-transgenic controls (figure 3). Densitometric 
quantitation of relative HO-I mR-NA levels in ccIls exposed to CoPP showed a tenfold 
increase in HO-I mRNA in group B as compared to group A. Between group C and D there 
was an eightfold increase. 
Heart peifusion and recovery of contractility 
In KH perfused hearts, a significant difference was detected between control mice (group I), 
in which 6 out of 13 hearts were unable to regain contractions, and HO-l induced mice (group 
2), in which 3 out of 12 hearts were unable to regain contractions (P = .018). Figure 2 shows 
the difference in flow after 30 minutes of warm ischemia in group 1 and 2. A significantly 
better recovery of the flow in the HO-I induced mice (group 2) (P = .020) was found, 
indicating that the difference in flow before and after the ischemic period in the CoPP 
pretreated hearts was smaller than in group 1. As shown in table 1, we observed a significant 
difference in heart survival betv,reen hCD55 transgenic mice and non-transgenic controls 
perfused with human serum, in both NaCI and CoPP injected animals (P = .030 and P = .041, 
respectively). Within the transgenic and non-transgenic groups, no differences were found 
between control mice and HO-l induced mice. 
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Figure 2. The difference in flow (flOWbc1brc minus flOWaftcr) after 30 minutes ofwann ischemia 
(P = .020). Hearts were perfused with Krebs-Henseleit (KH) for 10 minutes. than 30 minutes 
of wann ischemia was given, and 45 minutes of rcperfusion with KH. Group 1: controls, 
pretreated with NaCI; group 2: controls. pretreated with CoPP. 
Table 1. Mean survival times of hCD55 and control mice. pretreated with NaCI or CoPP. 
perfused with human serum (HS) in the Langendorff system 
Group Mean survival times (minutes) Average I 
3. controls + NaCl + HS 3-4-4-6-6-9 5.3 
4. hCD55 + NaCI + HS 6-10-15-18 12.3* 
5. controls + CoPP + HS 3-5-5-5-6-9 . 5.5 
i 6. hCD55 + CoPP + HS 6-8-8-9-11 8.4** 
* P - .030 for group 3 vs 4, and ** P - .041 for group 5 vs 6. 
ABC D 
Figure 3. Northern blot of control mice injected with CoPP (D), hCD55 mice injected with 
CoPP (B), control mice injected with NaCI (C), and hCD55 mice injected with NaCI (A). 
Densitometric quantitation of relative HO-l mRNA levels exposed to CoPP showed a tenfold 
increase in HO-l mRNA in B compared to A (8.3% versus 0.8%). Between C and D there 
was an eightfold increase (0.4% versus 3.5%). 
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Figure 1. Immunohistochemical staining of the hearts with anti-HO-I antibody showed a 
similar intensity of HO-I deposition, on the vascular endothelium and along the 
cardiomyocytes, in NaCl and CoPP pretreated non-transgenic mice. A: negative control, B: 
NaCI pretreated mouse heart, C: CoPP pretreated mouse heart (160x). 
A B 
c 
Figure 4. Infarct size after TTC staining in a control (A: NaC1 pretreated) and a HO·1 
induced mouse heart (B: CoPP pretreated). White areas are infarcted, red areas show vital 
heart tissue (160x). 
A B 
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Infarct size 
A part oftha results is shown in figure 4, 5 and 6. After 30 minutes ofwann ischemia (figure 
5), a highly significant decrease in the infarct size of the heart tissues could be demonstrated 
in response to upregulation ofHO-l by CoPP (group 2), as compared to controls (group 1) (P 
= ,000) (figure 4). Without 30 minutes of warm ischemia (figure 6), the infarct size was also 
clearly reduced in both CoPP pretreated controls and hCD55 mice (group 5 and 6), as 
compared to controls and hCD55 mice pretreated with NaCl (group 3 and 4) (P = .004 and P 
= .014, respectively). hCD55 transgenic mice injected with NaCl and perfused with human 
serum (group 4) showed a significant reduction in infarct size as compared to non-transgenic 
controls (group 3) (P = .042). Although the survival times between group 5 and 6 did differ, 
TTC staining in hCD55 transgenic mice pretreated with CoPP (group 6) was similar as in 
control hearts (group 5). 
group 1 group 2 
Figure 5. Infarct size measurement in non-transgenic controls after 30 minutes of warm 
ischemia, either pretreated with NaCl (group 1) or with CoPP (group 2). After perfusion in the 
Langendorff device, a syringe containing 2 ml of 2% TTC solution was attached to the 
cannula, and the heart was slowly flushed. Each heart was sectioned transversely into four 
parts. Areas that appear pale white after TTC staining were ischemic, whereas viable 
myocardium appears red. Computer analysis was perfonned on the two middle transverse 
sections. The infarct size was measured as a percentage of the complete section. A mean 
percentage of the infarct size was calculated. The mean infarct size in group 1 was 49% 
versus 25% in group 2 (P = .000). 
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Figure 6. Infarct size measurement in hCD55 mice and non-transgenic controls without 30 
minutes of warm ischemia, either pretreated with NaCl (group 3 and 4) or with CoPP (group 5 
and 6). After perfusion in the Langendorff device, a syringe containing 2 ml of 2% TTC 
solution was attached to the cannula. and thc heart was slowly flushed. Each heart was 
sectioned transversely into four parts. Areas that appear pale white after TTC staining were 
ischemic, whereas viable myocardium appears red. Computer analysis was performed on the 
two middle transverse sections. The infarct size was measured as a percentage of the complete 
section. A mean percentage of the infarct size was calculated. The mean infarct size in groups 
3.4,5 and 6 was 47%, 36%. 20% and 15%, respectively (group 3 vs 4, P = .042; group 3 vs 5, 
P = .004; group 4 vs 6, P= .014). 
Discussion 
HO-I is a stress enzyme which catalyzes the degradation of heme. All end products of heme 
degradation, including biliverdin, bilirubin, CO and free iron, are knovvn to modulate immune 
functions. Biliverdin and bilirubin act as potent free radical scavengers, CO contributes to 
endothelium-dependent vasodilatation and inhibits platelet aggregation, whereas free iron 
regulates the expression of ferritin, a cytoprotective gene. All these end products may have a 
positive influence on the viability of transplanted tissue. Upregulation of HO-l leads to 
cytoprotection and reduction of certain immune responses, such as IFNy- and Il-2-production 
and may provide a novel strategy to diminish xenograft rejection. We first examined the 
contribution of HO-l on the recovery of myocardial function after wann ischemia, and 
secondly, on the heart survival during xenoperfusion. We and others (14~24-27) have shown 
that complement regulation at the level of C3 leads to an increased graft survival when hearts 
are ex vivo perfused with human serum. 
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Northern blot analysis confmned the upregulation of HO-I mRNA in mouse hearts after 
pretreatment with CoPP. In the present experiments, we showed that upregulation of HO-I 
protects the heart subjected to ischemiaireperfusion injury, as marked by a reduced infarct 
size, and a better recovery of myocardial function after 30 minutes of wann ischemia. This 
fmding corresponds to previous observations by others (8;9). We found that after a warm 
ischemic period of 30 minutes, 6 out of 13 hearts failed to start beating again in the control 
group. In the HO-I group only 3 out of 12 hearts failed, which indicates that upregulation of 
HO-I improves the performance of the heart. However, further study using hCD55 transgenic 
hearts (group 6) revealed that upregulation of HO-I did not result in an additional effect on 
the prolongation of xenograft survival. In a study by Clarck et al. (17), an increased recovery 
of postischemic myocardial function in the rat was found after HO-l induction with hemin 24 
hours before ischemia. In another study performed by Soares et aI. (13), it was also found that 
expression of HO-l in a mouse-to-rat cardiac xenograft model is associated with xenograft 
survival (26). Furthermore, both Clarck et al. and Soares et al. evaluated heart performance in 
view of more specific parameters. We draw conclusions based on infarct size, myocardial 
function following 30 minutes of warm ischemia, heart rate, flow rate and heart beats. Our 
fmdings in the Langendorff model do not support the possibility for HO-I to improve the 
overall xenograft survival. But in the warm ischemic groups upregulation of HO-I has a 
positive effect on regaining heart contractions, flow recovery and reduction of the infarct size. 
In the groups without wann ischemia, HO-l also significantly reduces the infarct size, but 
does not prolong graft survival. Therefore, we postulate that in the Langendorff model 
upregulation of HO-I may contribute to the vitality of the transplanted organ, but has no 
additional effect on graft survival. Moreover, that there is no correlation betvveen the infarct 
size and the prolongation of xenograft survival. 
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CHAPTER 10 
SUMMARY & CONCLUSIONS 
1.1 Summary and conclusions 
This thesis describes investigations related to the efficacy of human complement regulatory 
proteins in hyperacute rejection of cardiac xenografts. In Chapter 1 an overview is given on 
several aspects of transplantation in general, and xenotransplantation in particular. Due to the 
difference in demand and supply of donor organs and the mortality of patients awaiting a 
donor organ, medical science is trying to find an answer to overcome the problem of organ 
shortage. Xenotransplantation, i.e. transplantation of cells, tissues or organs over a species 
barrier, may be a possible solution for the donor shortage. Xenotransplantation can be seen 
either as a permanent replacement of the diseased organ or as a temporary therapy awaiting a 
suitable human donor. However, as xenotransplantation may not become a clinical reality due 
to ethical reasons and virological problems, there are several alternatives. Bioartificial organs 
can be used to support the diseased organ. Stem cell transplantation, cloning of cells / tissues / 
organs, and gene therapy may be used to produce (parts of) organs. These new techniques are 
still in the early phases, but develop furiously. 
The emphasis in this thesis reclines on the protection of cardiac xenografts against HAR by 
genetic modification of the organ donor. Three human complement regulatory proteins are 
knovm to inhibit the activation of the complement cascade. We have investigated the effects 
of these hCRPs on protecting grafts against HAR not only in the isolated heart perfusion 
model, i.e. the Langendorff device, but in a rodent-to-primate transplantation model as well. 
Moreover, since ischemia reperfusion injury may contribute to graft dysfunction and loss, we 
examined the additional effect of upregulation of HO-l, which diminishes ischemia 
reperfusion injury, on the graft survival ofhCD55 transgenic mouse hearts in the Langendorff 
circuit. Furthermore, we studied the early cellular rejection process (i.e. PMN infiltration) by 
perfusing hCD55 rat hearts with human blood in the Langendorff system. Finally, we studied 
whether NK cells and macrophages contributed. to the late rejection process in the guinea pig-
to-rat model. 
We demonstrated that particularly regulation at the level of C3 leads to the desired effect: 
mouse hearts transgenic for hCD46 (MCP) showed a marked increased survival time when 
perfused with human serum, whereas hCD59 trans genes did not. In Chapter 3 we investigated 
whether expression of a second CRP (hCD55) would further improve xenograft survival. 
Therefore, hearts were first perfused with Krebs-Henseleit and after 10 minutes switched to 
perfusion with 15% human serum using a Langendorff device. Rejection was defined as 
complete cessation of heartbeats. The results indicated that hCD46 hearts show a 3-fold 
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increase in survival over controls. Complement regulation at the C3 level by hCD55 led to 
similar prolongation as regulation by hCD46. Expression of both hCD46 and hCD55 did not 
further enhance survival time. It thus appears that, as far as protection against HAR is 
concerned, inhibition at C3 by one CRP provides the maximal attainable effect. 
In Chapter 4 the survival of single and double transgenic mouse hearts in the Langendorff 
circuit by means of ex vivo heart perfusion with human serum was compared. Again we 
found that hCD46 or hCD55 mouse hearts are protected against HAR, whereas hCD59 hearts 
are not. Furthermore, hCD59xhCD55 and hCD59xhCD46 double transgenic mouse hearts are 
better protected against HAR than their controls, but not better than single transgenic mouse 
hearts (hCD55 or hCD46). Surprisingly, the combination hCD55xhCD46 was even worse 
than hCD55 or hCD46 alone. The main conclusion of this study was that to prevent HAR it is 
enough to be transgenic for one complement regulatory protein, which inhibits at the level of 
C3. 
In Chapter 5 we compared hDAF transgenic mouse hearts perfused with human serum in the 
Langendorff device and hDAF mouse hearts transplanted into cynomolgus monkeys. The first 
aim of this study was to determine whether perfusion of mouse hearts with higher human 
serum concentrations or human blood might explain some of the differences found in survival 
time of the performed experiments with rat heart xenografts (Chapter 6). Secondly, we 
investigated whether the observed differences in survival times of rat xenografts between in 
vivo and ex vivo transplantation would also hold for mouse hearts transgenic for hDAF. In 
conclusion, in the ex vivo situation, the efficacy of hDAF transgenesis in preventing HAR is 
limited by serum complement concentration. In the ex vivo heart perfusion model both 
homozygous and heterozygous hDAF mouse hearts survived longer as non-transgenic 
controls. However, in both in vivo and ex vivo model the amount of polymorphonuclear 
(P11N) adhering to the vascular endothelium was significantly lower in hDAF transgenes as 
compared to their controls. 
In Chapter 6 we evaluated the resistance of hDAF transgenic rat hearts against complement-
mediated damage by perfusion with human serum in the Langendorff device and by 
transplanting hDAF rat hearts into cynomolgus monkeys. Hemizygous transgenic hearts 
perfused with human serum showed normal function for more than 60 minutes. Hemi- and 
homozygous transgenic hearts transplanted into primates showed longer survival than 
controls. In addition, homozygous hearts survived longer than hemizygous, however. 
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homozygous rejected hearts expressed signs of A VR. In conclusion, endothelial-specific DAF 
expression increased the heart transplant survival in a rat-ta-primate model. 
In the Langendorff model we have demonstrated that rat hearts transgenic for human CD55 
(hCD55), perfused with human serum were protected against BAR. However, in the ex vivo 
situation these hearts were found to be destroyed by a process occurring after the period of 
HAR. In Chapter 7, we questioned whether transgenic hearts for hCD55 are also protected 
against adhesion and infiltration by cells implicated in the early phases of xenograft rejection. 
Therefore, transgenic rat hearts and their controls were perfused with either heat-inactivated 
or normal human blood solutions for 60 minutes. The results indicated that independent of the 
presence of C, hCD55 transgenic hearts revealed less adhering PMN-leukocytes to the 
endothelium as compared to controls (31% versus 60%). Furthermore, hCD55 expressed on 
rat hearts does not only inhibit complement activation, but also human leukocyte-adhesion. 
Apparently it functions as an anti-adhesion molecule. hCD55 is not only an efficient factor in 
protecting grafts against HAR, but protects the graft against adhesion of leukocytes as well. 
Hyperacute rejection (BAR) of a discordant xenograft can be avoided by complement 
manipulation, but acute vascular rejection (A VR) still leads to graft loss. It is generally 
assumed that macrophages and NK cells play key roles in A VR. In the study described in 
Chapter 8 the survival times and cellular infiltrate following guinea pig to rat heart 
transplantation was analyzed in the course of A VR, following aspecific and specific 
manipulation of macrophages and NK cells. HAR was overcome by a single injection of 
cobra venom factor 1 day before heart transplantation. To aspecifically reduce the 
inflammatory response dominating A VR, dexamethasone (DEXA) was given. Treatment with 
DEXA markedly reduced infiltration by NK cells, macrophages, and granulocytes. It also led 
to prolonged graft survival times. In the second series of experiments the specific roles ofNK 
cells and macrophages in A VR were further assessed. Monoclonal antibody 3.2.3 was used to 
selectively deplete NK cells. Liposome-encapsnlated dichloromehtylene-biphosphonate was 
given to achieve macrophage depletion. Neither of these specific treatments, alone or 
combined, led to prolonged graft survival. Immunohistology revealed that at day 2 after 
transplantation no NK cells or macrophages were present in grafts from the combined 
treatment group. Only a mild infiltration of grannlocytes was observed. Collectively, these 
results strongly suggest that NK cells and macrophages are not likely to be pivotal cell types 
inAVR. 
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Ischemia reperfusion injury may playa pivotal role in graft dysfunction and organ loss. In 
Chapter 9, we examined the effect of upregulation of HO~l, a molecule known to diminish 
IIR injury on the improvement of the performance of mouse hearts perfused with human 
serum in the Langendorff circuit. Our findings indicate that upregulation of HO-l protects 
mouse hearts from ischemic injury by reducing the infarct size. Furthermore, HO-l improves 
the performance of the hearts, however, an additional effect of HO-l on the prolongation of 
xenograft survival could not be detected. 
Concluding remarks 
This dissertation discusses the role and efficacy of human complement regulatory proteins in 
hyperacute rejection of cardiac xenografts. In discordant xenogeneic transplantation models, 
HAR is the main cause of graft failure. HAR is mediated by the binding of naturally occurring 
antibodies and complement activation. Complement acivation is normally regulated by 
regulatory factors, i.e. CD55, CD46, both regulators at C3 level, and CD59, regulator at C9 
level. To prevent HAR, it appears that manipulation at the level of complement factor C3 with 
one CRP, i.e. CD55 or CD46, provides the maximal attainable effect. Combinations of 2 
CRPs, either inhibiting at C3 level, or both at C3 and C9 level, does not add to the beneficial 
effect of only one CRP, mediating C3. Moreover, we have found that hCD59 does not protect 
mouse hearts against lIAR, but this may be due to the lower expression level of CD59 as 
compared to CD55 and CD46. Thus, the amount of expression of CRP is important. Organs 
which overexpress CRP are better protected against HAR than organs with low levels of CRP. 
This phenomenon has been illustrated by the following: hearts from mice expressing similar 
levels of pig CD59 or human CD59 were perfused ex vivo with human serum. When highly 
expressed on endothelium in transgenic mice, pig CD59 provided equivalent protection to 
human CD59 in a model of human complement-mediated xenograft rejection. Thus 
supranormal expression of endogenous porcine CRPs may be a feasible alternative to the 
expression of human CRPs in preventing HAR of pig-to-primate xenografts (1). 
It is dubious that xenogeneic heart transplantation will become clinical practice without 
further genetic modification to overcome the immunological barriers. We have investigated 
whether other contributing factors, like Heme oxygenase-l (HO-l), would improve xenograft 
survival, but in our Langendorff model HO-l did not add to the advantageous effect of 
hCD55 transgenic mouse hearts. In pigs, Galal-3Gal knockout techniques are not available 
yet (2), but they will be in the near future. If the knockout techniques could be combined with 
CRP transgenesis, xenograft survival should improve. However, only 85% of the Galal-3Gal 
proteins are known, thus the unknown 15% can cause new rejection problems. As progress 
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will be made in knockout and cloning techniques, this will contribute to a cautious 
introduction of xenotransplantation in the clinical situation. In the mean time, we must focus 
on the physiological and biochemical imbalances in heart function between pig and man, the 
virological problems and last but not least, the ethical considerations, 
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CHAPTER 11 
SAMENVATTING & 
CONCLUSIES 
1.1 Samenvatting en conclusies 
Deze dissertatie beschrijft het ,onderzoek gerelateerd aan het nut van humane complement 
regulerende eiwitten tijdens hyperacute afstoting van cardiale xenotransplantaten. In 
Hoofdstuk 1 wordt een overzicht gegeven van de verschillende aspecten van transplantatie in 
het aIgemeen, en van xenotransplantatie in het bijzonder. Door de discrepantie in vraag en 
aanbod van donor organen, en de mortaliteit van patienten die op een donor orgaan wachten, 
probeert de gezondheidszorg een antwoord te vinden om het orgaan-tekort op te lossen. 
Xenotransplantatie, dat wil zeggen de transplantatie van cellen, weefseIs of organen over een 
species barriere, kan een mogeJijke oplossing zijn voor het donor tekort. Xenotransplantatie 
kan gezien worden als een permanente vervanging van het zieke orgaan, of als een tijdelijke 
therapie tijdens het wachten op een geschikte humane donor. Echter, de mogelijkheid bestaat 
dat xenotransplantatie, om ethische en virologische redenen, klinisch niet haalbaar is. Dan 
zijn er verschillende altematieven. Bioartificiele organen kunnen gebruilct worden om het 
zieke orgaan te ondersteunen. StaIncel transplantatie, het klonen van cellen / weefsels / 
organen, en gentherapie kunnen ingezet worden om organen, of delen ervan, te produceren. 
Deze nieuwe technieken bevinden zich in een vroege ontwikkelingsfase, maar deze 
ontwikkelingen gaan razend sne!. 
De nadruk in deze dissertatie ligt op de bescherming van cardiale xenotransplantaten tegen 
hyperacute afstoting via genetische aanpassing van de orgaan donor. Drie humane 
complement regulerende eiwitten (hCREs) zijn bekend die de activatie van de 
complementscascade remmen. We hebben niet aIleen de effecten van deze hCREs op de 
bescherming van het transplantaat tegen hyperacute afstoting in het geYsoleerde hart perfusie 
model, het zogenaamde Langendorff systeem, onderzocht, maar ook in een lmaagdier-naar-
primaat transplantatie model. Omdat ischemie reperfusie schade een bijdrage kan leveren aan 
orgaan transplantaat falen en verlies, hebben we bovendien gekeken naar het additionele 
effect van opregulatie van HO-I, dat ischemic reperfusie schade vermindert, op de 
transplantaat overleving van hCD55 trans gene muizenharten in het Langendorff model. 
Verder hebben we de vroege cellulaire afstotingsreactie (PMN infiltratie) onderzocht door 
hCD55 rattenharten te perfunderen met humaan bloed in de Langendorff opstelling. 
Uiteindelijk hebben we in het cavia-naar-rat model bestudeerd of NK cellen en macrofagen 
bijdragen aan het late cellulaire afstotingsproces van een xenotransplantaat. 
In de beschreven studies hebben we aangetoond dat hoofdzakeJijk regulatie op C3 niveau 
leidt tot het gewenste effect: namelijk dat muizenharten die transgeen zijn voor hCD46 
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(MCP) een toename in Qverlevingstijd lieten zien, als ze geperfundeerd werden met humaan 
serum, terwijl hCD59 transgenen dit niet deden. In Hoofdstuk 3 onderzochten we of expressie 
van een tweede CRE, namelijk hCD55, tot een verdere toename van de xenotransplantaat 
overleving zou leiden. Daarom werden harten eerst geperfundeerd met Krebs-Henseleit en na 
10 minuten schakelden we om naar perfusie met 15% humaan serum, gebruikmakend van de 
Langendorff opstelling. In dit model wordt afstoting gedefinieerd als complete uitdoving van 
hartslagen (,stoppen met kloppen'). De resultaten hidden in dat hCD46 harten een 
drievoudige toename van de overleving lieten zien in vergelijking met controles. Complement 
regulatie op C3 niveau door hCD55 leidde tot vergelijkbare verlenging als regulatie door 
hCD46. Expressie van beide eiwitten, hCD46 en hCD55, leidde niet tot verlenging van 
overleving. Het bleek dus, voor zover het bescherming tegen hyperacute afstoting betrof, dat 
remming op C3 niveau door een CRE voor het maximaal, haalbare effect zorgde. 
In Hoofdstuk 4 is de overleving van enkel en dubbel transgene muizenharten in het 
Langendorff model vergeleken door ex vivo hart perfusie met humaan serum. Weer vonden 
we dat hCD46 of hCD55 muizenharten beschermd zijn tegen hyperacute afstoting, terwijl 
hCD59 harten dat niet waren. Daarnaast zijn hCD59xhCD55 en hCD59xhCD46 dubbel 
transgene muizenharten beter beschermd tegen hyperacute afstoting dan hun controles, maar 
niet beter dan enkel transgene muizenharten (hCD55 of hCD46). Verbazingwekkend was het 
dat harten met de combinatie hCD55xhCD46 zelfs een slechtere overleving hadden dan 
harten die aileen hCD55 of hCD46 transgeen waren. De be\angrijkste conc1usie van deze 
studie was dat het voldoende is om transgeen te zijn voor 6en complement regulerend eiwit, 
dat het complement remt op C3 niveau, om hyperacute afstoting te voorkomen. 
In Hoofdstuk 5 hebben we hDAF transgene muizenharten geperfundeerd met humaan serum 
in de Langendorff opstelling en deze vergeleken met hDAF muizenharten die 
getransplanteerd werden naar cynomolgus apen. Het doel van deze studie was ten eerste het 
perfunderen van muizenharten met een hogere humaan serum concentratie dan normaal (30% 
i.p.v. 15%) en met humaan bloed om zodoende misschien de verschillen in overlevingstijd, 
die we gevonden hadden bij eerdere experimenten met rattenhart xenotransplantaten 
(Hoofdstnk 6), te kunnen verklaren. Ten tweede onderzochten we of de geobserveerde 
verschillen in overlevingstijd van rattenhart xenotransplantaten tussen in vivo en ex vivo 
transplantatie ook voor hDAF transgene muizenharten zou gelden. We conc1udeerden dat in 
de ex vivo situatie de mate van effectiviteit van hDAF-transgenese ter preventie van 
hyperacute afstoting gelimiteerd was door de serum complement concentratie. In het ex vivo 
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hart perfusie model overleefden zowel homozygote en heterozygote hDAF muizenharten 
langer als niet-transgene controles. Echter, in beide modeUen (in vivo en ex vivo) was de 
hoeveelheid polymorfonucleaire cellen (PMN), die adhereerden aan het vasculaire endotheel, 
significant lager in hDAF transgene harten in vergelijking met hun controles. 
In Hoofdstuk 6 hebben we de weerstand van hDAF transgene rattenharten tegen complement-
gemedieerde schade geevalueerd door perfusie met humaan serum in het Langendorffmodel, 
en door bDAF rattenharten te transplanteren naar cynomolgus apen. Hemizygote transgene 
harten geperfundeerd met humaan serum lieten een normale functie zien gedurende meer dan 
60 minuten. Hemi- of homozygote transgene harten getransplanteerd naar primaten Beten een 
langere overleving dan controles zien. Weliswaar overleefden homozygote harten langer dan 
hemizygote, echter, homozygote afgestoten harten lieten verschijnselen van acute vasculaire 
afstoting zien. We concludeerden dat endotheel-specifieke DAF expressie de hart 
transplantaat Qverleving in een rat-naar-primaat model deed toenemen. 
In het Langendorffmodel hebben we gedemonstreerd dat rattenharten transgeen voor humaan 
CD55 (hCD55), geperfundeerd met humaan serum beschermd zijn tegen hyperacute afstoting. 
Echter, in de ex vivo situatie werden deze harten vemietigd door een proces dat na de periode 
van hyperacute afstoting plaatsvond. In Hoofdstuk 7, vroegen we ons dan ook af of hCD55 
transgene harten ook bescheIDld zouden zijn tegen adhesie en infiltratie van cellen die 
betrokken zijn in de vroege fases van xenotransplantaat afstoting. Daarom werden transgene 
rattenharten en hun controles geperfundeerd met Of complement-gelnactiveerd humaan bloed 
Of normaal humaan bloed oplossingen gedurende 60 minuten. De resultaten melden in dat 
onafhankelijk van de aanwezigheid van complement, hCD55 transgene harten minder 
adherentie van P1\.1N-Ieukocyten aan het endotheel lieten zien in vergelijking met controles 
(31% versus 60%). hCD55 functioneerde blijkbaar als een anti-adhesie molekuul. In 
conclusie, hCD55 was niet alleen een efficiente factor bij de bescherruing van transplantaten 
tegen hyperacute afstoting, maar het bescheIDlde het transplantaat ook tegen adhesie van 
leukocyten. 
Hyperacute afstoting van een discordant xenotransplantaat kan voorkomen worden door 
complement manipulatie, maar acute vasculaire afstoting leidt nog steeds tot transplantaat 
verlies. Het wordt algemeen verondersteld dat macrofagen en NK cellen sleutelrollen spelen 
in acute vasculaire afstoting. In het onderzoek beschreven in Hoofdstuk 8 zijn de 
overlevingstijden en cellulaire infiltraten na cavia-naar-rat hart ttansplantatie geanalyseerd in 
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de lijn van acute vasculaire afstoting, na aspecifieke en specifieke manipulatie van 
macrofagen en NK cellen. Hyperacute afstoting werd voorkomen door een enkele injectie met 
cobragif dag voordat de harttransplantatie plaatsvond. Om de aspecifieke 
ontstekingsresponse, die centraal staat in acute vasculaire afstoting, te reduceren, werd 
dexamethason (DEXA) gegeven. Behandeling met DEXA zorgde voor een waameembare 
reductie van de infiltratie door NK cellen, macrofagen en granulocyten. Het leidde ook tot 
verlengde transplantaatoverleving. In de tweede helft van de experimenten werden de 
specifieke rollen van NK cellen en macrofagen bij acute vasculaire afstoting verder 
uitgediept. Monoclonaal antilichaam 3.2.3 werd gebruikt om selectieve depletie van NK 
cellen te bewerkstelligen. Liposoom-ingekapselde dichloromehtyleen-bifosfonaat werd 
gegeven om de macrofagen te depleteren. Geen van beide specifieke therapiee~ alleen of 
gecombineerd, leidde tot verlenging van transplantaat-overleving. Immunohistologie liet zien 
dat na 2 dagen na transpiantatie geen NK cellen of macrofagen aanwezig waren in de 
transplantaten van de gecombineerd behande1de groep. AIleen een milde infiltratie met 
granulocyten werd geobserveerd. Alles samengenomen suggereerden deze resultaten dat NK 
cellen en macrofagen niet echt de be1angrijkste celtypen zijn bij acute vasculaire afstoting. 
Ischemie reperfusie (I/R) schade kan een be1angrijke rol spelen in transplantaat dysfimctie en 
orgaan verlies. In Hoofdstuk 9, hebben we het effect van opregnlatie van HO-l, een molekuul 
dat bekend staat om I/R schade te venninderen, bestudeerd op de verbetering van de prestatie 
van muizenharten geperfundeerd met humaan serum in het Langendorff model. Onze 
resultaten hielden in dat opregulatie van HO-l muizenharten beschennde tegen ischemische 
schade; dit was te zien aan een afuame van de infarct grootte. Bovendien verbeterde HO-l de 
prestatie van de harten, echter, een additioneel effect van HO-l op de verlenging van de 
transplantaatoverleving kon niet worden gedetecteerd. 
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